NZ768960A - Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease - Google Patents
Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune diseaseInfo
- Publication number
- NZ768960A NZ768960A NZ768960A NZ76896019A NZ768960A NZ 768960 A NZ768960 A NZ 768960A NZ 768960 A NZ768960 A NZ 768960A NZ 76896019 A NZ76896019 A NZ 76896019A NZ 768960 A NZ768960 A NZ 768960A
- Authority
- NZ
- New Zealand
- Prior art keywords
- tetrahydro
- amino
- pyrazino
- methyl
- compound
- Prior art date
Links
- -1 Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds Chemical class 0.000 title claims description 224
- 206010003816 Autoimmune disease Diseases 0.000 title description 4
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 351
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- 239000011780 sodium chloride Substances 0.000 claims abstract description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 130
- 125000004193 piperazinyl group Chemical group 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 25
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 16
- 229910052805 deuterium Inorganic materials 0.000 claims description 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 15
- 125000002393 azetidinyl group Chemical group 0.000 claims description 15
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims description 9
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 108060004749 CAD Proteins 0.000 claims 1
- 125000005961 oxazepanyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 55
- 238000001819 mass spectrum Methods 0.000 description 187
- 238000002360 preparation method Methods 0.000 description 159
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 149
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 110
- 238000005160 1H NMR spectroscopy Methods 0.000 description 105
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 77
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 64
- 239000000243 solution Substances 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 47
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 45
- 210000004027 cells Anatomy 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 40
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 40
- 235000019439 ethyl acetate Nutrition 0.000 description 38
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 38
- WDXARTMCIRVMAE-UHFFFAOYSA-N quinoline-2-carbonitrile Chemical compound C1=CC=CC2=NC(C#N)=CC=C21 WDXARTMCIRVMAE-UHFFFAOYSA-N 0.000 description 37
- CIIFKVFOVFJZDM-UHFFFAOYSA-N quinoline-8-carbonitrile Chemical compound C1=CN=C2C(C#N)=CC=CC2=C1 CIIFKVFOVFJZDM-UHFFFAOYSA-N 0.000 description 34
- 239000012044 organic layer Substances 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000012267 brine Substances 0.000 description 30
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 24
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 24
- 238000003818 flash chromatography Methods 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 23
- 102100006355 TLR7 Human genes 0.000 description 22
- 101700075266 TLR7 Proteins 0.000 description 22
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 19
- 238000004166 bioassay Methods 0.000 description 18
- 239000003054 catalyst Substances 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- 102100006354 TLR8 Human genes 0.000 description 16
- 101700071772 TLR8 Proteins 0.000 description 16
- PGSADBUBUOPOJS-UHFFFAOYSA-N Neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 15
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 15
- 239000012043 crude product Substances 0.000 description 14
- 239000011369 resultant mixture Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 125000003386 piperidinyl group Chemical group 0.000 description 11
- KIDIJBYYGAEULX-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-7-carbonitrile Chemical compound N#CC1=CC=CC2=CC=NN12 KIDIJBYYGAEULX-UHFFFAOYSA-N 0.000 description 11
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 10
- 230000003042 antagnostic Effects 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 150000007942 carboxylates Chemical class 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- PZWICOVTQKUHIH-UHFFFAOYSA-N 5-fluoroquinoline-8-carbonitrile Chemical compound C1=CC=C2C(F)=CC=C(C#N)C2=N1 PZWICOVTQKUHIH-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 231100000760 phototoxic Toxicity 0.000 description 8
- NSILYQWHARROMG-MRVPVSSYSA-N tert-butyl (3R)-3-(hydroxymethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN[C@@H](CO)C1 NSILYQWHARROMG-MRVPVSSYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- MNYTWTCGSPYQHC-UHFFFAOYSA-N methyl 5-bromo-4-fluoro-2-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=C(F)C=C1C MNYTWTCGSPYQHC-UHFFFAOYSA-N 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 6
- 206010034972 Photosensitivity reaction Diseases 0.000 description 6
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 6
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 150000004820 halides Chemical class 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 6
- 231100000018 phototoxicity Toxicity 0.000 description 6
- 235000015320 potassium carbonate Nutrition 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 229960000583 Acetic Acid Drugs 0.000 description 5
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 5
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 5
- 108090001123 antibodies Proteins 0.000 description 5
- 102000004965 antibodies Human genes 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000001808 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- QVHJQCGUWFKTSE-RXMQYKEDSA-N (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-RXMQYKEDSA-N 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- JPSMHTINHFWJTJ-UHFFFAOYSA-M COC1CCCN1C([O-])=O Chemical compound COC1CCCN1C([O-])=O JPSMHTINHFWJTJ-UHFFFAOYSA-M 0.000 description 4
- 229960002743 Glutamine Drugs 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 208000005777 Lupus Nephritis Diseases 0.000 description 4
- 206010025135 Lupus erythematosus Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229940049954 Penicillin Drugs 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 210000003491 Skin Anatomy 0.000 description 4
- 229960005322 Streptomycin Drugs 0.000 description 4
- RCZHBDVNXHJJRT-MRVPVSSYSA-N [(2R)-4-tert-butylpiperazin-2-yl]methanol Chemical compound CC(C)(C)N1CCN[C@@H](CO)C1 RCZHBDVNXHJJRT-MRVPVSSYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- CHKQALUEEULCPZ-UHFFFAOYSA-N amino 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S(=O)(=O)ON)C(C)=C1 CHKQALUEEULCPZ-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 229960000626 benzylpenicillin Drugs 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-M pyridine-3-carboxylate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
- 231100000027 toxicology Toxicity 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- HPXNTHKXCYMIJL-UHFFFAOYSA-N 1,1'-bis(diphenylphosphanyl)ferrocene Chemical compound C12C3C4C5[Fe]4322346(C7(C2C6C4C37)P(C=2C=CC=CC=2)C=2C=CC=CC=2)C15P(C=1C=CC=CC=1)C1=CC=CC=C1 HPXNTHKXCYMIJL-UHFFFAOYSA-N 0.000 description 3
- 101710016959 ALPG Proteins 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 206010073080 Autoinflammatory disease Diseases 0.000 description 3
- 210000003719 B-Lymphocytes Anatomy 0.000 description 3
- NIAUVDRUTMQEBK-UHFFFAOYSA-N Cc1c(F)cc(Br)cc1C(O)=O Chemical compound Cc1c(F)cc(Br)cc1C(O)=O NIAUVDRUTMQEBK-UHFFFAOYSA-N 0.000 description 3
- 208000002573 Connective Tissue Disease Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- MQUPWTBHHPUUMC-UHFFFAOYSA-N Isoindole Chemical compound C1=CC=C[C]2C=NC=C21 MQUPWTBHHPUUMC-UHFFFAOYSA-N 0.000 description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 3
- 238000006619 Stille reaction Methods 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N XPhos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 150000003951 lactams Chemical class 0.000 description 3
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000000069 prophylaxis Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 230000004936 stimulating Effects 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000002689 toll-like receptors Human genes 0.000 description 3
- 108020000411 toll-like receptors Proteins 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- XIVUBGOYMBSEMA-UHFFFAOYSA-N 1,4-dioxane;methylsulfinylmethane Chemical compound CS(C)=O.C1COCCO1 XIVUBGOYMBSEMA-UHFFFAOYSA-N 0.000 description 2
- CWLUFVAFWWNXJZ-UHFFFAOYSA-N 1-hydroxypyrrolidine Chemical compound ON1CCCC1 CWLUFVAFWWNXJZ-UHFFFAOYSA-N 0.000 description 2
- RBYQYPQIZQKEFL-UHFFFAOYSA-N 1-methoxypyrrolidine Chemical compound CON1CCCC1 RBYQYPQIZQKEFL-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- HERGPIKZUJHAPU-UHFFFAOYSA-N 2-bromo-N-fluoroaniline Chemical compound FNC1=CC=CC=C1Br HERGPIKZUJHAPU-UHFFFAOYSA-N 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 Chlorpromazine Drugs 0.000 description 2
- 210000004544 DC2 Anatomy 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 230000036095 Microsomal Stability Effects 0.000 description 2
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N Nicotinamide adenine dinucleotide phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- TXRPHPUGYLSHCX-UHFFFAOYSA-N Selectfluor Chemical compound F[B-](F)(F)F.F[B-](F)(F)F.C1C[N+]2(CCl)CC[N+]1(F)CC2 TXRPHPUGYLSHCX-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N Silver nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N Sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N Theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 208000002363 Torsades de Pointes Diseases 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- JXFUHCFLDZVPQH-UHFFFAOYSA-M ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;methanesulfonate;palladium(2+);2-phenylaniline Chemical compound [Pd+2].CS([O-])(=O)=O.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C JXFUHCFLDZVPQH-UHFFFAOYSA-M 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OSTIHFXUTPZJQL-UHFFFAOYSA-N fluoro benzoate Chemical compound FOC(=O)C1=CC=CC=C1 OSTIHFXUTPZJQL-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 231100000119 phototoxicity / photoirritation testing Toxicity 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000001184 potassium carbonate Substances 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 230000001172 regenerating Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000003595 spectral Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 201000009594 systemic scleroderma Diseases 0.000 description 2
- WPGLRFGDZJSQGI-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(N)C1 WPGLRFGDZJSQGI-UHFFFAOYSA-N 0.000 description 2
- XRRXRQJQQKMFBC-UHFFFAOYSA-N tert-butyl 3-hydroxyazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)C1 XRRXRQJQQKMFBC-UHFFFAOYSA-N 0.000 description 2
- XPDIKRMPZNLBAC-UHFFFAOYSA-N tert-butyl 3-iodoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(I)C1 XPDIKRMPZNLBAC-UHFFFAOYSA-N 0.000 description 2
- MVUNGZMGWJXPIM-UHFFFAOYSA-N tert-butyl N-(4-methylpiperidin-4-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1(C)CCNCC1 MVUNGZMGWJXPIM-UHFFFAOYSA-N 0.000 description 2
- BZSDDSIFAGBZLT-RQJHMYQMSA-N tert-butyl N-[(3S,4R)-4-fluoropyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CNC[C@H]1F BZSDDSIFAGBZLT-RQJHMYQMSA-N 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N water-d2 Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- GTIIVHODSNYECK-UHFFFAOYSA-N 1,1,1-trifluoropropane Chemical group [CH2]CC(F)(F)F GTIIVHODSNYECK-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-Dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CAFYRMZGLTYCHS-UHFFFAOYSA-N 1,4-oxazepan-6-amine Chemical compound NC1CNCCOC1 CAFYRMZGLTYCHS-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- IFGLECYAEGYLSJ-UHFFFAOYSA-N 2-bromo-3-fluoropyridine Chemical compound FC1=CC=CN=C1Br IFGLECYAEGYLSJ-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- ALPTZPFVGLVIKK-UHFFFAOYSA-N 2-methyl-2,6-diazaspiro[3.3]heptane Chemical compound C1N(C)CC11CNC1 ALPTZPFVGLVIKK-UHFFFAOYSA-N 0.000 description 1
- YYFLDZZDOUDZQM-UHFFFAOYSA-N 3-[1-[[4-(3-phenylquinolin-2-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 YYFLDZZDOUDZQM-UHFFFAOYSA-N 0.000 description 1
- CDDGNGVFPQRJJM-UHFFFAOYSA-N 3-fluoropyrrolidine Chemical compound FC1CCNC1 CDDGNGVFPQRJJM-UHFFFAOYSA-N 0.000 description 1
- QADXJCSDQCVCIS-UHFFFAOYSA-N 4-(fluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(CF)C=C1 QADXJCSDQCVCIS-UHFFFAOYSA-N 0.000 description 1
- OUZLPGJFGCOKJJ-UHFFFAOYSA-N 8-bromo-5-fluoroquinoline Chemical compound C1=CC=C2C(F)=CC=C(Br)C2=N1 OUZLPGJFGCOKJJ-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N Anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 102000003852 Autoantibodies Human genes 0.000 description 1
- 108090000206 Autoantibodies Proteins 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- VKNHQCANTUVMSG-UHFFFAOYSA-N BrC=1C(=CC(=C(C(=O)OC)C=1)C=O)F Chemical compound BrC=1C(=CC(=C(C(=O)OC)C=1)C=O)F VKNHQCANTUVMSG-UHFFFAOYSA-N 0.000 description 1
- JWMWGMQQBFOFHZ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NN1CCC(C1)OC Chemical compound C(C)(C)(C)OC(=O)NN1CCC(C1)OC JWMWGMQQBFOFHZ-UHFFFAOYSA-N 0.000 description 1
- UJHBTCNHHDVZIG-UHFFFAOYSA-N C1NCC11CNCCO1 Chemical compound C1NCC11CNCCO1 UJHBTCNHHDVZIG-UHFFFAOYSA-N 0.000 description 1
- 210000000182 CD11c+CD123- DC Anatomy 0.000 description 1
- BIVRALFYMUTHBC-UHFFFAOYSA-N COC(=O)c1cc(Br)cc(F)c1C Chemical compound COC(=O)c1cc(Br)cc(F)c1C BIVRALFYMUTHBC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N Cesium Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229960001657 Chlorpromazine hydrochloride Drugs 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 210000001163 Endosomes Anatomy 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- 229960002442 Glucosamine Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 229960002885 Histidine Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101700024037 IDH1 Proteins 0.000 description 1
- 101700030371 IDH2 Proteins 0.000 description 1
- 101700031495 IDH3A Proteins 0.000 description 1
- 102100014731 IDH3A Human genes 0.000 description 1
- 101700070228 IFN Proteins 0.000 description 1
- 101700066403 IFNA1 Proteins 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 210000002510 Keratinocytes Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 101710009221 LD Proteins 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 210000000088 Lip Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000003712 Lysosomes Anatomy 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 210000001589 Microsomes Anatomy 0.000 description 1
- 210000001853 Microsomes, Liver Anatomy 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N N,N-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N N-Aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- JGNMFINNXOSOBU-UHFFFAOYSA-M N1NCC12CCCC(C2)C(=O)[O-] Chemical compound N1NCC12CCCC(C2)C(=O)[O-] JGNMFINNXOSOBU-UHFFFAOYSA-M 0.000 description 1
- 238000006411 Negishi coupling reaction Methods 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- BFCWIVNYDKTSIH-UHFFFAOYSA-M OC1CNCCN(C1)C([O-])=O Chemical compound OC1CNCCN(C1)C([O-])=O BFCWIVNYDKTSIH-UHFFFAOYSA-M 0.000 description 1
- 101710027499 Os03g0268000 Proteins 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229910021120 PdC12 Inorganic materials 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 230000036451 QT interval Effects 0.000 description 1
- 238000000543 QT interval Methods 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N Resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 Resiquimod Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 229960005137 Succinic Acid Drugs 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229960004559 Theobromine Drugs 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N Trifluorotoluene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N Trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 239000012391 XPhos Pd G2 Substances 0.000 description 1
- 101700002161 ZO14 Proteins 0.000 description 1
- COERJHDMQUPDCV-UHFFFAOYSA-N [K].FB(F)F Chemical compound [K].FB(F)F COERJHDMQUPDCV-UHFFFAOYSA-N 0.000 description 1
- ZKJOXOJMGXFSPF-QYZPTAICSA-N [[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate;hydrate Chemical compound O.NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 ZKJOXOJMGXFSPF-QYZPTAICSA-N 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000003044 adaptive Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- OBFQBDOLCADBTP-UHFFFAOYSA-N aminosilicon Chemical compound [Si]N OBFQBDOLCADBTP-UHFFFAOYSA-N 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 108010051561 belimumab Proteins 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- XNRHTMDHGDWBGP-UHFFFAOYSA-N carbamic acid;hydrochloride Chemical compound Cl.NC(O)=O XNRHTMDHGDWBGP-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- FBSMERQALIEGJT-UHFFFAOYSA-N chlorpromazine hydrochloride Chemical compound [H+].[Cl-].C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FBSMERQALIEGJT-UHFFFAOYSA-N 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- OQCZRDWKZXSHGS-ZHZULCJRSA-N ethyl (2Z)-2-[(2-acetyloxyphenyl)methylidene]-7-methyl-3-oxo-5-phenyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate Chemical compound O=C1N2C(C=3C=CC=CC=3)C(C(=O)OCC)=C(C)N=C2S\C1=C/C1=CC=CC=C1OC(C)=O OQCZRDWKZXSHGS-ZHZULCJRSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 230000002132 lysosomal Effects 0.000 description 1
- 230000001868 lysosomic Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DZGUEAGZHYBMJT-UHFFFAOYSA-N methyl 2-bromo-6-formylbenzoate Chemical compound COC(=O)C1=C(Br)C=CC=C1C=O DZGUEAGZHYBMJT-UHFFFAOYSA-N 0.000 description 1
- SMCVPMKCDDNUCQ-UHFFFAOYSA-N methyl 3,3-dimethoxypropanoate Chemical compound COC(OC)CC(=O)OC SMCVPMKCDDNUCQ-UHFFFAOYSA-N 0.000 description 1
- ZYGJVCDDZZSSEE-UHFFFAOYSA-N methyl 5-bromo-2-formylbenzoate Chemical compound COC(=O)C1=CC(Br)=CC=C1C=O ZYGJVCDDZZSSEE-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 230000002020 noncytotoxic Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 102000004257 potassium channel family Human genes 0.000 description 1
- 108020001213 potassium channel family Proteins 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- XNUYYZFYOVSMJU-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine-2-carbonitrile Chemical compound C1=CC=CN2N=C(C#N)C=C21 XNUYYZFYOVSMJU-UHFFFAOYSA-N 0.000 description 1
- 101710034647 rI Proteins 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- LJRGBERXYNQPJI-UHFFFAOYSA-M sodium;3-nitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=CC(S([O-])(=O)=O)=C1 LJRGBERXYNQPJI-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000007921 solubility assay Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- DATRVIMZZZVHMP-MRVPVSSYSA-N tert-butyl (2R)-2-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-MRVPVSSYSA-N 0.000 description 1
- NSILYQWHARROMG-QMMMGPOBSA-N tert-butyl (3S)-3-(hydroxymethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN[C@H](CO)C1 NSILYQWHARROMG-QMMMGPOBSA-N 0.000 description 1
- OPTDWRLRSYCDKW-UHFFFAOYSA-N tert-butyl 2,6-diazaspiro[3.3]heptane-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1NCC11CNC1 OPTDWRLRSYCDKW-UHFFFAOYSA-N 0.000 description 1
- RZCWERACOAHBGR-UHFFFAOYSA-N tert-butyl 6-(hydroxymethyl)-1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC(CO)C1 RZCWERACOAHBGR-UHFFFAOYSA-N 0.000 description 1
- BFHSUIWEPMCBQR-UHFFFAOYSA-N tert-butyl N-(3-methylazetidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1(C)CNC1 BFHSUIWEPMCBQR-UHFFFAOYSA-N 0.000 description 1
- QAZVTJCOYJOJGO-RNFRBKRXSA-N tert-butyl N-[(3R,4R)-4-hydroxypyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CNC[C@H]1O QAZVTJCOYJOJGO-RNFRBKRXSA-N 0.000 description 1
- PIGDOXPNNMFBNA-HTQZYQBOSA-N tert-butyl N-[(3R,4R)-4-methoxypyrrolidin-3-yl]carbamate Chemical compound CO[C@@H]1CNC[C@H]1NC(=O)OC(C)(C)C PIGDOXPNNMFBNA-HTQZYQBOSA-N 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Abstract
The present invention relates to compounds of formula (I), wherein R1 to R6, m and n are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
Description
/064323
TETRAHYDRO-1 H—PYRAZINO[2,1 -AJ|SO|NDOLYLQU|NOL|NE NDS FOR THE TREATMENT OF AUTOIMMUNE
The present invention s to organic compounds useful for therapy and/or prophylaxis
in a mammal, and in particular to antagonist of TLR7 and/or TLR8 and/or TLR9 useful for
treating systemic lupus erythematosus or lupus nephritis.
FIELD OF THE INVENTION
Autoimmune connective tissue disease (CTD) include prototypical mune syndromes
such as Systemic Lupus Erythematosus (SLE), primary Sjégren’s me (ij S), mixed
connective tissue disease (MCTD), Dermatomyositis/Polymyositis (DM/PM), Rheumatoid
Arthritis (RA), and systemic sclerosis (SSc). With the exception of RA, no really effective and
safe therapies are available to ts. SLE ents the prototypical CTD with a prevalence of
20-150 per 100,000 and causes broad inflammation and tissue damage in distinct organs, from
commonly observed ms in the skin and joints to renal, lung, or heart failure. Traditionally,
SLE has been treated with nonspecific anti-inflammatory or immunosuppressive drugs. However,
long term usage of suppressive drug, e.g. corticosteroids is only partially effective, and
is associated with undesirable toxicity and side effects. Belimumab is the only FDA-approved
drug for lupus in the last 50 years, despite its modest and delayed efficacy in only a fraction of
SLE ts (Navarra, S. V. et al Lancet 2011, 377, 721.). Other biologics, such as anti-CD20
mAbs, mAbs against or soluble receptors of specific cytokines, have failed in most clinical
studies. Thus, novel therapies are required that provide sustained improvement in a greater
proportion of patient groups and are safer for chronic use in many autoimmune as well as auto-
ation diseases.
Toll Like Receptors (TLR) are an important family of pattern ition receptors (PRR)
which can initiate broad immune responses in a wide variety of immune cells. As natural host
defense sensors, mal TLRs 7, 8 and 9 recognize nucleic acids derived from viruses,
bacteria; specifically, TLR7/8 and TLR9 recognize single-stranded RNA (ssRNA) and single-
stranded CpG-DNA, respectively. However, aberrant nucleic acid sensing of TRL7,8,9 is
considered as a key node in a broad of autoimmune and auto-inflammatory diseases (Krieg, A.
M. et a]. Immunol. Rev. 2007, 220, 251. Jiménez—Dalmaroni, M. J. et al Autoimmun Rev. 2016,
, 1. Chen, J. Q., et al. Clinical Reviews in Allergy & Immunology 2016, 50, 1.). Anti-RNA and
anti-DNA antibodies are well established diagnostic markers of SLE, and these antibodies can
deliver both self-RNA and self—DNA to endosomes. While self—RNA complexes can be
recognized by TLR7 and TLR8, self-DNA complexes can trigger TLR9 activation. Indeed,
defective clearance of self-RNA and self-DNA from blood and/or s is evident in SLE
(Systemic Lupus Erythematosus) patients. TLR7 and TLR9 have been reported to be upregulated
in SLE tissues, and correlate with chronicity and activity of lupus nephritis, tively. In B
cells of SLE patients, TLR7 expression ates with anti-RNP antibody production, while
TLR9 expression with lL-6 and anti~dsDNA antibody . Consistently, in lupus mouse
, TLR7 is required for anti-RNA antibodies, and TLR9 is required for anti-nucleosome
antibody. On the other hand, overexpression of TLR7 or human TLRS in mice promotes
autoimmunity and autoinflammation. Moreover, tion of TLR8 cally contributes to
inflammatory cytokine secretion of mDC/macrophages, neutrophil NETosis, induction of Th1 7
cells, and suppression of Treg cells. In addition to the described role of TLR9 in promoting
autoantibody production of B cells, activation of TLR9 by self-DNA in pDC also leads to
induction of type I IFNs and other inflammatory cytokines. Given these roles of TLR9 in both
pDC and B cells, both as key contributors to the pathogenesis of autoimmune diseases, and the
ive ce of self-DNA complexes that could readily activate TLR9 in many patients
with mune diseases, it may have extra benefit to further block self—DNA mediated TLR9
pathways on top of inhibition of TLR7 and TLR8 pathways. Taken er, TLR7, 8, and 9
pathways represent new therapeutic targets for the treatment of mune and auto-
inflammatory diseases, for which no effective steroid-free and non—cytotoxic oral drugs exist,
and inhibition of all these pathways from the very upstream may deliver satisfying therapeutic
effects. As such, we invented oral compounds that target and suppress TLR7, TLR8 and TLR9
for the treatment of autoimmune and auto-inflammatory diseases.
Y OF THE INVENTION
The present invention relates to novel compounds of formula (1),
NlRZ
(R6 R4
(R )m (I),
wherein
R7 R7 R7
N R8 N R8 N R8
\ / \
/ N \ / N/j:R9
R1 is
, , , 9
R7 R7 R7 R7
/ N N
\ \> \> \>
\ \ \ \N s 0
, , ; wherein R7 is C1_6alkyl,
C]_éalkoxy, haloCLGalkyl, halogen, nitro or cyano; R8 is H or ium; R9 is H, deuterium
or C1_6alkyl; R10 is H or halogen;
R2 is H or Cmalkyl;
R3 is H;
R4 is H;
R5 is H, piperazinyl, halogen, kyl, halopyrrolidinylamino or hydroxypyrrolidinle1_
6alkylamino;
R6 is H;
(C1-6alkyl)2aminoC1.6alkoxy;
(C1-6a1kyl)2aminoC1-6alkylamino;
1,2,3,4,6,6a-hexahydropyrrolo[3,4—c]pyrroly1 tuted by C1_6alkoxy;
1,4-diazepanyl substituted by one or two substituents independently selected from hydroxy
and Cmalkyl;
1,4-oxazepanyl substituted by amino;
1 ,4-oxazepanylamino;
1,6-diazaspiro[3.3]heptanyl;
2,5-diazabicyclo[2.2. l ]heptanylcarbonyl;
2,6-diazaspiro[3.3]heptany1 unsubstituted or substituted by C]_6alkyl;
2-oxaazaspiro[3.4]octany1 substituted by amino;
3,4,4a,5,7,7a-hexahydro—2H-pyrrolo[3 ,4-b] [ l ,4]oxazinyl;
3,4a,5,6,7,7a-hexahydro-2H-pyrrolo[3,4—b][1,4]oxazinyl;
3,8—diazabicyclo[3 .2. l]octanylcarb0nyl;
3—oxa-7,9-diazabicyclo[3.3 . l ]nonany1;
3-oxo-1,5,6,7,8,8a-hexahydroi1nidazo[l ,5-a]pyraziny1;
-oxa—2,8-diazaspiro[3.5]nonanyl;
9-0xa—3 ,7-diazabicyclo[3 .3. 1 ]nonanyl;
amino(C1-6alky1)piperidinylcarbonyl;
azetidinyl unsubstituted or substituted by one or two substituents independently ed
from amino and C1-6alkyl;
azetidinylamino;
azetidinyloxy;
C1-6alkoxypipefidinylamino;
C1_6alkoxypyrrolidiny1(C1-6alkyl)amino;
C1-6alkoxypyrrolidinylamino;
etidinyl(C1-6a1kyl)amino;
halopyrrolidinylarnino;
1 5 halopyrrolidinylcl-6alkoxy;
halopyrrolidinle I .6alkylamino;
halopyrrolidinyloxy;
hydroxypyrrolidinleI-6alky1amino;
morpholiny1C1-6alkylamin0;
piperazinyl unsubstituted or substituted by C].6alkoxyC1_6alkyl, hydroxyC1-6alkyl or C1-
6alkyl;
piperazinylcarbonyl;
piperidinyl tituted or substituted by one or two substituents independently selected
from amino, C1.6alkoxy and ky1;
piperidinylamino; or
pyrrolidinyl substituted by one, two or three substituents independently selected from
amino, C1_6alkoxy, C1_6alkyl, C1-6alkylarnino, halogen, hydroxy and hydroxyC 1.6a1ky1;
mis 0,1, 2, or3;
nis 1,2, 3 or4;
m+nS4;
with the o that R5 and R6 are not H aneously;
or a phannaceutically acceptable salt thereof.
WO 33941 2019/064323
Another object of the present invention is related to novel compounds of formula (I) or (Ia)
or (Ib), their manufacture, medicaments based on a compound in accordance with the invention
and their tion as well as the use of compounds of formula (I) or (Ia) or (lb) as TLR7
and/or TLR8 and/or TLR9 antagonist, and for the treatment or prophylaxis of systemic lupus
erythematosus or lupus nephritis. The compounds of formula (I) or (Ia) or (lb) show superior
TLR7 and/or TLR8 and/or TLR9 antagonism ty. In on, the nds of formula (I)
or (Ia) or (lb) also show good hPBMC, cytotoxicity, solubility, human microsome ity and
SDPK profiles, as well as low CYP tion.
DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS
The term “Cmalkyl” denotes a saturated, linear or branched chain alkyl group containing 1
to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, tert-butyl and the like. Particular “Cmalkyl” groups are methyl, ethyl and n-propyl.
The term “halogen” and “halo” are used interchangeably herein and denote fluoro, ,
bromo, or iodo.
The term “haloC1_6alky1” denotes an alkyl group wherein at least one of the hydrogen
atoms of the alkyl group has been replaced by same or different halogen atoms, particularly
fluoro atoms. Examples of haloC1-6alkyl include monofluoro-, difluoro-or ro—methyl, -
ethyl or —propyl, for example 3,3,3—trifluoropropyl, 2—fluoroethyl, 2,2,2—trifluoroethyl,
fluoromethyl, difluoromethyl, trifluoromethyl and trifluoroethyl.
The term “oxy” denotes -O—.
The term lkoxy” denotes C1.6alkyl-O-.
The term “halopyrrolidinyl” denotes a pyrrolidinyl substituted once, twice or three times
by halogen. Examples ofhalopyrrolidinyl include, but not limited to, difluoropyrrolidinyl and
fluoropyrrolidinyl.
The term “haloazetidinyl” denotes a azetidinyl substituted once, twice or three times by
halogen. Examples of halopyrrolidinyl include, but not limited to, difluoroazetidinyl and
fluoroazetidinyl.
The term “enantiomer” denotes two stereoisomers of a compound which are non-
superimposable mirror images of one another.
The term “diastereomer” denotes a stereoisomer with two or more centers of chirality and
whose molecules are not mirror images of one another. Diastereomers have different physical
properties, e.g. melting points, boiling , spectral properties, and reactivities.
WO 33941
The term “as—isomers” and “trans-isomers” denote the relative stereochemistry of the
molecule or moiety. For e: the starting material of Example 16 (trans(boc—amino)
; similarly, the starting material of Example 17 (cis(boc-
>Lo fl
0%”Q
amino)-4—methoxypyrrolid1ne, \ ) as the “cis-isomers” refers to a mixture of
fl\O n >Lo n
DAN/Q CANMO
O\ é
and \
. The way of showing relative stereochemistry also applies
to the final compounds of this invention.
The term “pharmaceutically acceptable salts” denotes salts which are not biologically or
otherwise undesirable. Pharmaceutically acceptable salts e both acid and base addition
salts.
The term “pharmaceutically acceptable acid addition salt” denotes those ceutically
acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid,
ic acid, nitric acid, carbonic acid, phosphoric acid, and organic acids selected from
aliphatic, liphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of
organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic
acid, pyruvic acid, oxalic acid, malic acid, maleic acid, maloneic acid, succinic acid, fumaric
acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic
acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid,
ethanesulfonic acid, p-toluenesulfonic acid, and salicyclic acid.
The term “pharmaceutically acceptable base addition salt” denotes those pharrnaceutically
acceptable salts formed with an organic or inorganic base. Examples of acceptable inorganic
bases include , ium, ammonium, calcium, magnesium, iron, zinc, copper,
manganese, and aluminum salts. Salts derived from pharmaceutically acceptable c
nontoxic bases includes salts of primary, secondary, and tertiary , substituted amines
including naturally occurring substituted amines, cyclic amines and basic ion exchange resins,
such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine,
ethanolamine, 2-diethy1aminoethanol, trimethamine, ohexylamine, lysine, arginine,
histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine,
methylglucamine, theobromine, purines, piperizine, piperidine, N—ethylpiperidine, and polyamine
resins.
The term “A pharmaceutically active metabolite” denotes a pharmacologically active
product produced through metabolism in the body of a specified compound or salt thereof. After
entry into the body, most drugs are substrates for chemical reactions that may change their
physical properties and biologic s. These metabolic conversions, which usually affect the
polarity of the compounds of the invention, alter the way in which drugs are distributed in and
excreted from the body. However, in some cases, metabolism of a drug is required for
eutic effect.
The term “therapeutically effective amount” denotes an amount of a compound or
molecule of the t invention that, when administered to a subject, (i) treats or prevents the
particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more
symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of
one or more symptoms of the particular disease, condition or disorder described . The
therapeutically effective amount will vary depending on the compound, the disease state being
d, the severity of the e treated, the age and relative health of the subject, the route and
form of administration, the judgement of the attending medical or veterinary practitioner, and
other factors.
The term “pharmaceutical composition” denotes a mixture or on comprising a
therapeutically effective amount of an active pharmaceutical ingredient together with
pharmaceutically acceptable ents to be administered to a mammal, e.g., a human in need
ANTAGONIST OF TLR7 AND/OR TLRS AND/OR TLR9
The present invention relates to (i) a compound of formula (I),
N R
(R n R4
(R )m (I),
wherein
R7 R7 R7 R7
8 8 8
N R N R N R
\ / \
/ N\ / N/\IR9
R1 is
7 9 9 7
R7 R7 R7 R7
N N N N
/ N/ / N/
\ \> \> \>
\ \ \ \N s 0
, , ; wherein R7 is C1_6alkyl,
C1_6alkoxy, haloC1-6alkyl, halogen, nitro or cyano; R8 is H or ium; R9 is H, deuterium
or kyl; R10 is H or halogen;
R2 is H or C1_6alkyl;
R3 is H;
R4 is H;
R5 is H, piperazinyl, halogen, C1_6alky1, halopyrrolidinylamino or hydroxypyrrolidinle-
6alkylamino;
R6 is H;
(C1-6alkyl)2amin0C1.6alkoxy;
(C 1 -6alkyl)2aminoC 1 -6alkylamino;
1,2,3,4,6,6a-hexahydropyrrolo[3,4-c]pyrroly1 substituted by C1_(,alkoxy;
1,4-diazepanyl substituted by one or two substituents independently ed from hydroxy
and C1_6alkyl;
1,4-oxazepanyl substituted by amino;
1,4-oxazepanylamino;
1,6-diazaspir0[3.3]heptanyl;
2,5—diazabicyclo[2.2.1]heptanylcarbonyl;
2,6-diazaspiro[3.3]heptany1 tituted or substituted by CMalkyl;
2-oxaazaspiro[3.4]octany1 substituted by amino;
3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3 ,4—b][1,4]oxazinyl;
3,4a,5,6,7,7a~hexahydro-2H-pyrrolo[3 ,4-b] [1 ,4]oxaziny1;
3,8-diazabicyclo[3.2.1]octanylcarbony1;
3-oxa-7,9-diazabicyclo[3.3.1]nonany1;
3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl;
-oxa~2,8—diazaspiro[3.5]nonanyl;
9-0xa—3 ,7-diazabicyclo[3.3.1]nonany1;
amino(C1-6alky1)piperidinylcarbonyl;
azetidinyl unsubstituted or substituted by one or two substituents independently selected
from amino and C1_6alkyl;
azetidinylamino;
inyloxy;
C1.6a1koxypiperidinylamino;
C] -6alkoxypyrrolidinyl(C1-6alky1)amino;
C1-6alkoxypyrrolidinylamino;
haloazetidinyl(C1-6alkyl)amino;
halopyrrolidinylamino;
halopyrrolidinle1-6alkoxy;
halopyrrolidinleMalkylamino;
halopyrrolidinyloxy;
hydroxypyrrolidinle1-6alkylamino;
morpholinylcl-6alkylamino;
piperazinyl unsubstituted or substituted by C1.6alkoxyC1-6alkyl, hydroxyC1_6alkyl or C1-
6alky1;
zinylcarbonyl;
piperidinyl tituted or tuted by one or two tuents independently selected
from amino, Cmalkoxy and C1-6alkyl;
piperidinylamino; or
pyrrolidinyl substituted by one, two or three substituents independently selected from
amino, C1_6alkoxy, C]_6a1kyl, C1_6alkylamin0, halogen, hydroxy and hydroxyC1_6alkyl;
m is 0,1, 2, or 3;
nis 1,2,3 or4;
m+nS4;
with the proviso that R5 and R6 are not H simultaneously;
or a pharmaceutically acceptable salt thereof.
Another embodiment of present invention is (ii) a compound of formula (Ia),
(121)’
wherein
R7 R7 R7
N R8 N R8 N
j: N
\ / N/\ \>
/ N/ R9 \ \ S
R1 is or
, , ; wherein R7
is C1-6alkyl, haloC._6alkyl, halogen or cyano; R8 is H or deuterium; R9 is H or deuterium;
R10 is H or halogen;
R2 is H or C;.6alkyl;
R3 is H;
R4 is H;
R5 is H, piperazinyl, rrolidinylamino or hydroxypyrrolidinle1.6alkylamino;
R6 is H;
(C1-6alkyl)2aminoC1-6alkoxy;
(C1-6alkyl)2aminoC1-6alkylamino;
1,2,3,4,6,6a-hexahydropyrrolo[3,4-c]pyrrolyl substituted by koxy;
1,4-diazepanyl substituted by one or two tuents independently selected from hydroxy
and kyl;
1,4-oxazepanyl substituted by amino;
1,4-oxazepanylamino;
1,6-diazaspiro[3 .3]heptanyl;
2,5-diazabicyclo[2.2.1]heptany1carbonyl;
2,6—diazaspiro[3.3]heptanyl unsubstituted or substituted by C1_6alkyl;
2-oxa—7—azaspiro[3.4]octany1 substituted by amino;
3,4,4a,5,7,7a-hexahydro-2H—pyrrolo[3 ,4-b] [l ,4]oxaziny1;
3,4a,5,6,7,7a-hexahydro~2H—pyrrolo[3 ,4-b][1,4]oxazinyl;
3,8—diazabicyclo[3 .2. 1 ylcarbony1;
3—oxa—7,9—diazabicyclo[3.3. 1]nonany1;
3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyraziny1;
S-oxa—2,8-diazaspiro[3.5]nonanyl;
9-oxa-3 ,7-diazabicyclo[3 .3 . l ]nonanyl;
amino(C1-6alkyl)piperidinylcarbonyl;
azetidinyl unsubstituted or substituted by one or two substituents independently selected
from amino and C1.6alkyl;
azetidinylamino;
1 5 azetidinyloxy;
koxypiperidinylamino;
C1-6alkoxypyrrolidinyl(C1-6alky1)amino;
C1-6alkoxypyrrolidiny1amino;
haloazetidinyl(CMalkyDamino;
halopyrrolidinylamino;
halopyrrolidinle1-6alkoxy;
halopyrrolidinle]-6alkylamino;
halopyrrolidinyloxy;
hydroxypyrrolidinle1-6alkylamino;
morpholinle1-6alkylamino;
piperazinyl unsubstituted or substituted by C1.6alkoxyC1.6a1kyl, yC1.6alkyl or C1-
6alkyl;
piperazinylcarbonyl;
piperidinyl tituted or substituted by one or two tuents independently ed
from amino, C1_6alkoxy and C1_6a1kyl;
piperidinylamino; or
idinyl substituted by one, two or three substituents independently selected from
amino, CMalkoxy, Cmalkyl, C1_6a1kylamino, halogen, hydroxy and hydroxyC1_6alkyl;
or a pharmaceutically acceptable salt thereof.
Another embodiment of present invention is (iii) a compound of a (1b),
(lb),
R7 R7 R7
a 8
N R N R N
\ / /N
\ \>
/ N/IR9 \ \ S
Rlis or
, , ; wherein R?
is C1-6alkyl, haloCl-6alkyl, halogen or cyano; R8 is H or deuterium; R9 is H or deuterium;
R10 is H or halogen;
R2 is H or C1.6alky1;
R3 is H;
R4 is H;
R5 is H, piperazinyl, halopyrrolidinylamino or hydroxypyrrolidinle 1-6alkylamino;
R6 is H;
1ky1)2aminoC1-6alkoxy;
(C1_6alkyl)2aminoC1.6alkylamino;
1,2,3,4,6,6a-hexahydropyrrolo[3,4-c]pyrroly1 substituted by Cliéalkoxy;
1,4-diazepany1 substituted by one or two substituents independently selected from y
and C1_6alky1;
1,4-oxazepanyl substituted by amino;
1 ,4-oxazepanylamino;
1,6-diazaspiro[3 .3 ]heptanyl;
2,5-diazabicyclo[2.2.1]heptanylcarbonyl;
2,6-diazaspiro[3.3]heptany1 unsubstituted or substituted by C1-6alkyl;
2-oxaazaspiro[3.4]octanyl substituted by amino;
3,4,4a,5,7,7a-hexahydro—2H-pyrrolo[3,4-b][1,4]oxazinyl;
3,4a,5,6,7,7a—hexahydro—2H-pyrrolo[3,4—b] [l ,4]oxazinyl;
3,8—diazabicyclo[3.2.1]octanylcarbonyl;
7,9-diazabicyclo[3 .3 . l ]nonany1;
3-oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5—a]pyrazinyl;
5—oxa—2,8-diazaspir0[3.5]nonanyl;
9-oxa-3,7-diazabicyclo[3 .3. l yl;
amino(C] 1)piperidinylcarbonyl;
azetidinyl unsubstituted or substituted by one or two substituents ndently selected
from amino and C1-6alky1;
azetidinylamino;
azetidinyloxy;
C1-6alkoxypiperidinylamino;
C1-6alkoxypyrrolidinyl(C1.6a1kyl)amino;
C1-6alkoxypyrrolidinylamino;
haloazetidinyl(C1.6alkyl)amino;
halopyrrolidinylamino;
halopyrrolidinleMalkoxy;
rrolidinle 1 -6alkylamino;
halopyrrolidinyloxy;
hydroxypyrrolidiny1C1.6alkylamino;
morpholinle1 -6alkylamino;
piperazinyl unsubstituted or substituted by C1-6a1koxyC1-6alkyl, liydroxyC1-6alkyl or C]-
éalkyl;
piperazinylcarbonyl;
piperidinyl unsubstituted or tuted by one or two substituents independently selected
from amino, C1.6alkoxy and C1.6alkyl;
piperidinylamino; or
pyrrolidinyl substituted by one, two or three substituents independently selected from
amino, C1_6alk0xy, C1_6alkyl, ky1amino, halogen, hydroxy and hydroxyCMalkyl;
or a pharmaceutically acceptable salt thereof.
A fiirther embodiment of present invention is (iv) a compound of formula (I) or (Ia) or (Ib)
according to any one of (i) to (iii), or a pharmaceutically acceptable salt thereof, wherein R6 is H;
(C1_6alkoxyC1-6alky1)piperazinyl; (C1.6alkyl)2aminoC1.6alk0xy; lkyl)2aminoC 1 -6alkylamino;
(hydroxyC1-6alkyl)piperazinyl; 1,4-oxazepanylamino; l,6-diazaspiro[3.3]heptany1; 2,5-
diazabicyclo[2.2.1]heptanylcarbonyl; 2,6-diazaspiro[3.3]heptany1; 3,4,4a,5,7,7a—hexahydro-2H-
pyrrolo[3 ,4-b] [ l zinyl; 3,4a,5,6,7,7a-hexahydro—2H-pyrrolo[3,4-b][1,4]oxazinyl; 3 ,8-
diazabicyclo[3.2. l ]octanylcarbonyl; 7,9-diazabicyclo[3.3.1]nonanyl; 3-0xo-l ,5,6,7,8,8a—
droimidazo[ l ,5-a]pyrazinyl; 2,8-diazaspiro[3 .5]nonanyl; 9-oxa-3,7-
diazabicyclo[3.3 . l ]nonanyl; amino(C1-6alkoxy)piperidinyl; amino(C1-6alkoxy)pyrrolidinyl;
amino(C1-6alkyl)azetidinyl; amino(C1-6alkyl)piperidinyl; amino(C1-6alkyl)piperidiny1carbonyl;
amino(C1-6alkyl)pyrrolidinyl; amino(hydroxy)(C1-6alkyl)pyrrolidinyl;
amino(hydroxy)pyrrolidiny1; amino(hydroxyC1-6alkyl)pyrrolidinyl; 1,4-oxazepanyl;
amino-2—oxa—7-azaspiro[3.4]octany1; aminoazetidinyl; alopyrrolidinyl; aminopyrrolidinyl;
azetidinyl; azetidinylamino; azetidinyloxy; C1-6alkoxy(C1-6alkylamino)pyrrolidinyl; C1_6alkoxy-
l,2,3,4,6,6a—hexahydropyrrolo[3,4-c]pyrrolyl; C1-6alkoxypiperidinylamino; C1-
6a1koxypyrrolidiny1(C1-6alkyl)amino; C1-6alkoxypyrrolidinylamino; C1_6alkyl-2,6-
diazaspiro[3.3]heptanyl; C1_6alkylpiperazinyl; haloazetidinyl(C1-6alkyl)amino;
halopyrrolidinylamino; halopyrrolidinle1-6alkoxy; halopyrrolidinle1-6alkylamino;
halopyrrolidinyloxy; y(C 1 -6a1kyl)-1 ,4-diazepanyl; hydroxy(C1-6alkylamino)pyrrolidinyl;
hydroxy- l ,4-diazepanyl; hydroxypyrrolidinle1-6alkylamino; morpholinle1-6alkylamino;
piperazinyl; piperazinylcarbonyl; dinyl or piperidinylamino.
A further embodiment of present invention is (v) a compound of formula (I) or (la) or (lb)
according to any one of (i) to (iv), or a pharmaceutically acceptable salt thereof, wherein R6 is H;
(hydroxymethyl)piperaziny1; 1,4-oxazepanylamino; l,6-diazaspiro[3.3]heptan-6—yl; 2-
hylamino)ethoxy; 2-(dimethylamino)ethylamino; 2,5-diazabicyclo[2.2. 1 ]heptanyl
carbonyl; 2,6-diazaspiro[3.3]heptanyl; 2—morpholinylethylamino; 3-
(methoxymethyl)piperazin- l -yl; 3 ,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3 ,4—b] [ l ,4]oxazinyl;
3,4a,5,6,7,7a-hexahydro—2H-pyrrolo[3,4-b][l,4]oxazinyl; 3,8—diazabicyclo[3 .2. l]octanyl—3—
carbonyl; 3a-methoxy-l,2,3,4,6,6a—hexahydropyrrolo[3,4-c]pyrrolyl; 3-amino—3-
(hydroxymethyl)pyrrolidin-1—yl; omethyl-azetidin—l -yl; 3-a1ninomethy1-pyrrolidin—
l—yl; 3-amin0fluoro-pyrrolidin-1 -yl; 3-amino—4-hydroxy-pyrrolidinyl; 3-aminomethoxy-
1-piperidinyl; 3-amino1nethoxy-pyrrolidinyl; 3-aminoazetidin-l-yl; 3-aminopyrrolidin-l-yl;
3 -fluoroazetidinylmethylamino; 3-hydroxy—4—(methylamino)pyrrolidin-1 —y1; 3-
hydroxypyrrolidin-l -ylethy1amino; 3-methoxy—4-(methy1amino)pyrrolidin—l-yl; 3—methoxy
piperidinylamino; 3 -1nethylpiperazin- l —yl; 3-0xa—7,9~diazabicyclo[3 .3. l ]nonanyl; 3—oxo-
1,5,6,7,8,8a-hexahydroimidazo[ 1 yrazinyl; 3 -piperidiny1amino; 4—aminohydroxy
methyl—pyrrolidin- l -yl; 4-a1ninomethoxy—1-piperidinyl; 4-amino1nethyl-1—piperidinyl; 4—
aminomethyl—piperidinyl—l-carbonyl; 4-fluoropyrrolidinylmethoxy; 4-fluoropyrrolidin
ylmethylamino; 4-fluoropyrrolidinylamino; 4-fluoropyrrolidinyloxy; 4-methoxypyrrolidin-
3-yl(methyl)amino; 4-methoxypyrrolidinylamino; 5-aminooxaazaspiro[3.4]octanyl;
-oxa—2,8-diazaspiro[3.5]nonan—2~yl; 5—oxa-2,8—diazaspiro[3.5]nonan~8—yl; 6-amino-1,4-
oxazepanyl; 6-hydroxy—l,4-diazepan-l-yl; oxy—6-methyl-l ,4-diazepan-l-yl; 6—methyl—
2,6—diazaspiro[3.3]heptanyl; 9—oxa-3,7—diazabicyclo[3.3.l]n0nanyl; azetidin-3~yl; azetidin-
3-ylamino; azetidinyloxy; hydroxy—l ,4—diazepan- l -yl; morpholin-Z-ylmethylamino;
liny1methylamino; piperazin-l -yl; piperazinyl- l -carbonyl or piperidinyl.
A further ment of present invention is (vi) a nd of formula (I) or (Ia) or (lb)
according to any one of (i) to (v), or a pharmaceutically acceptable salt thereof, wherein R1
R7 R7
N\ R8
/ N/N
/ \ \
.
IS or ; wherein R7 is cyano; R8 is H or deuterium; R[0 is H or
halogen.
A further embodiment of present invention is (vii) a compound of formula (I) or (la) or (lb)
ing to any one of (i) to (vi), or a phannaceutically acceptable salt thereof, wherein R1
R7 R7
N R
\ / N/
/ \ \
R10 . , . . .
. 8
IS 01‘ ; whereln R7 15 cyano; R is H or deuterium; R10 IS H or
fluoro.
A r embodiment of present invention is (viii) a compound of formula (I) or (Ia) or
(1b) according to any one of (i) to (vii), or a pharmaceutically acceptable salt thereof, wherein R2
is C1_6alkyl and R5 is H.
A r embodiment of present invention is (ix) a compound of formula (1) or (la) or (lb)
according to (ii) or (iii), or a pharmaceutically acceptable salt f, wherein
R6 is (C1_6alkyl)2aminoC1-6alkylamino;
l,4—diazepanyl substituted by hydroxy;
1,4-oxazepanyl substituted by amino;
3,4,4a,5,7,7a-hexahydro—2H-pyrrolo[3,4—b] [l ,4]oxazinyl;
5-oxa-2,8-diazaspiro[3.5]nonanyl;
9-0xa-3 ,7-diazabicyclo[3 .3. l ]nonanyl;
azetidinyl substituted twice by amino and C1_6alkyl;
C1-6alkoxypyrrolidiny1amino;
halopyrrolidinylamino; or
pyrrolidinyl substituted by two or three substituents independently selected from amino,
C1-6alkoxy, C1_6all<yl and hydroxy.
A further ment of present ion is (x) a compound of formula (I) or (la) or (lb)
according to any one of (i) to (ix), or a pharmaceutically acceptable salt thereof, wherein R6 is
(C1-6alky1)2aminoC1-6alkylamino; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 5-
8-diazaspiro[3.5]nonanyl; 3,7-diazabicyclo[3.3. l ]nonanyl; C1-
6alkoxy)pyrrolidinyl; amino(C]-6alkyl)azetidiny1; amino(C1-6alkyl)pyrrolidinyl;
amino(hydroxy)(C1-6alky1)pyrrolidinyl; amino(hydroxy)pyrrolidinyl; amino—1 ,4-oxazepanyl; C]-
6alkoxypyrrolidinylamino; halopyrrolidinylamino or hydroxy-1,4-diazepanyl.
A further embodiment of present invention is (xi) a compound of formula (I) or (la) or (lb)
according to any one of (i) to (x), or a pharmaceutically acceptable salt thereof, wherein R6 is 2-
(dimethylamino)ethylamino; 3 ,4,4a,5,7,7a—hexahydro-2H-pyrrolo[3,4~b] [ l ,4]oxazinyl; 3 -
aminomethyl—azetidinyl; o—3—methyl-pyrrolidinyl; 3-aminohydroxy-
pyrrolidin- 1 ~yl; 3—aminomethoxy—pyrrolidinyl; o—3—hydroxy-3 l-pyrrolidin-1 -
yl; 4-fluoropyrrolidin-3—ylamino; 4-methoxypyrrolidiny1amino; 5-oxa-2,8-
diazaspiro[3.5]nonan-2—yl; 5-oxa-2,8—diazaspiro[3.5]nonan—8—yl; 6~amino-1,4-oxazepanyl; 9-
oxa-3 ,7-diazabicyclo[3 .3 . l ]nonan-3 -y1 or hydroxy-I ,4—diazepan— 1 -y1.
A further embodiment of present ion is (xii) a compound of formula (I) or (la) or (Ib)
according to any one of (i) to (xi), or a pharrnaceutically acceptable salt thereof, wherein
R7 R7
N\ R8
/ N’N
/ \ \
R1 is or ; wherein R7 is cyano; R8 is H or deuterium; R10 is H
or halogen;
R2 is C1-6alkyl;
R3 is H;
R4 is H;
R5 is H;
R6 is (C1.6alkyl)2aminoC1.6alkylamino;
1,4-diazepanyl substituted by hydroxy;
WO 33941
1,4-oxazepanyl substituted by amino;
3,4,4a,5,7,7a—hexahydro-2H-pyrrolo[3 ,4—b] [l ,4]oxaziny1;
—0xa-2,8—diazaspiro[3.5]nonanyl;
9-oxa-3 ,7-diazabicyclo[3 .3. l ]nonanyl;
azetidinyl substituted twice by amino and C1_(,alkyl;
C1-6alkoxypyrrolidinylamino;
halopyrrolidinylamino; or
pyrrolidinyl substituted by two or three substituents independently selected from amino,
C 1 -6alkoxy, C 1 .6alkyl and hydroxy;
or a pharmaceutically acceptable salt f.
A further embodiment of present invention is (xiii) a compound of formula (I) or (Ia) or
(Ib) according to any one of (i) to (xii), or a pharmaceutically acceptable salt f, wherein
R7 R7
N R
\ / N/
/ \ \
R1 is or ; wherein R7 is cyano; R8 is H or deuterium; R10 is H
or halogen;
R2 is C1_6a1kyl;
R3 is H;
R4 is H;
R5 is H;
R6 is (C1_6alkyl)2aminoC1-6alkylamino; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][l ,4]oxazinyl;
5-oxa-2,8—diazaspiro[3.5]nonany1; 9—oxa-3,7—diazabicyclo[3 .3. l ]nonanyl; amino(C1_
6alkoxy)pyrrolidinyl; amino(C1-6a1kyl)azetidinyl; a1nino(C1.6alky1)pyrrolidinyl;
hydroxy)(C1-6alkyl)pyrrolidiny1; hydroxy)pyrrolidinyl; amino-l ,4-
oxazepanyl; koxypyrrolidinylamino; halopyrrolidinylamino or hydroxy-l ,4-
diazepanyl;
or a pharmaceutically acceptable salt f.
A further embodiment of present invention is (xiv) a compound of formula (I) or (Ia) or (Ib)
according to any one of (i) to (xiii), or a pharmaceutically acceptable salt thereof, wherein
-1 g-
R7 R7
N\ R8
/ /N
/ \ \
R1 is or ; wherein R7 is cyano; R8 is H or deuterium; R10 is H
or fluoro;
R2 is methyl;
R3 is H;
R4 is H;
R5 is H;
R6 is 2-(dimethylamino)ethylamino; 3,4,4a,5,7,7a-hexahydro~2H-pyrrolo[3,4—b][1,4]oxazin-6—yl;
3-aminomethyl-azetidinyl; 3-aminomethyl-pyrrolidinyl; ohydroxy-
pyrrolidin- l ~yl; 3—aminomethoxy—pyrrolidinyl; 4-amin0—3—hydroxy—3 -methy1-
pyrrolidin-l-yl; 4-fluoropyrrolidinylamino; 4-methoxypyrrolidiny1amino; 5-oxa-2,8-
diazaspiro[3.5]nonan—2-yl; 5-oxa-2,8~diazaspiro[3.5]nonan-8—yl; 6-amino-1,4-oxazepan
yl; 9-oxa—3,7—diazabicyclo[3.3. l ]nonanyl or y-l ,4-diazepan-1 -y1;
or a pharmaceutically acceptable salt thereof.
The t invention relates to (i’)a compound of formula (I),
N R2
(R n R4
1 5 ( )m (I),
wherein
R7 R7 R7 R7
N N N N
\ \j / N/
\ \>
/ N/ \ \
R1 is or
, , ; wherein R7 is
cyano;
R2 is C1_Galky1;
R3 is H;
R4 is H;
R5 is H or piperazinyl;
R6 is H; (C1_6alkylamino)C1-6alkoxy; ((C]-6alkyl)2amino)Cl.6a1ky1amino; (C).
6alkoxypyrrolidinyl)amino; (halopyrrolidinyl)amino; xyC1-6alkyl)piperazinyl; 1,4-
diazepanyl substituted by hydroxy; 2-oxaazaspiro[3.4]octanyl substituted by amino; 3-
oxa-7,9-diazabicyclo[3 .3 . l ]nonanyl; 5-oxa-2,8—diazaspiro[3 .5]nonanyl; 3,7—
icyclo[3 .3 . l ]nonanyl; aminoazetidinyl; aminopyrrolidinyl; azetidinyl;
azetidinylamino; azetidinyloxy; piperazinyl; piperidinyl or pyrrolidinyl which is once or
twice substituted by substituents independently selected from amino, hydroxy, yCl-
6alkyl, C1_6alkoxy and C1_6alky1amino;
mis 0, 1, 2, or 3;
nis 1,2, 3 or4;
m+ns4;
with the proviso that R5 and R6 are not H simultaneously;
or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
Another embodiment of present invention is (ii’) a compound of formula (la),
(Ia),
wherein
R7 R7 R7 R7
N N /N N
/ N/ \ \
R] is or
, , ;wherein R7 is
cyano;
R2 is C1-6alkyl;
R3 is H;
W0 33941
R4 is H;
R5 is H or piperazinyl;
R6 is H; (C1-6alkylamin0)C1-6a1k0xy; ((C1-6alky1)2amino)C1-6alky1amino; (C1.
6alkoxypy1rolidinyl)amin0; (halopyrrolidinyl)amino; (hydroxyC 1-éalky1)piperazinyl; 1,4-
diazepanyl tuted by hydroxy; 2—oxaazaspiro[3.4]octanyl substituted by amino; 3-
oxa—7,9—diazabicyclo[3.3.1]nonanyl; 5-oxa-2,8-diazaspiro[3.5]nonany1; 9-oxa-3,7-
diazabicyclo[3 .3 .] ]nonanyl; aminoazetidinyl; aminopyrrolidinyl; azetidinyl;
azetidinylamino; azetidinyloxy; piperazinyl; piperidinyl or pyrrolidinyl which is once or
twice substituted by substituents independently ed from amino, hydroxy, hydroxyC1_
6alkyl, C1_6alkoxy and kylamino;
with the proviso that R5 and R6 are not H simultaneously;
or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
Another embodiment of present invention is (iii’) a compound of formula (Ib),
l 5 wherein
R7 R7
N N /N N
\ j / N
\ \>
/ N/ \ \
R1 is or ; wherein R7 is
cyano;
R2 is C1-6alkyl;
R3 is H;
R4 is H;
R5 is H or piperazinyl;
R6 is H; (C1.6alkylamino)C1.6alkoxy; alkyl)2amino)C1_6alkylamino; (C1-
6alkoxypyrrolidinyl)amino; (halopyrrolidinyl)amino; (hydroxyC 1.6alkyl)piperazinyl; 1,4-
diazepanyl substituted by hydroxy; 2-oxaazaspiro[3.4]octany1 substituted by amino; 3-
oxa-7,9-diazabicyclo[3.3.1]nonanyl; 5-oxa-2,8-diazaspiro[3.5]nonanyl; 9-oxa—3,7-
diazabicyclo[3.3.1]nonanyl; aminoazetidinyl; aminopyrrolidinyl; azetidinyl;
azetidinylamino; azetidinyloxy; piperazinyl; piperidinyl or pyrrolidinyl which is once or
twice substituted by tuents independently selected from amino, hydroxy, hydroxyC1_
6alkyl, C1_6alkoxy and C1_6alky1amino;
with the proviso that R5 and R6 are not H simultaneously;
or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
A further embodiment of present invention is (iv’) a compound of formula (I) or (la) or (Ib)
according to any one of (i’) to (iii’), wherein R6 is H; (C 1-6alkylamino)C1_6alkoxy; ((C1_
galkyl)2amino)C1.6alkylamino; (C1-6alkoxypyrrolidiny1)amino; (halopyrrolidinyl)amino;
(hydroxyC1-6alkyl)piperaziny1; 1,4-diazepany1 substituted by hydroxy; 2-oxa
azaspiro[3.4]octanyl substituted by amino; 3-oxa-7,9-diazabicyclo[3.3.1]nonanyl; 5—oxa-2,8-
diazaspiro[3 any1; 3 ,7-diazabicyclo[3 .3. 1 ]nonanyl; amino(C1-6alkoxy)pyrrolidinyl;
amino(hydroxy)pyrrolidinyl; amino(hydroxyC1.6a1kyl)pyrrolidinyl; aminoazetidinyl;
aminopyrrolidinyl; azetidinyl; azetidinylamino; inyloxy; C1_6alkoxy(C1_
6alkylamino)pyrrolidiny1; piperazinyl or piperidinyl.
A fithher embodiment of present ion is (v’) a nd of formula (I) or (Ia) or (lb)
according to any one of (i’) to (iv’), wherein R6 is alkyl)2amino)C1.6alkylamino; (C1-
6alkoxypyrrolidinyl)amino; (halopyrrolidinyl)amino; 1,4-diazepanyl substituted by hydroxy; 5-
oxa—2,8—diazaspiro[3 .5]nonanyl; 9-oxa-3,7-diazabicyclo[3.3. l yl or amino(C1_
6alkoxy)pyrrolidiny1.
A further embodiment of present invention is (vi’) a compound of formula (I) or (1a) or (lb)
ing to any one of (i’) to (iv’), wherein R6 is 9-0xa—3,7-diazabicyclo[3.3.l]nonanyl;
xypyrrolidinyl)amino; hydroxy—l ,4-diazepanyl; 2,8—diazaspiro[3 .5]nonanyl;
(dimethylamino)ethylamino; (fluoropyrrolidinyl)amino or amino(methoxy)pyrrolidinyl.
A further embodiment of present invention is (vii’) a compound of formula (I) or (la) or (Ib)
according to any one of (i’) to (vi’), wherein R1 is ; wherein R7 is cyano.
A further ment of present invention is (viii’) a compound of formula (I) or (Ia) or
(lb) according to any one of (i’) to (vii’), wherein R5 is H.
A further embodiment of present invention is (ix’) a compound of formula (I) or (la) or (Ib)
according to (ii’) or (iii’), wherein
R1 is ; wherein R7 is cyano;
R2 is C]_6alkyl;
R3 is H;
R4 is H;
R5 is H;
R6 is ((C1.6alkyl)2amino)C1-6alkylamino; (C1-6alkoxypyrrolidinyl)amino; (halopyrrolidinyl)amino;
azepanyl substituted by hydroxy; 5-oxa-2,8-diazaspiro[3.5]nonanyl; 9-oxa-3,7-
diazabicyclo[3 .3. ny1 or C1-6alkoxy)pyrrolidinyl;
or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
A further embodiment of present invention is (X’) a compound of formula (I) or (Ia) or (lb)
according to any one of (i’) to (ix’), wherein
R1 is ; wherein R7 is cyano;
R2 is methyl;
R3 is H;
R4 is H;
R5 is H;
R6 is 9-oxa-3,7—diazabicyclo[3.3.1]nonanyl; xypyrrolidiny1)amino; hydroxy-1,4-
diazepanyl; 5-oxa-2,8~diazaspiro[3.5]nonanyl; hylamino)ethylamino;
(fluoropyrrolidinyl)amino or amino(methoxy)pyrrolidinyl;
or a pharmaceutically able salt, enantiomer or diastereomer thereof.
Another embodiment of present invention is that (XV) compounds of formula (I) or (la) or
(lb) are selected from the following:
-23 _
-[(4R,10bS)—4-methy1piperazin—1-y1-3 ,4,6, 1 Ob-tetrahydro— 1 H-pyrazin0[2, 1 ind01—
2-y1]quinolinecarbonitrile;
—[(4S, 1 ObR)-4—methy1—8-piperazin—1 —y1~3 ,4,6,1Ob—tetrahydro—1H—pyrazin0[2,1~a]isoindol-
2-y1]quinolinecarbonitrile;
-(8—piperazin-1—y1—3,4,6,10b—tetrahydr0-1H—pyrazin0[2,1-a]isoi11d01—2-y1)quinoline—8—
carbonitrile;
7—(8—piperaziny1-3,4,6,1Ob-tetrahydro-1H—pyrazino[2,1-a]isoind01—2-y1)—1,3—
benzothiazolecarbonitrile;
4-[(4R,10bS)-4~methy1-8—piperaziny1-3,4,6,10b-tetrahydro-1H~pyrazino[2,1-a]isoindol-
2—y1]pyrazolo[1,5-a]pyridine-7—carbonitrile;
7~[(4R,1 0bS)-4—methy1~8-piperazin~1-y1-3,4,6,10b-tetrahydro-1H—pyrazino[2,1—a]isoindol—
2-y1]—1,3-benzothiazolecarbonitrile;
8-[(4R,10bS)methy1-8—piperazin—1—y1—3,4,6,10b-tetrahydro-1H—pyrazin0[2,1 —a]isoind01-
2-y1]quinoxaline-S-carb0nitrile;
5-[(4R,10bS)—4-methy1~7~piperazin-1—y1-3,4,6,lob—tetrahydro—lH-pyrazino[2,1~a]is0indol-
2-y1]quinolinecarb0nitrile;
-[(4R,10bS)-4—methy1—8-(4-piperidy1)-3,4,6,10b-tetrahydro—1H—pyrazino[2,1~a]isoindol
yl]quin01inecarbonitrile;
- [(4R, 10195')—8~[(2R)(hydroxy1nethy1)pipcraziny1]methy1—3,4,6,1Ob—tetrahydro-
azin0[2,1-a]isoindoly1]quinolinecarb0nitrile;
—[(4R,10bS)—8~[(2S)(hydroxymethyl)piperaziny1]-4—methy1—3 ,4,6,10b-tetrahydr0~
1H—pyrazino[2,1-a]isoindol-Z-yl]quinolinecarb0nitrile;
,10bS)[(3S)—3 —(hydroxymethy1)piperazinyl]methy1-3 ,4,6,10b-tetrahydr0-
1H—pyrazino[2,1-a]isoindol-2—y]]quinolinecarbonitrile;
5-[(4R,10bS)methy1—8-(3-oxa—7,9-diazabicyclo[3.3.1]n0nan—7-y1)-3,4,6,10b—tetrahydro-
1H-pyrazin0[2,1-a]isoindol-Z-yl]quinoline-S-carbonitrile;
-[(4R,10bS)methy1~8-(9-oxa-3,7-diazabicyclo[3.3.1]n0nany1)-3,4,6,10b-tetrahydro-
1H—pyrazin0[2,1—a]isoindol-Z-y1]quinoline-8~carbonitrile;
-[(4R,10bS)-8—(6-hydr0xy-1,4-diazepan—1-y1)—4-1nethy1-3 ,4,6,10b-tetrahydro-1H-
pyrazino[2, 1 -a]isoindol-2—y1]quin01inecarbonitrile;
-[(4R,10bS)—8—[transaminometh0xy—pyrrolidin—1-y1]methy1—3,4,6,1 rahydro-
1H—pyrazin0[2,1-a]isoindol-Z-yl]quinolinecarb0nitrile;
-[(4R,10bS)~8—[(3S,4S)amin0methoxy-pyrr01idin-1—y1]—4—methy1—3 ,4,6,10b—
ydro-1H-pyrazino[2, 1 -a]isoind01—2—y1]quinoline-S—carbonitrile;
-[(4R,10bS)-8—[(3R,4R)aminomethoxy—pyrrolidiny1]—4~methyl-3,4,6,10b—
tetrahydro-lH-pyrazino[2,1-a]is0indoly1]quinoline—8-carbonitrile;
-[(4R,10bS)—8—[cisamino-4—methoxy—pyrrolidiny1]—4-methy1—3,4,6,10b-tetrahydro-
1H—pyrazino[2,1 -a]isoind01y]]quinoline-S—carbonitrile;
—[(4R,101353—8—(5—amin00xa—7—azaspiro[3.4]octan—7-yl)—4~methy1-3,4,6, 10b—tetrahydro-
1H-pyrazino[2, 1 -a]isoind01y1]quinolinecarbonitrile;
-[(4R,10bS)-8—[3-amino—3~(hydroxymethyl)pyrr01idiny1]methy1-3,4,6,1 Ob-
tetrahydro- 1 H—pyrazino[2, 1 -a]isoindoly1] quinolinecarbonitrile;
-[(4R,10bS)—8-[(3R)—3 pyrrolidiny1]-4—methy1—3 ,4,6,10b—tetrahydro-1H—
pyrazino[2,1-a]isoindol-Z-yl]quinoline—8-carbonitrile;
-[(4R,1 019$)[trans—3—aminohydr0xy-pyrrolidin—1—y1]~4~methy1-3,4,6,1Ob-tetrahydro~
1H-pyrazino[2,1-a]is0ind01y1]quinolinecarbonitrile;
-[(4R,10bS)—8—(3 -aminoazetidiny1)—4-methy1-3,4,6,10b-tetrahydro-1.H-pyrazin0[2,1—
ndol-Z-yl]quinolinecarbonitrile;
5—[(4R, 1 ObS)—8—[(3S,4S)meth0xy(methy1amin0)pyrrolidin- 1 —y1]—4-methy1-3,4,6, 1 0b-
tetrahydro-1H—pyrazino[2,] -a]isoindo1—2-yl]quinoline-S—carbonitrile;
-[(4R,10bS)—4—methy1(5-oxa—2,8—diazaspir0[3.5]n0nanyl)-3,4,6,1Ob-tetrahydro-lH-
pyrazino[2,1-a]isoindoly1]quinolinecarbonitrile;
-[(4R,10bS)[2-(dimethy1amin0)eth0xy]methy1—3,4,6,1 Ob—tetrahydro— 1H—
pyrazino [2, 1 -a]isoind01y1] inecarbonitrile;
-[(4R, 1 ObS)[2—(dimethylamin0)ethylamino]—4—methy1—3,4,6,10b-tetrahydr0-1H—
pyrazino[2,1-a]is0ind01y1]quinoline-S-carbonitrile;
-[(4R,10bS)-8—(azetidin~3—y10xy)—4-methy1-3,4,6,1Ob-tetrahydro-1H-pyrazin0[2,1-
a]isoind01—2-y1]quinoline—8-carb0nitrile;
5-[(4R,10bS)-8—(azetidin-3—y1amino)methy1-3 0b-tetrahydro-1H—pyrazino[2, 1—
a]isoindoly1]quinoline—S-carbonitrile;
-[(4R, 1 0bS)—8—(azetidin~3 -y1)methy1—3 ,4,6,10b-tetrahydro-1H-pyrazin0[2,1-a]isoind01-
2-y1]quino1inecarbonitrile;
,10b53—8-[[(3S,4R)—4—flu0ropyrrolidin—3~y1]arnin0]methy1-3,4,6,1Ob-tetrahydro-
1H-pyrazino[2,1 -a]isoind01y1]quinoline-S-carbonitrile;
-[(4R,10bS)~8-[[(3S,4S)fluor0pyrr01idiny1]amino]—4-methy1-3 ,4,6,1 Ob-tetrahydro-
1H—pyrazin0[2,1-a]isoind01—2—y1]quinolinecarb0nitrile;
,1ObS)—8—[[(3R,4S)flu0ropyrrolidiny1]amin0]methy1-3 ,4,6,1 Ob-tetrahydro-
1H—pyrazin0[2,1-a]isoindol-Z—yl]quinoline-8—carbonitrile;
-[(4R,1 0b5)—8~[[(3R,4R)fluoropyrrolidiny1]amino]-4—methy1—3,4,6,10b-tetrahydro-
1H—pyrazino[2, 1 -a]isoindoly1]quinoline-8—carbonitrile;
—[(4R,10bS)—8—[[(3R,4R)-4~meth0xypyrrolidin—3-y1]amino]—4-methy1—3,4,6,10b-
tetrahydro-1H—pyrazino[2,1-a]isoindoly1]quinoline—S-carbonitrile;
-[(4R,10bS)—4-methy1~8—(5—0xa-2,8—diazaspiro[3.5]n0nany1)—3,4,6,10b—tetrahydro-1H—
pyrazino[2,1—a]isoind01y1]quinoline—8-carbonitrile;
,10bS)—8-(2,6-diazaspir0[3.3]heptan~2-y1)—4-methy1—3,4,6,1Ob-tetrahydro-IH-
pyrazino[2,1—a]isoind01y1]quinolinecarbonitrile;
-[(4R,10bS)-8~(1,6-diazaspiro[3.3]heptany1)-4—methyl-3,4,6,10b-tetrahydro-IH-
pyrazin0[2,1-a]isoindoly1]quinolinecarbonitrile;
—[(4R,10bS)methy1~8—(6-methy1-2,6-diazaspiro[3.3]heptan~2-y1)-3,4,6,IOb-tetrahydro-
1H—pyrazino[2,1-a]isoindoly1]quinolinecarbonitrile;
-[(4R,10bS)(3 -amino—3~methy1-azetidiny1)methy1-3,4,6,10b-tetrahydro—1H~
pyrazino[2,1-a]isoindol-Z-yl]quinolinecarb0nitrile;
5-[(4R,10bS)—8-[(3S,4S)-3—aminohydroxy-pyrr01idiny1]—4-methy1-3,4,6,10b-
tetrahydro-1H—pyrazino[2,l -a]isoindol-Z-y1]quinolinecarbonitrile;
,10bS)-8—[(3R,4R)amino—4-hydr0xy—pyrr01idin—1—y1]methy1-3 ,4,6,1 0b-
tetrahydro-lH-pyrazino[2,1-a]isoindol-Z-y1]quin01inecarbonitrile;
-[(4R,10bS)(3a-methoxy—1,2,3,4,6,6a-hexahydr0pyrrolo[3 ,4—c]pyrroly1)methyl-
3,4,6,10b-tetrahydro-1H-pyrazino[2,1—a]isoindol-Z-yl]quinoline-S-carbonitrile;
-[(4R,10bS)—8-[(3S,4S)hydr0xy—4—(methy1amin0)pyrrolidiny1]-4—methy1—3,4,6, 10b-
tetrahydro-1H—pyrazino[2,1-a]isoind01-2~y1]quinolinecarbonitri1e;
-[(4R,1ObS)—4—methy1—8-[(3R,4R)hydr0xy(methylamino)pyrr01idin—1-y1]-3,4,6,10b—
tetrahydro-lH—pyrazino[2,1—a]isoindoly1]quinoline-8—carbonitrile;
,10bS)methy1~8-[(4aR,7aR)—3,4,4a,5,7,7a-hexahydr0—2H-pyrrolo[3,4—
b][1,4]0xazin—6—y1]-3,4,6,1Ob-tetrahydro-1H—pyrazin0[2,1-a]isoind01y1]quinoline-8—
itrile;
-[(4R,10bS)methy1[trans—(3R,4R)-4—aminohydroxy—3—1nethy1-pyrrolidinyl]—
3,4,6,10b-tetrahydr0-1H—pyrazino[2,1 -a]isoind01—2-y1]quinoline-S-carbonitrile;
5—[(4.R,10bS)-8—[(3R,4R)—4-amino—3-hydr0xy—3—methy1—pyrr01idin-1~y1]-4—methyl—
3,4,6,10b—tetrahydro-1H—pyrazino[2,1 -a]isoindol—Z-yl]quinoline-S-carb0nitrile;
—[(4R,10bS)—8—[(3 S,4S)-4—amino—3-hydroxy-3 —methy1-pyrr01idin— 1 -y1]methy1—
3,4,6,1Ob-tetrahydro-lH-pyrazin0[2,1-a]isoindol-Z-yl]quinoline-S-carb0nitrile;
~26-
—[(4R,10bS)-8—[(3S,4R)amino—4—fluoro-pyrrolidin-1 —y1]—4-methy1-3,4,6,10b-tetrahydr0-
1H—pyrazino[2,1-a]isoindol-Z-y1]quinoline—S-carbonitfile;
-[(4R,10bS)-8—[(3R,4S)—3 ~aminofluor0-py1rolidiny1]-4~methy1-3,4,6,1Ob-tetrahydro-
1H-pyrazino[2,1-a]isoindol—Z—yl]quinolinecarb0nitrile;
-[(4R,10bS)[(3R,4R)amin0—4~fluor0-pyrr01idin-1—y1]—4-methy1-3,4,6,10b—tetrahydro-
1H—pyrazino[2, 1 -a]isoindoly1]quinolinecarb0nitrile;
-[(4R,10bS)[(3S,4S)amin0—4-fluor0-pyrrolidiny1]methy]—3,4,6,10b-tetrahydro-
1H-pyrazino[2,1-a]isoindol-Z-yl]quinolinecarbonitrile;
-[(4R,10bS)—8-[(3R)-3 -,(methoxymethy1)piperaziny1]methy1-3,4,6,1 Ob-tetrahydro—
1H—pyrazino[2,1-a]isoindol-Z—yl]quinolinecarb0nitrile;
—[(4R,10bS)—8—(4-amino-4—methy1~1-piperidy1)—4-methy1—3,4,6,10b-tetrahydro-IH-
pyrazino[2,1-a]isoindoly1]quinoline-S-carbonitrile;
-[(4R,10bS)-8—(3,4a,5,6,7,7a—hexahydr0-2H—pyrro10[3 ,4—b] [1 ziny1)~4-methy1-
3 ,4,6,10b-tetrahydro-1H—pyrazino[2,1-a]isoindol—Z-yl]quinoline—8-carb0nitrile;
5—[(4R,10bS)—8-[(65)-6—hydr0xy—1,4—diazepan—1—y1]methyl-3,4,6,1 0b-tetrahydr0~1H~
pyrazino[2, l -a]isoindoly1]quinolinecarbonitrile;
-[(4R,10bS)—8—[(6R)—6—hydr0xy—1,4—diazepany1]methy1—3,4,6,10b—tetrahydro—1H-
pyrazin0[2,1-a]isoindol-Z-yl]quinoline-S-carbonitrile;
—[(4R,10bS)-8—(6-amin0—1,4-oxazepany1)-4—methyl-3,4,6,10b-tetrahydro-IH-
pyrazin0[2,1 indol—Z-yl]quinolinecarbonitrile;
—[(4R,10bS)[(6R)amin0-1,4—0xazepan—4-y1]methy1-3,4,6,10b-tetrahydro-1H—
pyrazino[2,1-a]isoindol—2-y1]quinoline»8-carbonitrile;
—[(4R,10bS)—8-[(6S)—6-amino—1,4-oxazepan—4~y1]—4-methyl-3,4,6,10b-tetrahydro-IH-
pyrazino [2, 1 -a]isoind01—2-y1] inecarbonitrile;
5-[(4R,10bS)(6-hydr0xy—6-methy1-1,4-diazepan—1—y1)methy1-3 ,4,6,10b-tetrahydr0-
1H—pyrazino[2,1-a]isoindol—Z-yl]quinoline-8—carbonitrile;
-[(4R,10bSD[(6S)hydr0xy—6—methyl-1,4-diazepan—1—yl]methyl-3,4,6,10b~
tetrahydro-1H-pyrazin0[2, 1 -a]isoindol-2 -y1]quinolinecarbonitrile;
,10bS)-8—[(6R)~6—hydroxy-6—methy1-1,4-diazepan-1—y1]—4—methy1-3,4,6,10b-
tetrahydro-1H—pyrazin0[2,1-a]isoindol-Z-yl]quin01inecarb0nitrile;
-[(4R,10bS)methy1—8—(l ,4-0xazepan-6—y1amino)—3,4,6,1Ob-tetrahydro-1H—pyrazin0[2,1-
ndolyl]quinoline-8—carbonitrile;
-[(4R,10bS)methy1[[(6R)—1,4-oxazepany1]amin0]-3,4,6,10b-tetrahydro-1H—
pyrazino[2,1-a]isoindol-Z-yl]quinoline—S-carbonitrile;
-[(4R,1ObS)methy1[[(6S)—1,4-oxazepan-6—y1]amin0]6,4,6,1Ob-tetrahydro-IH-
pyrazino[2,1-a]isoind01—2-y1]quinoline-S-carbonitrile;
-[(4R,1 0bS)—4—methy1(m0rpholiny11nethy1amino)-3 ,4,6, 1 Ob-tetrahydro—IH—
pyrazino[2,1-a]isoindol-Z—yl]quinolinecarb0nitrile;
-[(4R,10bS)—4-methy1[[(2S)-morph01iny1]methy1amin0]-3,4,6,1Ob-tetrahydro-IH-
pyrazino[2,1—a]isoindoly1]quinoline-S-carbonitrile;
-[(4R,10bS)-4~methy1[[(2R)-m0rpholin-2—y1]methylamino]-3,4,6,10b—tetrahydr0—1H-
pyrazino[2,1-a]isoindol-Z-yl]quinoline-8—carbonitrile;
-[(4R,10bS)[[(35,4R)methoxypyrrolidin-3~yl]amino]-4—methyl-3,4,6,10b—
tetrahydro-lH—pyrazin0[2,1-a]isoindol-2—yl]quinoline-S—carbonitrile;
—[(4R,10bS)—8—[[(3R,4S)—4—meth0xypyrr01idiny1]amino]—4—methyl—3,4,6,1 Ob-
tetrahydro-1H—pyrazino[2,1 ind01—2-yl]quinolinecarbonitrile;
-[(4R,10bS)—8~[[(3S,4S)—4-methoxypyrrolidin—3 -y1] amino]methy1~3,4,6, 1 Ob—tetrahydro-
1H—pyrazin0[2,1 -a]isoindoly1]quinoline-S-carbonitrile;
,10bS)—8-[[(3R,4R)—4-methoxypyrrolidin~3 —y1]amino]—4,9-di1nethy1-3,4,6, 10b~
tetrahydro— 1H-pyrazino[2, 1 -a]isoind01y1] quinoline-S—carbonitrile;
-[(4R,10bS)-8—[[(35,45)methoxypyrrolidin—3 ~y1]—methy1-amin0]-4—methy1—3,4,6, 1 Ob-
tetrahydro-1H—pyrazino[2,1-a]isoindol-Z—yl]quinoline-8—carbonitrile;
-[(4R,1ObS)methy1-8—[[(3R)-3~piperidy1]amin0]-3,4,6,1Ob-tetrahydro-lH-pyrazin0[2,1—
a]isoindol-Z-yl]quinolinecarb0nitrile;
-[(4R,10bS)[[(3S,4R)—3-methoxy-4—piperidy1]amin0]—4-methy1—3 ,4,6,10b-tetrahydro-
azin0[2,1-a]isoindol-Z-yl]quinolinecarbonitrile;
-[(4R,10bS)methy1~8-(2-morph01inoethylamino)-3,4,6,1 Ob-tetrahydro— 1H-
pyrazino[2,1-a]isoindol—Z—yl]quinoline-S-carbonitrile;
,10bS)~8—[2-[(3S)-3—hydroxypyrrolidiny1]ethylamino]-4—methyl~3 ,4,6,10b-
tetrahydro—lH—pyrazino[2,1-a]is0indol—2-y1]quinoline-S-carbonitrile;
-[(4R,10bS)[(3-flu0roazetidiny1)methy1amino]-4—methy1-3,4,6,10b—tetrahydro—IH—
pyrazin0[2,1 -a]isoindol~2-y1]quinolinecarb0nitrile;
-[(4R,10bS)—8-[[(2S,4S)flu0r0pyrrolidin-2—yl]methylamino]methy1-3,4,6, 10b—
tetrahydro—1H—pyrazin0[2,1—a]isoindoly1]quinoline—S—carbonitri]e;
-[(4R,10bS)-8—[(8aS)-3 -0x0—1,5,6,7,8,8a-hexahydroimidaz0[1,5-a]pyrazin-2—y1]methy1-
3 ,4,6,10b-tetrahydro-1H—pyrazin0[2,1-a]isoindol-Z-yl]quinolinecarbonitrile;
-[(4R,10bS)—8-H8aR)0xo—1,5,6,7,8,8a—hexahydroimidazo[1,5-a]pyrazin—2—y1]—4-
-3,4,6,1 Ob—tetrahydro-1H—pyrazin0[2,1-a]isoind01y1]quinolinecarbonitrile;
—[(4R,10bS)-8—[(3S,4S)—4-fluor0pyrrolidin~3-y1]0xy—4-methy1—3,4,6,10b-tetrahydro-IH-
pyrazino[2,1-a]isoindol-Z-yl]quinoline-S-carbonitrile;
-[(4R,10bS)-8—[[(2S,4S)flu0r0pyrr01idin—2-y1]methoxy]-4—methy1-3,4,6,1Ob—tetrahydro-
1H—pyrazino[2,1-a]isoindol-Z-yl]quinolinecarbonitrile;
(4R,10bS)-N-[(3S,4R)—4—fluoropyrrolidin-3—y1]~4—methy1(8—methy1-5—quin01y1)-
3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindolamine;
(4R,10bS)-N-[(3S,4R)—4-flu0r0pyrrolidin-3 -yl]methy1—2—(8—methquuinoxalin—5~y1)~
3 ,4,6,10b—tetrahydro-1H-pyrazin0[2,1-a]isoind01amine;
(4R,1 ObS)-N—[(3S,4R)fluor0pyrrolidin~3~y1]—4-methy1[8-(trifluoromethy1)quinoxalin-
3,4,6,10b~tetrahydro-1H—pyrazin0[2,1-a]isoindol—8-amine;
7-[(4R,10bS)-8—[[(3S,4R)-4—flu0r0pyrr01idin-3~y1]amino]—4—methy1-3 ,4,6,10b-tetrahydro-
1H—pyrazino[2,1-a]isoindoly1]-1,3 -benzothiazolecarbonitri1e;
(4R,10bS)(8-chlor0—5-quinoly1)—N-[(3S,4R)fluor0pyrr01idin-3 -y1]—4-methy1—
3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindolamine;
5-[(4R,10bS)-7—[2-[(3S)—3-hydr0xypyrrolidiny1]ethylamin0]—4-methyl-3 ,4,6,10b—
ydro- 1H-pyrazino[2, 1 -a]isoind01y1]quin01inecarb0nitrile;
-[(4R,10b5)-7~[[(3S,4R)fluoropyrrolidin—3 -y1]amin0]—4—methyl-3,4,6,10b-tetrahydr0—
1H-pyrazino[2,1-a]isoindol—Z-yl]quinolinecarb0nitrile;
—[(4R,10bS)—8-[(3R,4R)-4—amin0-3~hydr0xy—3-methy1-pyrrolidin-1 —y1]fluoromethy1-
3,4,6,1 Ob-tetrahydro-1H-pyrazino[2,1 -a]isoindol—Z-y1]quinolinecarbonitrile;
-[(4R,10bS)-8—[(3S,4S)-4—amino—3-hydr0xy—3—methy]—pyrr01idin—1~y1]—9—flu0r0—4-methyl-
3 ,4,6,10b-tetrahydro-1H—pyrazino[2,1-a]isoindol-Z-yl]quinolinecarbonitrile;
—[(4R, 1 0bS)—8—(2,6—diazaspir0[3 .3]heptan-Z-y1)—9-fluoro—4-methyl-3,4,6,1 Ob—tetrahydro-
1H—pyrazin0[2,1—a]isoindol-Z-y1]quin01inecarb0nitrile;
5-[(4R,10bS)flu0r0-4—methy1(9-oxa—3 ,7—diazabicyclo[3 .3 . 1 ]n0nan—3 ~y1)—3 ,4,6,10b-
tetrahydro- 1H-pyrazino[2, 1 -a]isoind01yl]quinolinecarbonitrile;
-[(4R,10bS)methy1-8—(piperazine—1 -carbony1)—3,4,6, 1 rahydr0-1H—pyrazino[2, 1 —
a]isoindoly1]quinolinecarb0nitrile;
—[(4R,10bS)-8—[(1S,4S)-2,5—diazabicyclo[2.2. 1]heptanecarb0ny1]methy1-3 ,4,6,10b-
ydro-1H—pyrazino[2,1-a]isoindol-Z—yl]quinoline-8—carb0nitrile;
-[(4R,10bS)-8—(4-aminomethy1-piperidine—1—carbony1)methyl-3 ,4,6,10b-tetrahydro-
azino[2,1-a]isoind01y1]quinoline-S-carb0nitrile;
,10bS)-8—(3,8-diazabicyclo[3.2.1]octane—3-carb0ny1)methy1-3,4,6,10b-tetrahydro-
1H—pyrazino[2,1—a]isoindol-Z-yl]quinoline—8-carb0nitrile;
-[(4R,1ObS)-4—methy1(5—0xa—2,8—diazaspir0[3.5]nonan-2—yl)-3 0b-tetrahydro—1H—
pyrazino[2, 1 -a]isoind01-2—y1]—2-deuterio-quinoline—8-carb0nitrile;
~[(4R,10bS)—8—[[(3S,4R)—4-flu0r0pyrr01idiny1]amino]—4—methyI-3,4,6,10b—tetrahydr0-
1H—pyrazin0[2,1-a]isoindol-Z-yl]deuteri0-quinoline-8—carbonitrile;
—[(4R,10bS)—8-(3 -amino-3~methyl—azetidiny1)~4—methy1—3 ,4,6,10batetrahydro-1H-
pyrazino[2,1-a]isoindolyl]-2—deuterio-quinolinecarbonitrile;
-[(4R,10bS)methy1—8—(9-oxa-3 ,7-diazabicyclo [3 .3. 1 ]nonan-3 -y1)-3 ,4,6,10b-tetrahydro—
1H-pyrazino [2, 1 -a]isoindoly1] deuteri0-quinolinecarb0nitrile;
4-[(4R,1ObS)~8—[(3R,4R)—3-aminometh0xy—pyrrolidin-1~y1]—4-1nethy1—3,4,6,1Ob-
tetrahydro-1H-pyrazino[2, 1-a]isoindol-Z-yl]pyrazolo[1,5-a]pyn'dine-7—carbonitrile;
4—[(4R,10bS)[(3S,4S)a1nin0—4—methoxypyrrolidiny1]—4—1nethy1~3,4,6,10b-
tetrahydro-lH—pyrazino[2,1-a]isoindol-Z-yl]pyrazolo[1,5-a]pyridinecarbonitrile;
4-[(4R,1ObS)—8-[(3R)-3—aminopyrrolidiny1]-4—1nethy1-3,4,6,1Ob—tetrahydro-1H—
pyrazino[2,1-a]isoindoly1]pyrazolo[1,5-a]pyridinecarbonitrile;
4-[(4R,10bS)methy1—8—[(3R)methylpiperazin—1-y1]—3,4,6,10b-tetrahydro-IH-
pyrazino[2,1-a]isoindol-Z-yl]pyrazolo[1,5-a]pyridinecarb0nitrile;
4-[(4R,10bS)-8—[[(3S,4R)—4-fluoropyrrolidiny1]amino]—4-methy1-3 ,4,6,10b-tetrahydr0-
1H-pyrazino[2,1-a]isoindol-Z-yl]pyrazolo[1,5-a]pyridinecarbonitri1e;
4-[(4R,10bS)-8—[(312,4S)aminofluoro-pyrr01idin-1 ~y1]—4—methy1-3 ,4,6,10b-tetrahydro-
2O 1H—pyrazino[2,1-a]isoindol-Z-y1]pyrazolo[1,5-a]pyridinecarbonitrile;
4-[(4R,10bS)-8—(4-amino-4~methylpiperidy1)methy1—3 ,4,6,10b-tetrahydro-1H-
no[2,1-a]isoindol-Z-y1]pyrazolo[1,5-a]pyridine—7-carb0nitrile;
4—[(4R,10bS)—8-[(6R)amino~1,4-0xazepan—4—y1]—4-methy1-3 ,4,6, 1 Ob—tetrahydro— 1H-
pyrazin0[2,1-a]isoindol—Z-yl]pyrazolo[1,5—a]pyridine-7—carbonitri1e;
4—[(4R,10bS)—4-methy1—8-(5—oxa—2,8-diazaspiro[3.5]nonan-2»yl)-3 ,4,6,10b-tetrahydro-1H-
pyrazin0[2,1-a]isoindol—2-y1]pyrazolo[1,5—a]pyridine-7—carbonitrile;
,10bS)[(3R)-3—amino—3~methy1-pyrrolidin—1-y1]methy1-3 0b—tetrahydro—
1H—pyrazino[2,1-a]isoind01yl]pyrazolo[1,5-a]pyridine—7—carb0nitrile;
4-[(4R,10bS)[(3R,4R)amin0—3-meth0xy—1~piperidy1]methy1-3 ,4,6,10b—tetrahydro~
1H—pyrazino[2,1 -a]isoindolyl]pyrazolo[I ,5-a]pyridinecarbonitrile;
4-[(4R,10bS)[(3R,4S)—4-amin0—3—methoxy-1—piperidy1]—4-methy1-3 ,4,6,10b-tetrahydr0-
1H-pyrazino[2,1-a]isoind01-2—yl]pyrazolo[1,5-a]pyridinecarbonitrile;
,1 0bS)-8—[(3R,4S)amino-4—methoxypiperidy1]—4-1nethyl-3 ,4,6,10b-tetrahydro-
1H—py1‘azino[2,1-a]isoindol-2—y1]pyrazolo[1,5-a]pyridinecarb0nitri1e;
-3 0-
4-[(4R,10bS)—4-methyl(9-oxa-3,7-diazabicyclo[3.3.l]nonan—3—y1)—3,4,6,lOb-tetrahydro—
lH-pyrazino[2,1-a]isoindol-2—yl]pyrazolo[1,5-a]pyridinecarbonitrile;
4-[(4R, l 0bS)—8—[(3R,4R)—4-aminohydroxy—3 -methyl-pyrrolidin—l -yl]—4—methyl-
3 ,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-Z-yl]pyrazolo[1 ,5-a]pyridine—7-carbonitrile;
4—[(4R_,l 0bS)[(3S,4S)a1nino-3—hydroxy-3—methyl—pyrrolidin— l -yl] methy1-
3,4,6,10b-tetrahydro—lH-pyrazino[2,1 -a]isoindol-Z-yl]pyrazolo[l,5-a]pyridinecarbonitrile;
4-[(4R,10bS)—8—[(3R,4R)—3—aminohydroxy-pyrrolidin-l -yl]—4—methy1-3,4,6,1 0b-
tetrahydro—lH—pyrazino[2,1-a]isoindol-Z-yl]pyrazolo[l ,5-a]pyridinecarbonitrile;
4—[(4R, l 0bS)—8~[(3S,4S)-3—amino—4-hydroxy-pyrrolidin—l -yl]—4-methyl-3 0b—
tetrahydro-lH—pyrazino[2,1-a]isoindol-Z-yl]pyrazolo[1,5—a]pyridine—7—carbonitrile;
4-[(4R, l 0b5)[(3S,4S)amino~3—hydroxy—3-methy1~pyrrolidin-l -yl]—4-methyl-
3,4,6, 1 Ob-tetrahydro— 1 H-pyrazino[2, l -a]isoindolyl]—3 -pyrazolo[l ,5-a]pyridine-7—
carbonitrile; and
4-[(4R, 1 0bS)[(3R,4R)-3—a1ninomethoxy-py1rolidin-l-y1]methyl-3,4,6,1 Ob-
tetrahydro-1H—pyrazino[2,1-a]isoindoly1]—3-fluoro-pyrazolo[l,5~a]pyridine-7—carbonitrile;
or a pharmaceutically acceptable salt, enantiomer or diastereomer f.
SYNTHESIS
The nds of the present ion can be prepared by any tional means.
Suitable processes for synthesizing these compounds as well as their starting materials are
provided in the schemes below and in the examples. All substituents, in particular, R] to R6 are
as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated,
all reactions, reaction ions, abbreviations and symbols have the meanings well known to a
person of ordinary skill in organic chemistry.
A general synthetic route for preparing the compound of formula (I) is shown in Scheme 1
below.
Scheme]
II? Rs
8 Re If 9 9 I
:I,——. IV—— IV —OH R/HVR o N R o N R
N R9
R2 2
HN HN H2N R Iv
HZN R2
IV v VI
o o
I FIRB
N R9
'I 'I F?
N N X—-R1 N
XIII
_—._... l 2 2 l2
N R l
N R —‘ N R
R R3
6 R3
(R n R4 (R n R4
(R (R )m )m
xn I
wherein X is halogen or g group, for example, OH or OMs; m is O, l, 2, or 3; n is l,
2, 3 or 4; m+nS4; R7 and R8 are protecting groups, for e, R7 is Boc and R8 is benzyl; R9 is
alkylsilyl, for example, trimethylsilyl.
The amide coupling of protected amino acid (11) and silylamine (III) can be achieved using
coupling reagents, such as HATU and DIPEA, to afford intermediate (IV). After R7 is removed
by selective ection, the amide bond in the resulting intermediate (V) can be reduced under
reductive conditions, such as treatment of LAH, to afford diamine (VI). Imine (VIII), which can
be formed by condensation of aldehyde (VII) and diamine (VI) under typical dehydration
conditions, is cyclized under photo-redox ions, which is catalyzed by blue light and Ir—
based catalyst, such as [Ir(dtbbpy)(ppy)2][PF6], to afford lic lactam (IX). When d
with reducing reagent, such as LAH, lactam (IX) can be reduced to compound of formula (X), in
which both R3 and R4 are hydrogen atoms. Alternatively, lactam (IX) can also be treated with
dimethyl titanocene, then reduced by hydrogenation to install an alkyl group at R3 or R4.
Compound of formula (X) can be used as a common intermediate for further functionalization
under metal catalyzed coupling conditions, such as Buchwald-Hafiwig amination, Suzuki
coupling, Negishi coupling, Stille coupling, or Pd-catalyzed C=O insertion. For example, under
-3 2-
Buchwald-Hartwig amination conditions (ref: Acc. Chem. Res. 1998, 31, 805-818; Chem. Rev.
2016, 116, 12564-12649; Topics in Current Chemistry, 2002, 219, 9; and references cited
therein) with a catalyst, such as Ruphos Pd—G2, and a base, such as CszCO3, compound of
formula (XI) can be generated from compound of formula (X). After selective deprotection of R8
group under typical ions (6.g. removal of benzyl protecting group by hydrogenation over
catalytic amount of Palladium on carbon), the resulting compound of formula (XII) can be
submitted to nucleophilic aromatic substitution conditions (6.g. heating with halide (XIII) in the
ce of DIEPA in DMSO), or Buchwald-Hartwig amination conditions (6.g. g with
halide (XIII) in the presence of a catalyst, such as Ruphos Pd-G2, and a base, such as CszCO3, to
afford compound of formula (I). In some embodiment, the compound of a (XII) may
contain a protecting group, e.g. Boc, which will be removed before affording the final compound
of formula (1).
Scheme 2
x——R1 N
-——> l2
N R
(R n R4
(x )m (X)m
.____. Ml
N R2
(R R“
After R8 is removed from formula (X) by selective deprotection, the resulting nd of
formula (XIV) can react with halide (XIII) to afford compound of formula (XV) by nucleophilic
aromatic substitution in the presence of a base, such as DIEPA. nd of formula (I) can be
ed from compound of formula (XV) via metal catalyzed coupling conditions: Buchwald-
Hartwig amination in the presence of a catalyst, such as Ruphos Pd-G2, and a base, such as
CszC03; Suzuki coupling with boronic acid, boronic ester, or potassium trifluoroborate, in the
ce of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) or [l,l‘-
bis(diphenylphosphino)ferrocene]dichloropalladium (ll), complex with dichloromethane and a
base, such as potassium carbonate in solvent; Stille coupling with organotin reagent, in the
presence of a palladium(0) catalyst, such as is(triphenylphosphine)palladium(0); or Negishi
W0 2019/233941
coupling with organozinc reagent in the presence of a palladium(0) catalyst, such as
tetrakis(triphenylphosphine)palladium(0) or [1,1 '—bis(diphenylphosphino)ferrocene]
dichloropalladium (II). In some embodiment, the compound of a (XII) may contain a
protecting group, e.g. Boc, which will be removed before affording the final compound of
formula (1).
Compounds of this invention can be obtained as mixtures of diastereomers or enantiomers,
which can be separated by methods well known in the art, e.g. (chiral) HPLC or SFC.
This invention also relates to a process for the preparation of a compound of formula (I),
(la) or (lb) comprising any of the ing steps:
a) the substitution reaction of compound of formula (XII),
(R )m (:XH)7
and halide (XIII) in the presence of a base;
b) the Buchwald—Hartwig amination reaction of compound of a (XII),
(R )m (X11),
and halide (XIII) in the presence of a st and a base;
c) the Buchwald-Hartwig ion reaction of compound of formula (XV),
N R2
(R n R4
(XV),
and halide (XIII) in the presence of a catalyst and a base;
d) the Suzuki coupling reaction of compound of formula (XV),
Nj\R2
(R n R4
( X )m
(XV),
and boronic reagent in the presence of a catalyst and a base;
6) the Stille coupling reaction of nd of formula (XV),
(R n R4
(XV),
and organotin reagent in the presence of a catalyst;
f) the i coupling reaction of compound of formula (XV),
(R n R4
( X )m
(xv),
and organozinc t in the presence of a catalyst;
wherein,
in step a), the base can be, for example, DIPEA;
in step b) and c), the catalyst can be, for example, Ruphos Pd-G2; the base can be, for
example, CszC03;
in step d), the catalyst can be, for example, tetrakis(triphenylphosphine)palladium(0) or
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II); the base can be, for example,
K2CO3;
in step e), the catalyst can be, for example, tetrakis(triphenylphosphine)palladium(0);
in step t), the catalyst can be, for example, is(triphenylphosphine)palladium(0) or
[ 1 , l '-bis(diphenylphosphino)ferrocene] dichloropalladium (II).
A compound of formula (I), (la) or (lb) when manufactured according to the above process
with achiral or chiral starting materials is also an object of the invention.
INDICATIONS AND METHODS OF TREATMENT
The present invention provides compounds that can be used as TLR7 and/or TLR8 and/or
TLR9 antagonist, which inhibits pathway activation through TLR7 and/or TLR8 and/or TLR9 as
well as respective downstream biological events including, but not d to, innate and
adaptive immune ses mediated through the production of all types of cytokines and all
forms of auto-antibodies. Accordingly, the compounds of the ion are useful for blocking
TLR7 and/or TLR8 and/or TLR9 in all types of cells that s such receptor(s) including, but
not limited to, plasmacytoid dendritic cell, B cell, T cell, macrophage, monocyte, neutrophil,
keratinocyte, epithelial cell. As such, the compounds can be used as a therapeutic or prophylactic
agent for systemic lupus erythematosus and lupus tis.
The present invention provides s for treatment or prophylaxis of systemic lupus
erythematosus and lupus nephritis in a patient in need thereof.
r embodiment includes a method of treating or preventing systemic lupus
erythematosus and lupus tis in a mammal in need of such treatment, wherein the method
-3 6-
comprises administering to said mammal a eutically effective amount of a compound of
formula (I), a stereoisomer, tautomer, prodrug or phannaceutically acceptable salt thereof.
EXAMPLES
The invention will be more fully understood by reference to the ing examples. They
should not, however, be construed as limiting the scope of the invention.
ABBREVIATIONS
The invention will be more fully understood by reference to the following examples. They
should not, however, be construed as limiting the scope of the invention.
Abbreviations used herein are as follows:
ACN: itrile
B0020: di-tert—butyl dicarbonate
TfZO: triflic anhydride
DCM: dichloromethane
DDI drug-drug-interaction
DIPEA diethylisopropylamine
DMA ylacetamide
BA or EtOAc: ethyl acetate
FA: formic acid
HATU 1 -[Bis(dimethylamino)methylene]—1H-1,2,3 - triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate
HLM human liver ome
hr hour
hrs hours
lC50: half inhibition concentration
LCMS liquid chromatography-mass spectrometry
LYSA lyophilisation solubility assay
MS: mass spectrometry
PE: petroleum ether
prep—HPLC: preparative high performance liquid chromatography
rt: rt
RT: retention time
RuPhos Pd G2: chloro(2-dicyclohexylphosphino-2’,6'-diisopropoxy—l ,l ’-
yl)[2-(2’-amino-1 ,1 ’-biphenyl)]palladium(ll) 2nd generation
SFC: supercritical fluid chromatography
WO 33941
TFA: trifluoroacetic acid
v/v volume ratio
GENERAL EXPERIMENTAL CONDITIONS
Intermediates and final compounds were purified by flash chromatography using one of the
following instruments: i) Biotage SP1 system and the Quad 12/25 Cartridge module. ii) ISCO
combi-flash tography instrument. Silica gel brand and pore size: i) KP-SIL 60 A, particle
size: 40-60 pm; ii) CAS registry NO: Silica Gel: 632314, particle size: 47-60 micron silica
gel; iii) ZCX from Qingdao Haiyang Chemical C0,, Ltd, pore: 200300 or 300-400.
ediates and final compounds were d by preparative HPLC on reversed phase
column using XBridgeTM Prep-C18 (5 um, OBDTM 30 X 100 mm) column, SunFireTM 18
(5 um, OBDTM 30 X 100 mm) column, Phenomenex Synergi-Cl8 (10 um, 25 X 150 mm) or
Phenomenex Gemini—C18 (10 um, 25 X 150 mm). Waters AutoP purification System (Sample
Manager 2767, Pump 2525, Detector: Micromass ZQ and UV 2487, solvent system: acetonitrile
and 0.1% um hydroxide in water; acetonitrile and 0.1% FA in water or acetonitrile and
0.1% TFA in water). Or Gilson-281 purification System (Pump 322, Detector: UV 156, solvent
system: acetonitrile and 0.05% ammonium ide in water; acetonitrile and 0.225% FA in
water; acetonitrile and 0.05% HCl in water; acetonitrile and 0.075% TFA in water; or
acetonitrile and water).
For SFC chiral separation, intermediates were ted by chiral column (Daicel chiralpak
IC, 5 pm, 30 X 250 mm), AS (10 um, 30 X 250 mm) or AD (10 um, 30 >< 250 mm) using Mettler
Toledo Multigram III system SFC, Waters 80Q preparative SFC or Thar 80 preparative SFC,
solvent system: C02 and IPA (0.5% TEA in IPA) or C02 and MeOH (0.1% NH3'H20 in MeOH),
back pressure 100bar, detection UV@ 254 or 220 nm.
LC/MS spectra of compounds were obtained using a LC/MS (WatersTM Alliance 2795—
Micromass ZQ, Shimadzu Alliance 2020-Micromass ZQ or Agilent Alliance 6110-Micromass
ZQ), LC/MS conditions were as follows (running time 3 or 1.5 mins):
Acidic condition I: A: 0.1% TFA in H20; B: 0.1% TFA in acetonitrile;
Acidic condition 11: A: 0,0375% TFA in H20; B: 0.01875% TFA in acetonitrile;
Basic condition I: A: 0.1% 0 in H20; B: acetonitrile;
Basic condition II: A: 0.025% NH3-H20 in H20; B: acetonitrile;
Neutral condition: A: H20; B: acetonitrile.
Mass spectra (MS): lly only ions which te the parent mass are reported, and
unless otherwise stated the mass ion quoted is the positive mass ion (MH)+.
W0 2019/233941
-38—
NMR Spectra were obtained using Bruker Avance 400 MHz.
The microwave assisted reactions were d out in a Biotage Initiator Sixty microwave
synthesizer. All reactions involving air-sensitive reagents were performed under an argon or
nitrogen atmosphere. Reagents were used as received from cial ers without further
purification unless otherwise noted.
PREPARATIVE EXAMPLES
The following examples are intended to illustrate the meaning of the present invention but
should by no means represent a limitation within the meaning of the present invention:
Example 1
—[(4R,10bS)-4—methyl-S-piperazinyl—3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindol—2-
noline-S-carbonitrile
The title compound was prepared according to the following scheme:
Zn(CN))Ru:hos Pd G2 \
/ /
70%HZSO4
OH Q/HwéNSV \F/Ql3/
M | L'A'H4
NS\/\ ————-——-—-—-——. OIVSKN - W
/ N 4/
HN HATU,D|EA THF
A0 DMF,rt > LV \
1 HZN
1d 19 1f 19
o o
Br S[|r(dtbbpy)(ppy)2]P Fe NI N
——.7——. BHS/THF
4A molecular steves, ’lip/m\ _..__._.___..
CHSCN E (9: 1) N N
Br 0\ blue light
Br Br
1h 1i 1i
(\NH Q
>r ‘n’ N
0 1c
Pd-C/H2
_.____.__....__.
XPhos Pd (53 052003 MBOH DIEA, DMSO
dioxane, 80°C {(51.3
O 76‘
H N
H ‘
ij TFA/DCM N
——-.~—————. Nj\
1m Example 1
Step 1: preparation of 8—bromofluoro~quinoline (compound 1b)
In a 100 mL haped flask, 2-bromofluoroaniline (2.0 g, 10.5 mmol), e-1,2,3-
triol (969 mg, 10.5 mmol) and sodium 3-nitrobenzenesulfonate (2.4 g, 10.5 mmol) were
combined with 70% H2804 (20 mL) to afford a dark brown solution, which Was heated to 150 0C
and stirred for 3 hrs. After cooled to room temperature, the reaction e was poured into ice-
water, and lized with sodium hydroxide solution. The resultant mixture was filtered. The
filter cake was dissolved in EtOAc and filtered. The resultant filtrate was concentrated in vacuo.
The crude material was purified by flash tography (silica gel, 40 g, 0% to 30% EtOAc in
PE) to afford compound lb (2.0 g, 84% yield). MS: calc’d 226 and 228 [(M+H)+], measured 226
and 228 [(M+H)+].
Step 2: preparation of S-fluoroquinoline—8—carbonitrile (compound 1c)
To a solution of 8-bromo-5—fluoroquinoline (compound lb, 4.9 g, 21.7 mmol) in DMF (30
mL) was added dicyanozinc (5.0 g, 43.4 mmol) and RuPhos Pd 62 (CAS: 1375325—68-0,
Aldrich, g: 753246, 842 mg, 1.1 mmol). The reaction mixture was stirred at 100 0C
for 3 hrs, then cooled to room temperature. The reaction mixture was filtered and the filtrate was
diluted with water (50 m1), then extracted with BA (80 mL) for three times. The combined
organic layer was washed with brine, dried over Na2804, filtered and concentrated in vacuo. The
residue was purified by flash chromatography (silica gel, 40 g, 0% to 70% EtOAc in PE) to
afford compound 1c (3.0 g, 80 % yield). MS: calc’d l73 [(M+H)+], measured l73 [(M+H)+]. 1H
NMR (400 MHz, METHANOL-d4) 5 ppm 9.11 (dd, J: 4.28, 1.71 Hz, 1 H), 8.64 (dd, .1: 8.56,
1.71 Hz, 1 H), 8.29 (dd, J: 8.19, 5.62 Hz, 1 H), 7.76 (dd, J: 8.56, 4.28 Hz, 1 H), 7.49 (dd, J:
9.35, 8.25 Hz, 1 H).
Step 3: ation of tert-butyl N-[(1R)—2-[benzyl(trimethylsilylmethyl)aminoI—l—
methyl-Z-oxo-ethyl]carbamate (compound 1e)
To a solution of (2R)—2—(tert—butoxycarbonylamino)propanoic acid (10.0 g, 52.9 mmol) in
DMF (40 mL) was added N-benzyl—l—(trimethy1silyl)methanamine (10.2 g, 52.9 mmol), HATU
(20.1 g, 52.9 mmol) and DIEA (13.6 g, 18.4 mL, 105.8 mmol). The reaction mixture was stirred
at room temperature overnight. The reaction was quenched with water (150 mL), and ted
with DCM (100 mL) for three times. The combined organic layer was washed with brine, dried
over Na2804, filtered and concentrated in vacuo. The residue was purified by flash
chromatography (silica gel, 40 g, 0% to 30% EtOAc in PE) to afford compound 1e (13.1 g, 68 %
yield). MS: calc’d 365 [(M+H)+], measured 365 [(M+H)+].
Step 4: preparation of (2R)amino—N—benzyl-N-(trimethylsilylmethyl)-propanamide
(compound 11)
To a solution of tert—butyl N-[(1R)[benzyl(trimethylsilylmethyl)amino]~l~1nethyl—2—oxo-
ethyl]carbamate (compound 1e, 13.0 g, 35.7 mmol) in DCM (60 mL) was added TFA (10 mL).
The resultant mixture was stirred at room ature for 4 hrs, then concentrated in vacuo, and
the residue was partitioned n sat. NaHCO3 (aq.) and EA. The c layer was separated
and the basic aqueous layer was extracted with BA (80 mL) twice. The combined organic layer
was dried over Na2804, filtered and concentrated in vacuo to afford compound 1f (91 g, 96 %
yield) without further purification. MS: calc’d 265 [(M+H)+], measured 265 [(M+H)+].
Step 5: preparation of (2R)-N1-benzyl-N1-(trimethylsilylmethyl)propane-1,2-diamine
(compound 1g)
To an ice—cooled solution of (2R)amino-N-benzyl-N—(trimethylsilylmethyl)-propanamide
(compound 1f, 9.0 g, 34.0 mmol) in anhydrous THF (100 mL) was added LiAlH4 (3.9 g, 102.0
mmol) slowly. After the addition was completed, the mixture was heated under reflux overnight,
then cooled to room temperature and quenched with NaOH (10 mL, 20% aq. solution) before
filtered and washed with EtOAc. The combined filtrate was concentrated in vacuo to afford
compound 1g (5.7 g, 67% yield) without further purification. MS: calc’d 251 +],
measured 251 [(M+H)+].
Step 6: preparation of bS)benzyl-S-bromomethyl-1,3,4,10b-
ydropyrazino[l,2-b]isoindolone (compound 1i)
A mixture of the (2R)-N1-benzyl—Nl-(trimethylsilylmethyl)propane-l,2—diamine
(compound 1g, 3.0 g, 12.0 mmol), methyl 5-bromo—2-formylbenzoate (2.9 g, 12.0 mmol), and
4A MS (5.0 g) in MeCN (80 mL) under N2 was stirred overnight at room temperature. The
reaction mixture was filtered and the filter cake was washed with DCM. The filtrate was
concentrated in vacuo and the residue was re-dissolved in MeCN/TFE (45 mL/5 mL), followed
by the addition of [lr(dtbbpy)(ppy)2][PF(,] (CAS: 6765252, TCI, Catalog: D4887, 109 mg,
120 umol). The reaction was d at room temperature under the exposure of blue LEDs
(synLED—l6 A Discover, 12 W, wavelength 465-470 nm, purchased from SYNLED corp.) for 2
days. After the solvents were removed in vacuo, the residue was purified by flash
chromatography (silica gel, 80 g, 20% to 70% BA in PE) to afford compound 1i (1.8 g, 42 %
yield). The stereochemistry was ed by NOESY. MS: calc’d 371 and 373 [(M+H)+],
measured 371 and 373 [(M+H)+]. 1H NMR (400 MHZ, METHANOL-d4) (5 ppm 7.75 (d, J: 1.71
Hz, 1 H), 7.63 (dd, J: 8.01, 1.77 Hz, 1 H), 7.19 - 7.35 (m, 6 H), 4.43 (dd, J: 10.88, 3.67 Hz, 1
H), 3.67 - 3.86 (in, 1 H), 3.56 (s, 2 H), 3.41 - 3.45 (m, l H), 2.79 - 2.87 (m, 1 H), 1.86 (t, J:
11.07 Hz, 1 H), 1.67 (d, J: 6.97 Hz, 3 H), 1.64 (t, J: 11.07 Hz, 1 H).
Step 7: preparation of (4R,10bS)benzyl—8-bromomethyl—3,4,6,10b-tetrahydro-
1H-pyrazino[2,l-a}isoindole (compound lj)
A mixture of (4R,10bS)—2—benzyl-8—bromo—4—methyl-1,3,4,10b-tetrahydropyrazino[l,2-
b]isoindol—6—one (compound 1i, 1.9 g, 5.0 mmol) and BH3 solution (1M in THF, 40 mL, 40
mmol) was stirred at 80 0C for 5 hrs. HCl solution (6 N, 10 mL) was added slowly to the reaction
mixture at 0 0C. The ant mixture was stirred at room temperature overnight, then d
with a NaOH solution (2 N) to pH 10. The mixture was extracted with EtOAc twice, and the
combined organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude
material was purified by flash chromatography a gel, 40 g, 30% to 100% EtOAc in PE) to
afford compound lj (1.5 g, 85 % yield). MS: calc’d 357 and 359 [(M+H)+], measured 357 and
359 [(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) 5 ppm 7.49 (s, 1 H), 7.32 - 7.43 (m, 5 H),
7.26 - 7.32 (m, 1 H), 7.05 (d, J= 7.95 Hz, 1 H), 4.18 (d, J= 12.59 Hz, 1 H), 3.71 (br d, J: 10.51
Hz, 1 H), 3.55 (dd, J: 12.47, 2.32 Hz, 1 H), 3.36-3.31(m, l H), 2.97-2.89(m, 1 H), 2.77 - 2.87
(m, 1 H), 2.12 (t, J== 10.64 Hz, 1 H), 2.00 (t, 4 Hz, 1 H), 1.14 (d, J: 6.48 Hz, 3 H).
Step 8: preparation of tert-butyl 4-[(4R,10bS)benzylmethyl-3,4,6,10b-
tetrahydro-lH—pyrazino[2,]-a]isoindolyl]piperazine-l-carboxylate (compound 1k)
To a solution of (4R,10bS)—2-benzyl—8~bromo—4-methyl—3,4,6,l0b-tetrahydro-lH—
pyrazino[2,1-a]isoindole (compound lj, 0.4 g, 1.1 mmol) in e (15 mL) was added tert-
butyl piperazine—1-carboxylate (209 mg, 1.1 mmol), CszC03 (365 mg, 1.1 mmol) and XPhos Pd
G3 (CAS: 14450851, BePharm, g: D449923, 94.8 mg, 0.1 mmol). The reaction
e was stirred at 80 0C overnight, then cooled to room temperature, diluted with water (50
mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed
with brine, dried over Na2304, filtered and concentrated in vacuo. The residue was purified by
flash chromatography (silica gel, 40 g, 0% to 100% EtOAc in PE) to afford compound 1k (420
mg, 81.1 % yield). MS: calc’d 463 [(M+H)+], measured 463 [(M+H)+].
Step 9: preparation of utyl 4—l'(4R,10bS)methyl—1,2,3,4,6,10b-
hexahydropyrazino[2,l-a]isoindol—8-yl]piperazinc—l-carboxylate (compound 11)
A mixture of tert—butyl 4-[(4R,10bS)—2~benzy1—4—methy1—3,4,6,10b-tetrahydro—lH-
pyrazino[2,1-a]isoindol-S—yl]piperazine—1-carboxylate und 1k, 240 mg, 519 umol) and
Pd-C (16.6 mg, 156 umol) in MeOH (20 mL) was hydrogenated with a hydrogen balloon at
room temperature for 5 hrs. After the catalyst was filtered off, the filtrate was concentrated in
vacuo to afford compound 11 (181 mg, 94 % yield) which was used directly for the next step
without further purification. MS: calc’d 373 [(M+H)+], measured 373 [(M+H)+].
Step 10: preparation of tert—butyl 4-[(4R,10bS')(8—cyano-S-quinolyl)methyl-
3,4,6,10b-tetrahydro—lH—pyrazino[2,1-a]isoindol-8—yl]piperazine—l-carboxylate
(compound 1m)
To a solution of 5-fluoroquinolinecarbonitrile (compound 1c, 20.1 mg, 112 umol) in
DMSO (3 mL) was added tert—butyl 4—[(4R,10bS)~4~methyl-1 ,6,10b-
hexahydropyrazino[2,1-a]isoindolyl]piperazinecarboxylate (compound 11, 42 mg, 112
umol) and DIEA (73 mg, 560 umol). The on mixture was stirred at 120 0C for 5 hrs. After
cooled to room temperature, the reaction was quenched with water (30 mL) and extracted with
EA (50 mL) twice. The combined organic layer was washed with brine, dried over NaZSO4,
filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel,
24 g, 0% to 100% EtOAc in PE) to afford compound 1m (41 mg, 68 % yield). MS: calc’d 525
+], measured 525[(M+H)+].
Step 11: preparation of 5-[(4R,10bS)methylpiperazinyl-3,4,6,10b-tetrahydro-
lH-pyrazino[2,1-a]isoindol-Z-yl]quinoline-S-carbonitrile (Example 1)
To a solution of tert—butyl 4-[(4R,10bS)—2-(8-cyanoquinolyl)—4-methy1-3,4,6,10b-
tetrahydro-1H—pyrazino[2,1-a]isoindolyl]piperazinecarboxylate (compound 1m, 100 mg) in
DCM (10 mL) was added TFA (2 mL). The reaction mixture was stirred at room temperature for
min, then trated to afford a crude t, which was d by prep-HPLC to afford
Example 1 (33 mg, 77 %). MS: calc’d 425[(M+H)+], measured 425[(M+H)+]. IH NMR (400
MHz, METHANOL—d4) 6 ppm 9.02 (dd, J: 4.22, 1.53 Hz, 1 H), 8.73 (dd, J: 8.56, 1.59 Hz, 1
H), 8.18 (d, J: 8.07 Hz, 1 H), 7.71 (dd, J: 8.56, 4.28 Hz, 1 H), 7.35 (d, J: 8.07 Hz, 1 H), 7.14
(d, J: 8.31 Hz, 1 H), 7.06 (s, 1 H), 6.88 (dd, J: 825, 2.02 Hz, 1 H), 4.29 (d, J: 12.10 Hz, 1 H),
4.10 (br d,J=10.51Hz, 1 H), 3.89 (br d, J: 11.49 Hz, 1 H), 3.70 (br (1, J== 11.86 Hz, 1 H), 3.46
(br (1, J: 11.74 Hz, 1 H), 3.34—3.38 (m, 1H), 3.07 — 3.19 (m, 4 H), 2.94 - 3.05 (m, 5 H), 2.73 -
2.92 (m, 1 H), 1.28 (d, J: 6.48 Hz, 3 H).
Example 2
-[(4S,10bR)methyl-S-piperazinyl-3,4,6, 1Oh-tetrahydro-1H-pyrazino[2,1-a]isoindol-Z-
yl]quinoline—8-carbonitrile
The title compound was prepared in y to the preparation of Example 1 by using
(2.5')—2-(tert-butoxycarbonyla1nino)propanoic acid instead of (2R)—2-(tert-
butoxyearbonylamino)propanoic acid (compound 1d). Example 2 (12 mg) was obtained. MS:
calc’d 425[(M+H)+], measured 425[(M+H)+]. 1H NMR (400 MHz, METHANOL—a’4) 5 ppm 9.02
(dd, J= 4.28, 1.59 Hz, 1 H), 8.72 (dd, .1: 8.56, 1.47 Hz, 1 H), 8.19 (d, J = 7.95 Hz, 1 H), 7.72
(dd, J: 8.56, 4.28 Hz, 1 H), 7.35 (d, J: 8.07 Hz, 1 H), 7.14 (d, J: 8.3] Hz, 1 H), 7.05 (s, 1 H),
6.87 (dd, J= 8.31, 1.96 Hz, 1 H), 4.23 - 4.25 (m, 1 H), 4.28 (d, J=12.10 Hz, 1 H), 4.09 (br (1, .1:
.51 Hz, 1 H), 3.88 (br (1, .1: 11.37 Hz, 1 H), 3.70 (br d, J: 11.98 Hz, 1 H), 3.45 (br d, J:
11.25 Hz, 1 H), 3.34-3.38 (m, 1H), 3.07 - 3.18 (m, 4 H), 2.96 - 3.06 (m, 5 H), 2.79 - 2.91 (In, 1
H), 1.28 (d, J: 6.36 Hz, 3 H).
Example 3
-(8-piperazinyl-3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindol—Z-yl)quinoline
carbonitrile
W0 2019/233941
The title compound was ed in analogy to the preparation of Example 1 by using 2-
(z‘ert-butoxycarbonylamino)acetic acid instead of (2R)(tert-butoxycarbonylamino)-propanoic
acid (compound 1d). Example 3 (19.7 mg) was obtained. MS: calc’d 411[(M+H)+], ed
411 [(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) 5 ppm 9.05 (dd, .1 = 4.28, 1.59 Hz, 1 H),
8.71 (dd, J: 8.62, 1.53 Hz, 1 H), 8.21 (d, J= 8.07 Hz, 1 H), 7.72 (dd, J: 8.68, 4.28 Hz, 1 H),
7.42 (dd, J: 8.25, 4.71 Hz, 2 H), 7.23 (s, 1 H), 7.13 (dd, J= 8.44, 2.08 Hz, 1 H), 5.31 (dd, J:
8.50, 4.46 Hz, 1 H), 4.91-4.96 (1n, 1H), 4.76 - 4.84 (1n, 1 H), 3.95 — 4.06 (m, l H), 3.87 (br d, J:
.41 Hz, 1 H), 3.78 (br d,J= 13.33 Hz, 1 H), 3.37 - 3.64 (m, 11 H).
Example 4
7-(8—piperazin—1-yl—3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindolyl)—1,3-
benzothiazole-4—carbonitrile
The title compound was prepared in analogy to the preparation of Example 3 by using 7-
fluoro-l,3-benzothiazole-4—carbonitrile instead of 5-fluoroquinoline-8—carbonitrile (compound
1c). Example 4 (15 mg) was obtained. MS: calc’d 417 [(M+H)+], measured 417 [(M+H)+]. lH
NMR (400 MHZ, METHANOL-d4) 0‘ ppm 9.46 (s, 1 H), 7.95 (d, J = 8.19 Hz, 1 H), 7.45 (d, J =
8.44 Hz, 1 H), 7.26 (d, J: 8.19 Hz, 1 H), 7.21 (s, 1 H), 7.13 (dd, J: 8.44, 2.20 HZ, 1 H), 5.19
(br s, 1 H), 4.81 (s, 2 H), .10 (m, 1 H), 3.76 - 3.92 (m, 1H), 3.55-3.65 (m, 2 H), 3.45 - 3.53
(m, 5 H), 3.37 - 3.44 (m, 5 H).
W0 2019/233941
—46-
Example 5
4-[(4R,10bS)methyl—S-piperazinyl-3,4,6,1 Ob-tetrahydro-1H-pyrazino[2,1-a]isoindol-Z-
yl] pyrazolo[1,5-a] pyridine-7—carbonitrile
The title compound was prepared according to the following scheme:
NN]\ / N’N\
N’N\ /
\ \\ / N’N\
\ \\ \ \\
TFA/DCM
RuPhos Pd 62
(—N CSZCOS, dioxane
+9 NO
53 Example 5
Step 1: preparation of tert-butyl 4-[(4R,10bS)—2-(7-cyanopyrazolo[1,5—a]pyridinyl)—
4-methyl—3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindol—8—yl]piperazine—l—carboxylate
(compound 53)
To a on of tert-butyl 4-[(4R,10bS)methyl-l,2,3,4,6,10b-hexahydropyrazino[2,l-
a]isoindol-8—y1]piperazinecarboxylate (compound 11, 42.0 mg, 113 umol) in dioxane (5 mL)
was added 4—chloropyrazolo[1,5-a]pyridinecarbonitrile (20 mg, 113 umol), RuPhos Pd G2
(CAS: 13753250, Sigma-Aldrich, Catalog: 753246; 8.7 mg, 11.3 umol) and CszC03 (110
mg, 338 umol). The reaction mixture was stirred at 90 0C for 20 hrs, then cooled to room
temperature, diluted with water (20 mL), and ted with EA (30 mL) for three times. The
combined organic layer was washed with brine, dried over , filtered and concentrated in
vacuo. The residue was purified by flash chromatography (silica gel, 24 g, 0% to 100% EtOAc in
PE) to afford compound Sa (15 mg, 26 % yield). MS: calc’d 514 [(M+H)+], ed 514
[(M+H)+l-
Step 2: preparation of 4-[(4R,10bS)—4-methylpiperazinyl-3,4,6,10b-tetrahydro-
lH-pyrazino[2,1-a]isoindolyl]pyrazolo[1,5-a]pyridinecarbonitrile (Example 5)
To a solution of tert—butyl 4—[(4R,10bS)-2—(7-cyanopyrazolo[1,5-a]pyridinyl)—4-methyl-
3,4,6,10b-tetrahydro-1H—pyrazino[2,1-a]isoindolyl]piperazinecarboxylate (compound 5a,
mg, 29.2 umol) in DCM (3 mL) was added TFA (1 mL). The reaction was stirred at room
temperature for 30 min, then concentrated to afford a crude product, which was purified by prep-
HPLC to afford Example 5 (3.3 mg, 27 % yield). MS: calc’d 414 [(M+H)+], measured 414
[(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) 5 ppm 7.96 (d, J = 2.32 Hz, 1 H), 7.39 (d, J =
8.07 Hz, 1 H), 7.09 (d, J: 8.31 Hz, 1 H), 6.94 (s, 1 H), 6.83 (d, J: 2.45 Hz, 1 H), 6.79 (dd, J:
8.31, 2.08 Hz, 1 H), 6.59 (d, J= 8.07 Hz, 1 H), 4.08 - 4.24 (m, 2 H), 3.67 - 3.88 (m, 2 H), 3.55
(br d, J: 13.33 Hz, 1 H), 2.97 - 3.13 (m, 5 H), 2.85 - 2.96 (m, 5 H), 2.73 (dd, J: 12.35, 10.51
Hz, 1 H), 1.18 (d, J= 6.48 Hz, 3 H).
Example 6
7-[(4R,10bS)—4-methyl—8—piperazinyl-3,4,6,10b—tetrahydr0—lH-pyrazino[2,1-a]isoindol—2—
yl]-1,3-benzothiazole-4—carbonitrile
The title compound was prepared in analogy to the preparation of Example 1 by using 7-
fluoro-l,3-benzothiazolecarbonitrile instead of 5-fluoroquinolinecarbonitrile (compound
1c). Example 6 (15 mg) was obtained. MS: calc’d 431 [(M+H)+], ed 431 +]. IH
NMR (400 MHz, METHANOL-d4) (5 ppm 9.44 (s, 1 H), 7.92 (d, J: 8.31 Hz, 1 H), 7.21 (d, J:
8.31 Hz, 1 H), 7.18 (d, J: 8.19 Hz,1 H), 7.05 (d, J= 1.47 Hz, 1H), 6.90 (dd, J: 8.31, 2.08 Hz,
1 H), 4.28 (d, J: 12.35 Hz, 1 H), 4.22 (br d, .1: 11.13 Hz, 1 H), 3.90 (br (1, J: 10.39 Hz, 1 H),
3.79 (br (1, .1: 11.74 Hz, 1 H), 3.67 (br d, J: 12.10 Hz, 1 H), 3.10 — 3.21 (m, 5 H), 2.94 — 3.07
(1n, 5 H), 2.83 - 2.92 (m, 1 H), 1.30 (d, J: 6.24 Hz, 3 H).
Example 7
8-[(4R,10bS)—4—methyl-8—piperazinyl-3,4,6,10b-tetrahydro—lH—pyrazino[2,1-a]is0indol—2-
yl]quinoxaline—S-carbonitrile
W 95.l N
The title compound was prepared in analogy to the preparation of Example 5 by using 8-
bromoquinoxaline—5-carbonitrile instead of 4-chloropyrazolo[1,5-a]pyridinecarbonitrile.
Example 7 (3.3 mg) was obtained. MS: calc’d 426 [(M+H)+], measured 426 +]. 1H NMR
(400 MHz, METHANOL-d4)(5 ppm 8.85 (dd, J: 11.25, 1.71 Hz, 2 H), 8.04 (d, J: 8.31 Hz, 1
H), 7.21 (d, J: 8.31 Hz, 1 H), 7.06 (d, .1: 8.07 Hz, 1 H), 6.94 (s, 1 H), 6.78 (dd, J: 8.25, 2.02
Hz, 1 H), 4.58 (br (1, J = 11.13 Hz, 1 H), 4.10 - 4.21 (m, 2 H), 3.90 (br (1, J: 10.88 Hz, 1 H),
3.55 (br d, J: 12.72 Hz, 1 H), 3.13 — 3.18 (m, 1 H), 3.02 — 3.06 (m, 4 H), 2.98 (t, J: 11.07 Hz,1
H), 2.88 - 2.93 (m, 4 H), 2.78 - 2.86 (m, 1 H), 1.17 (d, J: 6.48 Hz, 3 H).
Example 8
-[(4R,10bS)—4-methylpiperazinyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol—2-
yl]quinoline-S-carbonitrile
The title compound was ed in analogy to the preparation of Example 1 by using
methyl 2-bromo—6-formyl-benzoate instead of 5-bromoformy1benzoate. Example 8 (19.6 mg)
was obtained. MS: calc’d 425 [(M+H)+], measured 425 [(M+H)+]. 1H NMR (400 MHZ,
METHANOL-d4) 6 ppm 9.02 (dd, J: 4.28, 1.59 Hz, 1 H), 8.74 (dd, J: 8.56, 1.59 Hz, 1 H), 8.19
(d, J = 7.95 Hz, 1 H), 7.71 (dd, J = 8.56, 4.28 Hz, 1 H), 7.36 (d, J: 8.07 Hz, 1 H), 7.23 (t, J:
7.70 Hz, 1 H), 6.91 (d, J: 7.70 Hz, 2 H), 4.31 (d, J=11.98 Hz, 1 H), 4.15 (br d, J: 10.27 Hz,1
H), 3.93 (br d, J: 10.76 Hz, 1 H), 3.69 (dd, Jr- 11.98, 2.20 Hz, 1 H), 3.42 - 3.53 (m, 1 H), 3.35-
3.38 (m, 1H), 2.90 - 3.13 (m, 9 H), 2.85 (dd, J: 11.86, 10.27 Hz, 1 H), 1.30 (d, J: 6.36 Hz, 4
Example 9
—[(4R,10bS)-4—methyl(4-piperidyl)—3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindol—Z-
yl]quinoline-S—carbonitrile
The title compound was prepared ing to the following scheme:
Q N
N 0%
k °6
dppf.DCM KZCO3 MeOH
e/water
Br fl:
11‘ 9b
IT N
/ 35:“:
——“-—""—’
_._____._... :50
DIEA DMSO MlN
>Lo0a
Examp|e9
Step 1: preparation of tert—butyl 4-[(4R,10bS)benzyl—4-methyl-3,4,6,10b-tetrahydro-
lH-pyrazino[2,1-a]isoindol-S-yl]-3,6-dihydro-2H-pyridine-l-carboxylate (compound 9a)
To a 10 mL microwave Vial was added tert—butyl ,5,5-tetramethyl-1,3,2-dioxaborolan—
2-yl)—3,6-dihydro-2H—pyridine-l-carboxylate (130 mg, 420 umol), (4R,lObS-Z-benzyl—S—bromo-
4-methyl-3,4,6,10b-tetrahydro-lH—pyrazino[2,l~a]isoindole (compound lj, 100 mg, 280 pmol),
PdC12(dppt)'DCM adduct (20.5 mg, 28 pmol), and K2CO3 (77.4 mg, 560 umol) in dioxane (4
mL) and water (0.4 mL). The reaction mixture was heated in the microwave at 100 0C for 30
min, then cooled to room temperature, diluted with water (50 mL) and extracted with DCM (30
mL) for three times. The combined organic layer was washed with brine, dried over Na2804,
filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel,
40 g, 0% to 30% EtOAc in PE ) to afford compound 9a (83 mg, 64% yield). MS: calc’d 460
[(M+H)+], measured 460 [(M+H)+].
Step 2 : preparation of tert—butyl 4-[(4R,10bS)methyl-1,2,3,4,6,10b-
hexahydropyrazino[2,1-a]isoindolyl]piperidine-l-carboxylate und 9b)
A mixture of tert—butyl ,10bS)-2—benzylmethyl-3,4,6,lOb—tetrahydro—IH-
pyrazin0[2,l—a]isoindolyl]-3,6-dihydro-2H-pyridine-l-carboxylate (compound 9a, 83 mg, 180
umol) and Pd(OH)2 (10 mg) in MeOH (20 mL) was hydrogenated with a hydrogen n at
room temperature for 30 min. After the catalyst was filtered off, the filtrate was concentrated in
vacuo to afford compound 9b (62 mg, 75% yield) which was directly used for the next step
without further purification. MS: calc’d 372 [(M+H)+], measured 372 [(M+H)+].
Step 3: preparation of tert-butyl 4-[(4R,10bS)(8-cyano—5—quinolyl)—4-methyl-
3,4,6,10b-tetrahydro—lH-pyrazino[2,1—a]isoindolyl]piperidine-l-carboxylate (compound
To a solution of oquinolinecarbonitrile (compound 1c, 19 mg, 113 umol) in
DMSO (2 mL) was added tert-butyl 4-((4R,10bS)~4—methyl-1,2,3,4,6,10b-
hexahydropyrazino[2,1-a]isoindolyl)piperidine-l-carboxylate (compound 9b, 42 mg, 113
umol) and DIEA (73 mg, 565 umol). The reaction e was stirred at 120 0C for 5 hrs, then
cooled to room ature, diluted with water (10 mL), and extracted with EA (15 mL) twice.
The combined organic layer was washed with brine, dried over Na2SO4, filtered and
concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 24 g, 0% to
100% EtOAc in PE) to afford compound 9c (40 mg, 68% yield). MS: calc’d 524 [(M+H)+],
measured 524 [(M+H)+].
Step 4: ation of ,10bS)methyl—8-(4—piperidyl)—3,4,6,10b-tetrahydro-1H—
pyrazino[2,1-a]isoindol—2-yl]quinoline-S-carbonitrile (Example 9)
To a on of tert—butyl 4-((4R,10bS)(8—cyanoquinolinyl)methyl-1,2,3,4,6,10b-
hexahydropyrazino[2,1 -a]isoindoly1)piperidinecarboxylate (compound 9c, 40 mg, 76.4
mMMMEMOmeww®dWAUmUTMmmmmmmmMMmemmmmmbr
30 min, then concentrated to afford a crude product, which was purified by prep-HPLC to afford
Example 9 (12 mg, 38 % yield). MS: calc’d 424 [(M+H)+], measured 424 [(M+H)+]. ‘H NMR
(400 MHz, METHANOL-d4) 5 ppm 9.07 (dd, J: 4.22, 1.65 Hz, 1 H), 8.81 (dd, J: 862, 1.53
Hz, 1 H), 8.22 (d, J: 7.95 Hz, 1 H), 7.76 (dd, J: 8.56, 4.28 Hz, 1 H), 7.47 - 7.53 (m, 2 H), 7.35
- 7.45 (m, 2 H), 5.34-5.38 (m, 1 H), 4.98 (br (1, J: 13.69 Hz, 1 H), 4.68 (br d, J: 13.94 Hz, 1
H), 4.33 (br s, 1 H), 3.85-4.15 (m, 1 H), 3.65-3.72 (1n, 1 H), 3.54 (br d, J: 12.72 Hz, 2 H), 3.12 -
3.24 (in, 3 H), 2.96 - 3.09 (m, 1 H), 1.87 - 2.15 (m, 5 H), 1.56 (d, J: 6.72 Hz, 3 H).
Example 10
-[(4R,10bS)-8—[(2R)(hydr0xymethyl)piperazin-1—yl]methyl—3,4,6,lOb-tetrahydrO-IH-
pyrazino[2,1-a]isoindol-Z-yl]quinoline—S-carbonitrile
The title compound was prepared according to the following scheme:
%ng:Qék;:;:::—~=—~~¥—~ @kiii;
N II
HO“ H
/Z \—/z
OA< N
TFA/DCM
___.._.____. Nj\
tBuXPhos Pd G3, t~BuONa
e HO
HO‘ "v
10c Example 10
Step 1 : preparation of (4R, 1 0bS)bromomethyl-1,2,3,4,6,10b—
hexahydropyrazino[2,1-a1isoindole (compound 10a)
To a stirred solution of (4R,10bS)—2~benzylbr0mo—4-methy1~3,4,6,10b-tetrahydro-IH—
pyrazino[2,1-a]isoindole (compound 1j, 900 mg, 2.4 mmol) in DCE (30 mL) at room
temperature was added l—chloroethyl ochloridate (1.7 g, 12.1 mmol). The reaction mixture
was heated under reflux overnight and cooled to room temperature before concentrated in vacuo.
The residue was dissolved in MeOH (20 mL) and heated under reflux for additional 2 hrs, then
cooled to room temperature and concentrated in vacuo. The residue was diluted with water (10
mL), basified with aq. NaHC03, and ted with EtOAc twice. The ed organic layer
was washed with brine, dried over Na2804, filtered and concentrated in vacuo to afford
compound 10a (660 mg, 98% yield), which used directly to the next step. MS: calc’d 267 and
269 [(M+H)+], measured 267 and 269 +].
Step 2: preparation of 5-[(4R,10bS)-8—bromo-4—methyl-3,4,6,10b-tetrahydro—1H—
pyrazino[2,1-a]isoindolyl]quinoline-S-carbonitrile (compound 10b)
To a solution of 5-fluoroquinoline-8~carbonitrile (compound 1c, 258 mg, 1.5 mmol) in
DMSO (10 mL) was added (4R,10bS)bromo—4-methyl-1,2,3,4,6,10b-hexahydropyrazino[2,1-
a]isoindole (compound 103, 400 mg, 1.5 mmol) and DIEA (1.3 mL, 7.5 mmol). The reaction
mixture was d at 120 0C for 5 hrs, then cooled to room temperature, quenched with water
(50 mL), and extracted with BA (80 mL) twice. The combined organic layer was washed with
brine, dried over Na2804, filtered and trated in vacuo. The residue was purified by flash
chromatography to afford compound 10b (450 mg, 72 % yield). MS: calc’d 419 and 421
[(M+H)+], measured 419 and 421 [(M+H)+].
Step 3: preparation of tert—butyl (3R)—4-[(4R,10bS)—2-(8-cyano-5—quin01yl)—4-methyl-
3,4,6,10b-tetrahydr0-lH-pyrazino[2,1-a]isoindolyl](hydroxymethyl)—piperazine—1—
ylate (compound 10c)
To a solution of 5-[(4R,10bS)—8-bromomethyl-3,4,6,10b-tetrahydro—1H—pyrazino[2,1-
ndol—Z-y1]quinoline-S—carbonitrile (compound 10b, 70 mg, 167 umol) in dioxane (10 mL)
was added tert-butyl (3R)—3-(hydroxymethyl)piperazine—l—carboxylate (CAS: 2787882,
Accela ChemBio, Catalog: SYOl7685, 43.2 mg, 200 umol), t—BuONa (32.1 mg, 334 umol) and
tBuXPhos Pd G3 (CAS: 1447963—75-8, Sigma-Aldrich, Catalog: 762229, 13.3 mg, 167 umol).
The reaction e was stirred at 90 0C overnight, then cooled to room temperature, diluted
with water (50 mL) and extracted with BA (30 mL) for three times. The combined organic layer
was washed with brine, dried over , filtered and concentrated in vacuo. The residue was
purified by flash chromatography (silica gel, 40 g, 30% to 100% EtOAc in PE) to afford
compound 10c (21 mg, 23 % yield). MS: calc’d 555 [(M+H)+], measured 555 [(M+H)+].
Step 4: preparation of ,10bS)[(2R)(hydroxymethyl)piperazinyl]
methyl-3,4,6,l0b-tetrahydro-lH—pyrazino[2,1-a]isoindol—Z-yl]quinoline—8-earbonitrile
(Example 10)
To a solution of tert-butyl (3R)[(4R,10bS)(8-cyanoquinoly1)—4-methy1-3,4,6,10b-
tetrahydro—1H—pyrazino[2,1~a]isoindol-8—yl]-3—(hydroxymethyl)—piperazine- 1 —earboxylate
(compound 10c, 21 mg, 38 umol ) in DCM (2 mL) was added TFA (1 mL). The reaction mixture
was d at room temperature for 30 min, then concentrated to afford a crude product, which
was purified by PLC to afford Example 10 (8 mg, 46% yield). MS: calc’d 455 [(M+H)+],
measured 455 +]. 1H NMR (400 MHz, METHANOL-d4) (5 ppm 9.01 (dd, J = 4.16, 1.47
Hz, 1 H), 8.73 (dd, J = 8.62, 1.53 Hz, 1 H), 8.19 (d, J = 7.95 Hz, 1 H), d, J= 8.56, 4.28
Hz, 1 H), 7.35 (d, J: 8.07 Hz, 1 H), 7.14 (d, J: 8.19 Hz, 1 H), 7.07 (s, 1 H), 6.90 (br d, J: 8.19
Hz, 1 H), 4.28 (d, J= 12.23 Hz, 1 H), 4.09 (br (1, J= 10.51 Hz, 1 H), 3.87 (br d, J: 10.76 Hz, 1
H), 3.61 — 3.78 (m, 3 H), 3.41 — 3.49 (m, 2 H), 3.14 - 3.25 (m, 2 H), 2.97 — 3.13 (m,5 H), 2.80
2.93 (m, 2 H), 1.28 (d, J= 6.36 Hz, 3H).
Example 11
-[(4R,10bS)[(ZS)(hydroxymethyl)piperazinyl]methyl-3,4,6,10b-tetrahydr0—1H—
pyrazino[2,1-a]isoindol—2-yl]quinoline—S—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl (3S)—3-(hydroxymethyl)piperazineCarboxylate (CAS: 3147417, Accela
ChemBio, Catalog: SY020478) instead of tert-butyl (3R)—3-(hydroxymethyl)piperazine—1-
carboxylate. Example 11 (24 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455
[(M+H)+]. 1H NMR (400 MHZ, METHANOL—d4) (5 ppm 9.02 (dd, J = 4.16, 1.47 Hz, 1 H), 8.73
(dd, J: 8.62, 1.53 Hz, 1 H), 8.19 (d, J: 7.95 Hz, 1 H), 7.71 (dd, J: 8.56, 4.28 Hz, 1 H), 7.35
(d, J: 8.07 Hz, 1 H), 7.14 (d, J: 8.19 Hz, 1 H), 7.07 (s, 1 H), 6.90 (br (1, J: 8.19 Hz, 1 H), 4.28
(d, J= 12.23 Hz,1 H), 4.09 (br d, J=10.51 Hz, 1 H), 3.89 (br d, J: 10.76 Hz, 1 H), 3.61 - 3.78
(111,3 H), 3.41 — 3.49 (m, 2 H), 3.14 — 3.25 (m, 2 H), 2.96 — 3.12 (m,5 H), 2.80 — 2.93 (m, 2 H),
1.28 (d, J: 6.36 Hz, 3H).
Example 12
-['(4R,10bS)[(3S)—-3—(hydr0xymethyl)piperazin-l-yl]methyl-3,4,6,10b-tetrahydro-IH-
pyrazino[2,1-a]isoindolyl]quinoline-S-carbonitrile
The title compound was ed in analogy to the preparation of Example 10 by using
tert-butyl (25)—2-(hydroxymethyl)piperazinecarboxy1ate (CAS: 10303779, Accela
ChemBio, Catalog: SY018056) instead of utyl -(hydroxymethy1)piperazine-1~
carboxylate. Example 12 (8.6 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455
[(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) 6 ppm 9.07 (dd, J = 4.28, 1.59 Hz, 1 H), 8.80
(dd, J: 8.62, 1.53 Hz, 1 H), 8.22 (d, J= 7.95 Hz, 1 H), 7.75 (dd, .1: 8.56, 4.28 Hz, 1 H), 7.35 -
7.47 (m, 2 H), 7.24 (s, 1 H), 7.13 (dd, J: 8.50, 2.14 Hz, 1 H), 5.24—5.31 (m, 1 H), 4.95 (br d, J:
13.57 Hz, 1 H), 4.65 (br d, J: 13.69 Hz, 1 H), 4.34 (br s, 1 H), 3.82 - 3.95 (m, 4 H), 3.72-3.80
(m, 1 H), 3.67 (br s, 1 H), 3.46 - 3.56 (m, 3H), 3.34—3.39 (m, 1H), 2.96 — 3.24 (m, 3 H), 1.56 (d, J
= 6.72 Hz, 3 H).
Example 13
-[(4R,10bS)methyl—8-(3—0xa—7,9—diazabicyclo[3.3.1]n0nan—7—yl)—3,4,6,IOb-tetrahydro—
lH—pyrazino[2,1-a]isoindol—Z-yl]quinoline-S-carbonitrile
(in);O
The title compound was ed in analogy to the preparation of Example 10 by using
tert-butyl 3 —oxa-7,9—diazabicyclo[3 .3. 1 ]nonanecarboxy1ate (CAS: 1251010-45—3,
PharmaBlock, Catalog: PB07078) instead of utyl (3R)(hydroxymethyl)piperazine
carboxylate. Example 13 (8.2 mg) was obtained. MS: calc’d 467 [(M+H)+], measured 467
[(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) (5 ppm 9.02 (dd, J = 4.28, 1.59 Hz, 1 H), 8.73
(dd, J: 8.56, 1.59 Hz, 1 H), 8.18 (d, J: 7.95 Hz, 1 H), 7.71 (dd, J: 8.62, 4.22 Hz, 1 H), 7.34
(d, J = 8.07 Hz, 1 H), 7.13 (d, J= 8.31 Hz, 1 H), 7.01 (d, J= 1.71 Hz, 1 H), 6.83 (dd, J= 8.31,
2.20 Hz, 1 H), 4.29 (d, J = 12.23 Hz, 1 H), 4.10 (b1 (1, J = 10.27 Hz, 1 H), .02 (m, 4 H),
3.77 - 3.91 (m, 3 H), 3.71 (br d, J= 12.23 Hz, 1 H), 3.46 (br d, J= 11.49 Hz, 1 H), 3.09 - 3.19
(111,2 H), 2.96 - 3.09 (m, 1 H), 2.93—3.07 (m, 3H), 2.82 - 2.92 (m, 1 H), 1.28 (d, J: 6.36 Hz, 3 H).
Example 14
-[(4R,10bS)—4-methyl(9-oxa-3,7-diazabicyclo[3.3.1]n0nanyl)-3,4,6,10b-tetrahydro-
1H-pyrazino[2,1-a]isoindol—Z-yl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl 9-oxa-3,7-diazabicyclo[3.3.1]nonanecarboxylate (CAS: 4786470, WuXi
Pharma, Catalog: WX120052) instead of tert—butyl (3R)-3—(hydroxymethyl)piperazine—1-
carboxylate. Example 14 (7.2 mg) was ed. MS: calc’d 467 [(M+H)+], measured 467
+]. 1H NMR (400 MHz, METHANOL-d4) 6 ppm 9.02 (dd, J = 4.22, 1.53 Hz, 1 H), 8.71
(dd, J: 8.56, 1.47 Hz, 1 H), 8.18 (d, J = 7.95 Hz, 1 H), 7.72 (dd, J: 8.56, 4.28 Hz, 1 H), 7.33
(d, J: 8.07 Hz, 1 H), 7.14 (d, J= 8.31 Hz, 1 H), 7.09 (s, 1 H), 6.90 (dd, J2 8.25, 2.02 Hz, 1 H),
4.29 (d, J = 12.23 Hz, 1 H), 4.08 (br (1, J= 10.15 Hz, 1 H), 3.87 (br s, 3 H), 3.77 (br dd, J =
11.68, 6.17 Hz, 2 H), 3.69 (br d, J: 12.10 Hz, 1 H), 3.45 (br d, J: 11.74 Hz, 1 H), 3.24-3.35 (m,
3H), 3.09 - 3.23 (m, 4 H), 3.02 (t, J= 10.88 Hz, 1 H), 2.85 (t, J = 11.07 Hz, 1 H), 1.27 (d, J:
6.48 Hz, 3 H).
Example 15
-[(4R,10bS)(6-hydroxy-1,4-diazepan—1-yl)methyl-3,4,6,10b—tetrahydro—1H—
pyrazino[2,1-a]isoindolyl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
utyl 6—hydroxy—1,4-diazepane—1-earboxylate (CAS: 956317~40-1, WuXi Pharma, Catalog:
WX604354) instead of tert-butyl (3R)(hydroxymethyl)piperazinecarboxy1ate. Example 15
(7.2 mg) was obtained. MS: calc’d 455 +], measured 455 [(M+H)+]. 1H NMR (400 MHz,
METHANOL-d4) 0‘ ppm 9.00 (d, J: 3.06 Hz, 1 H), 8.69 (d, J: 8.56 Hz, 1 H), 8.15 (d, J = 8.07
Hz, 1 H), 7.69 (dd, J: 8.56, 4.28 Hz, 1 H), 7.30 (d, J: 8.07 Hz, 1 H), 7.04 (d, .1: 8.31 Hz, 1 H),
6.87 (s, 1 H), 6.68 (d, J: 8.31 Hz, 1 H), 4.23 (br d, J= 12.23 Hz, 1 H), 3.98 — 4.13 (m, 2 H),
3.76 - 3.94 (m, 2 H), 3.54 - 3.49 (m, 4 H), 2.92 - 3.08 (m, 3 H), 2.69 - 2.89 - 3.74 (m, 2 H), 3.33
(m, 3 H), 1.26 (d, J: 6.36 Hz, 3 H).
-58—
Example 16
-[(4R,10bS)[transaminomethoxy-pyrrolidinyl]methyl—3,4,6,10b-tetrahydro-
1H-pyrazin0[2,1-a]isoindoI-Z-yl]quinoline-S-carbonitrile
The title nd was prepared in azalogy to the preparation of Example 10 by using
trans(boc~amino)-4—meth0xypyrrolidine (CAS: 128739-924, PharmaBlock, Catalog:
21069) instead of tert—butyl (3R)(hydr0xymethyl)piperazine-1—carb0xylate. Example
16 (58 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H NMR (400
MHz, METHANOL-d4) 0‘ ppm 9.01 (dd, J = 4.22, 1.65 Hz, 1 H), 8.72 (dd, .1: 8.56, 1.59 Hz, 1
H), 8.17 (d, J: 7.95 Hz, 1 H), 7.70 (dd, J: 8.62, 4.22 Hz, 1 H), 7.34 (d, J: 8.19 Hz, 1 H), 7.07
(d, J = 8.07 Hz, 1 H), 6.64 (d, J: 1.47 Hz, 1 H), 6.46 (dd, J: 8.25, 2.02 Hz, 1 H), 4.26 (d, J:
12.10 Hz, 1 H), 4.08 (br d, J: 10.51 Hz, 1 H), 3.86 (br d,J= 11.13 Hz, 1 H), 3.77 — 3.83 (ml
H), 3.64 - 3.74 (1n, 2 H), 3.49 - 3.57 (m, 2 H), 3.45-3.49(m, 1H), 3.44 (s, 3 H), 3.35-3.40 (in, 1H),
3.25 (dd, .1: 10.51, 2.81 Hz, 1 H), 3.06 - 3.17 (m, 1 H), 2.96 — 3.04 (m, l H), 2.80 - 2.92 (m, 1
H), 1.28 (d, .1: 6.48 Hz, 3 H).
2019/064323
Example 16A and 16B: 5-[(4R,10bS)—8-[(3S,4S)—3-amin0methoxy—pyrrolidin—1-yl]-4—
methyl-3,4,6,10b-tetrahydro-lH-pyrazino[2,1—a]isoindol-Z-yl]quinoline—S-carbonitrile and
-[(4R,10bS3-8—[(3R,4R)amino—4-methoxy-pyrrolidin-l-yl]—4—methyl—3,4,6,10b—
tetrahydro—lH-pyrazino[2,1-a]isoindol—2-yl]quinoline-S—carbonitrile
N N
N\ N
/ /
Preparation of Example 16A & 16B:
N N N
I I | I | |
N N N
\ \ \
/ / /
N N N
j\ SFC chiral separation j\ + l
N N N
HN HN/O HN“'Q
o 5 0/40 5 0’4
7g 0 \ 7g \ 7g 0 °\
16c-a&16c-b
TFA’DCM l TFA/DCM
16A&1GB
Intermediate 16c (162 mg) was resolved by SFC to give two single isomers: 16c-a (faster
eluting, 62 mg, yield: 38%) MS: calc'd 555 (M+H) +, measured 555 ; and compound 16c-
b (slower eluting, 76 mg, yield: 47%) MS: calc'd 555 (M+H) +, measured 555 (M+H)+, with 40%
l (0.25% )/C02 on OJ (5 pm, 250><20 mm) column.
To a on of compound 16c-a (62 mg, 112 umol) in DCM (4 mL) was added TFA (1
mL). The reaction mixture was stirred at room temperature for 30 min, then concentrated to
afford a crude product, which was purified by prep-HPLC to afford Example 16A (42 mg, 82%
yield). MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H NMR (400 MHZ, METHANOL—
d4) 5 ppm 9.01 (dd, J = 4.22, 1.65 Hz, 1 H), 8.72 (dd, J= 8.56, 1.59 Hz, 1 H), 8.17 (d, J= 7.95
Hz, 1 H), 7.70 (dd, J: 8.62, 4.22 Hz, 1 H), 7.34 (d, J: 8.19 Hz, 1 H), 7.07 (d, J: 8.07 Hz, 1 H),
6.64 (d, J= 1.47 Hz, 1 H), 6.46 (dd, J= 8.25, 2.02 Hz, 1 H), 4.26 (d, J= 12.10 Hz, 1 H), 4.08 (br
d, J: 10.51 Hz, 1 H), 3.86 (br d, J: 11.13 Hz, 1 H), 3.77 - 3.83 (m, 1 H), 3.64 - 3.74 (m, 2 H),
3.49 - 3.57 (m, 2 H), 3.45-3.49(m, 1H), 3.44 (s, 3 H), 3.35-3.40 (m, 1H), 3.25 (dd, J: 10.51,
2.81 Hz, 1 H), 3.06 - 3.17 (m, 1 H), 2.96 — 3.04 (m, l H), 2.80 - 2.92 (m, 1 H), 1.28 (d, J: 6.48
Hz, 3 H).
Example 16B was prepared in analogy to Example 16A (51 mg, 82% yield). MS: calc’d
455 [(M+H)+], measured 455 [(M+H)+]. 'H NMR (400 MHz, METHANOL-d4) 5 ppm 9.01 (dd,
J: 4.28, 1.59 Hz, 1 H), 8.72 (dd, J: 8.68, 1.59 Hz, 1 H), 8.18 (d, J: 8.07 Hz, 1 H), 7.71 (dd, J
= 8.56, 4.28 Hz, 1 H), 7.34 (d, .1: 8.07 Hz, 1 H), 7.06 (d, J = 8.19 Hz, 1 H), 6.64 (s, 1 H), 6.46
(dd, J: 8.25, 2.02 Hz, 1 H), 4.26 (d, J: 12.10 Hz, 1 H), 4.08 (hr (1, J: 10.27 Hz, 1 H), 3.86 (br
d, J: 11.25 Hz, 1 H), 3.78 - 3.83 (m, 1 H), 3.63 - 3.75 (m, 2 H), 3.49 — 3.58 (m, 2 H), 3.40-3.47
(m, 1 H), 3.44 (s, 3 H), 3.35-3.38 (m, 1H), 3.24 (dd, J=10.51,2.81 Hz, 1 H), 3.07 — 3.17 (m, l
H), 2.96 - 3.04 (m, 1 H), 2.78 — 2.93 (m, 1 H), 1.28 (d, J: 6.48 Hz, 3 H).
Example 17
-[(4R,10bS)—8-leisamino—4-methoxy-pyrrolidinyl]methyl-3,4,6,lOb-tetrahydro-IH-
pyrazino[2,1-a]isoindol—Z-yl]quinoline-S—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using cis-
3—(boc—amino)methoxypyrrolidine (CAS: 1287399, PharmaBlock, Catalog: PBXA8055)
d of tert-butyl (3R)(hydroxymethy1)piperazine-1—carboxylate. Example 17 (36 mg) was
obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H NMR (400 MHz,
METHANOL-d4) 5 ppm 9.02 (dd, J: 4.28, 1.59 Hz, 1 H), 8.72 (dd, .1: 8.62, 1.53 Hz, 1 H), 8.18
(d, J: 7.95 Hz, 1 H), 7.71 (dd, J = 8.56, 4.28 Hz, 1 H), 7.33 (d, .1: 8.07 Hz, 1 H), 7.05 (d, J =
8.07 Hz, 1 H), 6.60 (s, 1 H), 6.42 (dd, J: 8.25, 1.90 Hz, 1 H), 4.25 (d, J: 12.23 Hz, 1 H), 4.07
(br d, J: 10.27 Hz, 1 H), 3.91 (br (1, J: 293 Hz, 1 H), 3.85 (br (1, J: 11.00 Hz, 1 H), 3.67 (br d,
J: 12.10 Hz, 1 H), 3.55 - 3.63 (m, 1 H), 3.39 — 3.54 (m, 8 H), 2.96 - 3.11 (m, 2 H), 2.79 - 2.91
(m, 1 H), 1.27 (d, J: 6.48 Hz, 3 H).
e 18
-I(4R,10bS)(5-amin0oxaazaspiro[3.4]octanyl)methyl-3,4,6,10b-tetrahydro-
1H—pyrazin0[2,1-a]isoindol—Z-yl]quinoline-S-carbonitrile
W0 2019/233941
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl N—(2—oxaazaspiro[3.4]octany1)carbamate (CAS: 14224964, Block,
Catalog: PBLG1162) instead of tert—butyl (3R)(hyd1'oxymethyl)piperazinecarboxy1ate.
Example 18 (12 mg) was ed. MS: cale’d 467 +], measured 467 [(M+H)+]. lH
NMR (400 MHz, METHANOL-d4) (5 ppm 9.01 (dd, J: 4.28, 1.59 Hz, 1 H), 8.73 (dd, J = 8.56,
1.59 Hz, 1 H), 8.17 (d, J= 7.95 Hz, 1 H), 7.69 (dd, J= 8.62, 4.22 Hz, 1 H), 7.34 (d, J= 8.07 Hz,
1 H), 7.08 (d, J: 8.19 Hz, 1 H), 6.65 (s, 1 H), 6.47 (dd, J: 8.13, 1.90 Hz, 1 H), 4.96 (d, J z 6.72
Hz, 1 H), 4.54 — 4.68 (m, 3 H), 4.27 (d, J= 12.23 Hz, 1 H), 4.09 (br d, J: 10.03 Hz, 1 H), 3.87
(br d, J: 11.49 Hz, 1 H), 3.58 - 3.56 (m, 3 H), 3.07 — 3.17 (m, — 3.78 (m, 4 H), 3.42 1 H), 2.94 -
3.04 (m, 1 H), 2.80 - 2.92 (m, 1 H), 1.28 (d, J= 6.36 Hz, 3 H).
Example 19
,10bS)—8-[3-amino-3—(hydroxymethyl)pyrrolidin-l—yl]methyl-3,4,6,10b-tetrahydrolH-pyrazino
[2,1-alisoindolyl]quinoline-8—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl N-[3-(hydroxymethyl)pyrrolidiny1]carbamate (CAS: No, PharmaBlock, Catalog:
PBXA7029-l) instead of tert-butyl (3R)(hydroxymethyl)piperazine-l-carboxy1ate. Example
19 (7.7 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H NMR (400
MHz, METHANOL-d4) 6 ppm 9.06 (dd, J = 4.28, 1.59 Hz, 1 H), 8.79 (dd, J: 8.56, 1.34 Hz, 1
H), 8.21 (d, J = 7.95 Hz, 1 H), 7.75 (dd, J = 8.56, 4.28 Hz, 1 H), 7.41 (br (1, J = 5.62 Hz, 1 H),
7.36 (d, J: 8.44 Hz, 1 H), 6.82 (s, 1 H), 6.71 (dd, J: 8.44, 2.08 Hz, 1 H), 5.27 (br s, 1 H), 4.93
(br d, J: 13.57 Hz, 1 H), 4.62 (br (1, J: 13.82 Hz, 1 H), 4.33 (br s, l H), 3.78 (s, 2 H), 3.75-3.82
(m, 1H), 3.60 - 3.52 (m, 2H), 2.85-3.00 (m, 1H), 2.30 - 2.40
- 3.72 (in, 2 H), 3.54 (s, 2H), 3.43
(m, 1 H), 2.19 - 2.30 (m, l H), 1.55 (d, J: 6.72 Hz, 3 H).
2019/064323
Example 20
- [(4R,10bS)—8—[(3R)amin0pyrrolidin-l-yl}methyl-3,4,6,10b-tetrahydro-1H-
pyrazino[2,1-alisoindol—2-yl]quinoline-8—carb0nitrile
The title compound was prepared in 2analogy to the preparation of e 10 by using
tert-butyl N—[(3R)—pyrrolidinyl]earbamate (CAS: 1225360, Accela ChemBio, Catalog:
SY006424) instead of tert-butyl (3R)(hydroxymethyl)piperazinecarboxylate. Example 20
(8.6 mg) was obtained. MS: calc’d 425 [(M+H)+], measured 425 [(M+H)+]. 1H NMR (400 MHZ,
METHANOL-d4) (3 ppm 9.06 (dd, .1: 4.28, 1.59 Hz, 1 H), 8.80 (d, J: 8.68 Hz, 1 H), 8.21 (d, J
= 7.83 Hz, 1 H), 7.75 (dd, .1: 8.56, 4.28 Hz, 1 H), 7.40 (br s, 1 H), 7.36 (d, J: 8.44 Hz, 1 H),
6.82 (s, 1 H), 6.72 (dd, J: 8.38, 2.02 Hz, 1 H), 5.27 (br s, 1 H), 4.95 (br d, .1: 12.80 Hz, 1 H),
4.62 (br d, J== 13.94 Hz, 1 H), 4.32 (br s, 1 H), 4.08 (br s, 1 H), 3.56 - 3.87 (m, 5 H), 3.39 - 3.54
(m, 2 H), 2.85-3.10 (m, 1H), 2.45 — 2.58 (m, 1 H), 2.15 - 2.26 (m, 1 H), 1.55 (d, J: 672 Hz, 3 H).
1 5 Example 2 1
-[(4R,10bS)-8—[trans-3—amin0hydroxy-pyrrolidin-1~yl]methyl-3,4,6,10b—tetrahydr0-
lH-pyrazino[2,l-a]isoindol—Z—yl]quinoline—S-carbonitrile
The title compound was prepared in analogy to the preparation of e 10 by using
trans(boc—amino)hydroxypyrrolidine (CAS: 8706326, PharmaBlock, Catalog:
2019/064323
—64-
PB07572) d of tert—butyl (3R)—3~(hydroxymethyl)piperazine-l-carboxylate. Example 21
(8.6 mg) was obtained. MS: calc’d 441 [(M+H)+], measured 441 [(M+H)+]. ‘H NMR (400 MHz,
METHANOL—d4) (5 ppm 9.01 (dd, J== 4.28, 1.59 Hz, 1 H), 8.72 (dd, .1: 8.56, 1.59 Hz, 1 H), 8.18
(d, J = 8.07 Hz, 1 H), 7.70 (dd, J: 8.62, 4.34 Hz, 1 H), 7.33 (d, J = 8.07 Hz, 1 H), 7.05 (d, J:
8.07 Hz, 1 H), 6.61 (s, 1 H), 6.31 - 6.53 (m, 1 H), 4.26 (d,J= 12.23 Hz, 1 H), 4.01 ~ 4.17 (m, 2
H), 3.85 (br d, J= 11.13 Hz, 1 H), 3.57 — 3.75 (m, 3 H), 3.45 (br d, J= 11.86 Hz, 1 H), .40
(m, 2H), 3.12 — 3.20 (m, 1 H), 3.05 - 3.12 (m, 1 H), 3.00 (br t, J: 12.00 Hz, 1 H), 2.86 (br t, J:
11.07 Hz, 1 H), 1.27 (d, J= 6.36 Hz, 3 H).
Example 22
-[(4R,1(le)—8—(3-amin0azetidin-1—yl)methyl—3,4,6,10b-tetrahydr0-lH-pyrazino[2,1-
a]isoindol—Z-yl]quinoline-8—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl N—(azetidin—3-y1)carbamate instead of tert—butyl (3R)~3—(hydroxymethyl)piperazine
carboxylate. Example 22 (34 mg) was obtained. MS: calc’d 411 [(M+H)+], measured 411
[(M+H)+]. 1H NMR (400 MHz, METHANOL—d4)5 ppm 8.89 (dd, J = 4.28, 1.59 Hz, 1 H), 8.58
(dd, J: 8.56, 1.59 Hz, 1 H), 8.02 (d, J: 7.95 Hz, 1 H), 7.55 (dd, J: 8.56, 4.28 Hz, 1 H), 7.18
(d, J = 8.07 Hz, 1 H), 7.03 (d, J: 8.07 Hz, 1 H), 6.48 (d, J: 1.59 Hz, 1 H), 6.31 (dd, J: 8.07,
2.08 Hz, 1 H), 4.24 (d, .1: 12.59 Hz, 1 H), 4.04 — 4.16 (in, 3 H), 3.63 - 3.84 (m, 4 H), 3.27 — 3.44
(m, 3 H), 2.87 (t, J=11.13 Hz, 1 H), 2.74 - 2.82 (m, 1 H), 1.18 (d, J: 6.24 Hz, 3 H).
-65—
Example 23
-[(4R,10bS)[(3S,4S)meth0xy(methylamino)pyrrolidin-l-yl]—4-methyl-3,4,6,10b—
tetrahydro-lH—pyrazino[2,1-a]isoindolyl]quinoline-S-carbonitrile
The title compound was ed in analogy to the preparation of e 10 by using
tert—butyl N—[(3S,4S)methoxypyrrolidiny1]-N—methyl-carbamate (CAS: 174727—04—9,
PharrnaBlock, Catalog: PBN20121070) instead of tert—butyl (3R)-3~(hydroxymethyl)piperazine-
oxylate. Example 23 (34 mg) was obtained. MS: calc’d 469 [(M+H)+], measured 469
[(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 6 ppm 9.02 (d, J = 3.06 Hz, 1 H), 8.71 (d, J =
8.68 Hz, 1 H), 8.19 (d, J: 7.95 Hz, 1 H), 7.72 (dd, J= 8.56, 4.28 Hz, 1 H), 7.18 - 7.47 (m, 1 H),
7.06 (d, J: 8.19 Hz, 1 H), 6.65 (s, 1 H), 6.47 (br d, J=8.19 Hz, 1 H), 4.26 (d, J: 11.98 Hz, 1 H),
4.07 (br d, J: 9.78 Hz, 1 H), 3.88 - 3.95 (m, 1 H), 3.85 (br d, .1: 11.37 Hz, 1 H), 3.62 - 3.71 (m,
2 H), 3.56 (dd, J= 9.72, 6.17 Hz, 1 H), 3.43-3.46 (m, 1 H), 3.44 (s, 3 H), 3.23-3.33 (m, 3H), 3.17
(dd, J: 9.78, 3.67 Hz, 1 H), 3.00 (t, J: 1100 Hz, 1 H), 2.86 (br t, J: 11.07 Hz, 1 H), 2.46 (s, 3
H), 1.27 (d, J= 6.36 Hz, 3 H).
Example 24
-[(4R,10bS)—4-methyl(5-oxa-2,8—diazaspiro[3.5]nonanyl)-3,4,6,10b-tetrahydro-IH-
pyrazino[2,1-a]isoindol—2-yl]quinoline—8—carbonitrile
-66—
The title compound was prepared in analogy to the ation of Example 10 by using
tert—butyl 5-oxa-2,8-diazaspiro[3.5]nonanecarboxylate (CAS: 18, PharmaBlock,
Catalog: PBN20111063) instead of tert—butyl (3R)—3~(hydroxymethy1)piperazine-1—carboxylate.
Example 24 (16 mg) was obtained. MS: calc’d 467 [(M+H)+], measured 467 [(M+H)+]. 1H
NMR (400 MHz, METHANOL—d4) (5 ppm 9.04 (dd, J = 1.65, 4.22 Hz, 1H), 8.78 (dd, J: 1.59,
8.56 Hz, 1H), 8.19 (d, J = 7.95 Hz, 1H), 7.73 (dd, J: 4.28, 8.56 Hz, 1H), 7.32 - 7.46 (m, 2H),
7.20 (s, 1H), 7.09 (dd, J: 2.26, 8.50 Hz, 1H), 5.28 (br s, 1H), 4.93 (br d, J: 13.69 Hz, 1H), 4.62
(br (1, J: 13.82 Hz, 1H), 4.32 (br s, 1H), 4.04 - 4.19 (m, 4H), 3.51 - 4.03 (m, 4H), 3.40 (s, 2H),
3.14 - 3.21 (m, 1H), 2.90 - 3.23 (m, 1H), 1.54 (d, J= 6.85 Hz, 3H).
Example 25
-[(4R,10bS)[2-(dimethylamino)ethoxy]methyl—3,4,6,10b-tetrahydro—1H-pyrazino[2,l-
a]isoindol—Z-yl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
N,N-dimethylethanolamine (CAS: 1080, Aldrich, Catalog: 471453) d of tert—butyl
(3R)—3—(hydroxymethyl)piperazine—1-carboxylate. Example 25 (9.4 mg) was ed. MS:
calc’d 428 [(M+H)+], measured 428 [(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) 5 ppm
8.99 (dd, J: 1.65, 4.22 Hz, 1H), 8.71 (dd, J: 1.6, 8.6 Hz, 1H), 8.15 (d, J: 7.95 Hz, 1H), 7.67
(dd, J: 4.22, 8.62 Hz, 1H), 7.32 (d, J: 8.1 Hz,1H), 7.15 (d, J: 8.19 Hz,1H), 7.00 (d, J: 1.96
Hz, 1H), 6.83 (dd, J: 2.32, 8.19 Hz, 1H), 4.28 (d, J: 12.35 Hz, 1H), 4.04 - 4.13 (m, 3H), 3.82 -
3.92 (m, 1H), 3.69 (br d, J: 12.23 Hz, 1H), 3.40 - 3.48 (m, 1H), 3.33 - 3.38 (m, 1H), 2.93 - 3.05
(m, 1H), 2.71 — 2.88 (m, 3H), 2.35 (s, 6H), 1.25 (d, J: 6.5 Hz, 3H).
e 26
-[(4R,10bS)[2-(dimethylamino)ethylamino]methyl-3,4,6,10b-tetrahydro—IH-
pyrazino[2,1-alisoindolyl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using 2-
ylaminoethylamine (CAS: 108~00-9, TCI, Catalog: D0719) instead of tert-butyl (3R)
(hydroxymethyl)piperazine—1~carboxylate. Example 26 (19 mg) was obtained. MS: calc’d 427
[(M+H)+], measured 427 [(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) (5 ppm 8.98 (dd, J =
1.59, 4.28 Hz, 1H), 8.70 (dd, J: 1.59, 8.56 Hz, 1H), 8.15 (d, J = 8.07 Hz, 1H), 7.66 (dd, J:
4.22, 8.62 Hz, 1H), 7.31 (d, .1: 8.07 Hz, 1H), 7.00 (d, .1: 7.95 Hz, 1H), 6.69 (d, J: 183 Hz,
1H), 6.52 (dd, J: 2.02, 8.13 Hz, 1H), 4.22 (d, J: 12.10 Hz, 1H), 4.04 (br (1, J: 10.03 Hz, 1H),
3.84 (br d, J: 11.25 Hz,1H), 3.63 (br d, J: 11.98 Hz,1H), 3.33 - 3.38 (m, 1H), 3.43 (br (1, J:
11.49 Hz, 1H), 3.23 (t, J: 6.66 Hz, 2H), 2.98 (t, J: 1088 Hz, 1H), 2.83 (dd, .1: 10.33, 11.80
Hz, 1H), 2.58 (t, J: 6.66 Hz, 2H), 2.31 (s, 6H), 1.25 (d, J = 6.48 Hz, 3H).
Example 27
-[(4R,10bS)(azetidin—3-yloxy)methyl—3,4,6,10b-tetrahydro-lH-pyrazino{2,1-
a]isoindol—Z-yl]quinoline-S—carbonitrile
HNO‘O
WO 33941
The title compound was prepared in analogy to the preparation of e 10 by using
tert—butyl 3—hydroxyazetidine-l—carboxylate (CAS: 141699—55-0, PharmaBlock, Catalog:
PB00001) instead of tert—butyl (3R)(hydroxymethyl)piperazine—1-carboxylate. Example 27
(13 mg) was obtained. MS: calc’d 412 [(M+H)+], measured 412 [(M+H)+]. 1H NMR (400MHz,
METHANOL-d4) 6 ppm 8.90 (dd, J: 1.7, 4.2 Hz, 1H), 8.64 (dd, J: 1.7, 8.6 Hz, 1H), 8.04 (d, J
= 8.1 Hz, 1H), 7.59 (dd, J: 4.2, 8.6 Hz, 1H), 7.27 (dd, J= 8.2, 18.3 Hz, 2H), 6.94 (d, J= 2.2 Hz,
1H), 6.78 (dd, J: 2.3, 8.4 Hz, 1H), 5.15 - 5.02 (m, 1H), 4.92 (dd, J: 3.7, 11.0 Hz, 1H), 4.69 (d,
J: 13.6 Hz, 1H), 4.43 (d, J = 13.6 Hz, 1H), 4.03 - —
- 4.54 (m, 2H), 4.33 4.11 (m, 2H), 3.94
4.02 (m, 1H), 3.80 -
- 3.87 (m, 1H), 3.45 — 3.55 (1n, 1H), 2.96 3.13 (m, 2H), 1.37 (d, J: 6.6 Hz,
3H).
Example 28
,10bS)—8-(azetidin—3-ylamino)—4-methyl-3,4,6,10b-tetrahydro—1H—pyrazino[2,1-
a]isoindol—Z-yl]quinoline-S—carbonitrile
HNO._§
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl 3-aminoazetidinecarboxylate (CAS: 193269-78—2, PharmaBlock, Catalog:
PB00002) instead of lert-butyl (3R)—3—(hydroxymethyl)piperazine-1~carboxylate. Example 28
(30 mg) was obtained. MS: calc’d 411 [(M+H)+], measured 411 +]. 1H NMR (400 MHz,
METHANOL-d4) . 5 ppm 9.03 (dd, J: 1.7, 4.2 Hz, 1H), 8.76 (dd, J: 1.6, 8.6 Hz, 1H), 8.18 (d,
J: 7.9 Hz, 1H), 7.72 (dd, J: 4.3, 8.6 Hz, 1H), 7.37 (d, J: 8.1 Hz, 1H), 7.23 (d, J: 8.3 Hz, 1H),
6.73 (d, J: 1.8 Hz, 1H), 6.61 (dd, J: 2.1, 8.3 Hz,1H), 4.93 - 4.96 (m, 1H), 4.71 (d, J: 13.3 Hz,
1H), 4.51 - 4.62 (m, 1H), 4.39 - 4.49 (1n, 2H), 4.34 (d, J: 13.4 Hz, 1H), 3.97 - 4.13 (m, 3H),
3.84 - 3.95 (1n, 1H), 3.51 — 3.6.5 (m, 1H), 3.03 - 3.24 (m, 2H), 1.47 (d, J: 6.7 Hz, 3H).
Example 29
- [(4R,10bS)(azetidin-S-yl)methyl-3,4,6,1 rahydro-lH-pyrazino [2, 1 -a] isoindol-Z-
noline—S-carbonitrile
The title compound was prepared according to the following scheme:
31):; | l
MEL )40 N:
!p \/2
<39 a
10b 293 H Example 29
Step 1: preparation of tert-butyl 3-[(4R,10bS)(8—cyanoquinolyl)methyl-3,4,6,10b-
tetrahydro—lH-pyrazino[2,1-a]isoindolyl]azetidine-l-carboxylate (compound 29a)
To a suspension of zinc (156 mg, 2.4 mmol) in DMF (3 mL) was added 1,2-dibromoethane
(44.8 mg, 238 umol). The resultant mixture was heated at 60 0C for 10 min, and then cooled to
room temperature. trimethylsilane (25.9 mg, 238 umol) was added to the mixture, stirred
at 60 0C for 10 min, then cooled to room temperature. A solution of tert—butyl 3-iodoazetidine
carboxylate (CAS: 254454-54—1, PharmaBlock, Catalog: PB00430, 675 mg, 2.4 mmol) in DMF
(1 mL) was then added and the e was stirred at room temperature for 1 hr. 5-[(4R,lObS)
bromo-4—methyl —3 ,4,6,10b-tetrahydro—1H-pyrazino[2,l -a]isoindol-Z-yl]quinoline-S-carbonitrile
(compound 10b, 500 mg, 1.2 mmol) and Pd(PPh3)2Clz (83.7 mg, 0.1 mmol) were added
sequentially and the reaction mixture was heated to 80 0C for 4 hrs, then cooled to room
temperature and partitioned between EA and sat.NH4Cl on. The aqueous layer was
extracted with EA twice, and the combined organic layer was washed with water and brine, dried
over Na2804, d and concentrated in vacuo. The residue was purified by flash
chromatography to afford compound 29a (202 mg, 34 % . MS: calc’d 496 [(M+H)+],
measured 496 [(M+H)+].
Step 2: preparation of 5-[(4R,10bS)(azetidin~3-yl)—4-methyl—3,4,6,10b-tetrahydro—1H—
pyrazino[2,1—a]isoindol-Z-yl]quinoline-S-carbonitrile (Example 29)
To a solution of tert-butyl 3-[(4R,10bS)(8-cyano—5—quinolyl)—4-methyl-3,4,6,10b-
tetrahydro-lH-pyrazino[2,1-a]isoindol-8—yl]azetidine-l-carboxylate und 29a, 42 mg, 85
umol ) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room
temperature for 30 min, then trated to afford a crude product, which was purified by pre-
HPLC to afford Example 29 (23 mg, 68 % yield). MS: calc’d 396 [(M+H)+], measured 396
[(M+H)+]. 1H NMR (400 MHz, METHANOL—d4)5 ppm 9.02 (dd, J = 1.71, 4.28 Hz, 1H), 8.79
(dd, J: 1.59, 8.56 Hz, 1H), 8.17 (d, J: 8.07 Hz, 1H), 7.73 (dd, J: 4.28, 8.56 Hz, 1H), 7.61 (s,
1H), 7.54 - 7.58 (m, 1H), 7.43 - 7.52 (m, 1H), 7.39 (d, J = 8.07 Hz, 1H), 5.41 (br dd, J=3.85,
11.19 Hz, 1H), 5.01 (d, J: 13.82 Hz, 1H), 4.72 (d, J: 13.94 Hz, 1H), 4.20 - 4.46 (m, 6H), 3.99
(br s, 1H), 3.68 (br d, .1: 12.96 Hz, 1H), 3.33 - 3.36 (m, 1H), 3.10 - 3.25 (m, 1H), 1.56 (d, J:
6.72 Hz, 3H).
e 30
-[(4R,10bS)-8—| [(3S,4R)—4-fluoropyrrolidinyl]amino]methyl-3,4,6,10b-tetrahydro-IH-
pyrazino[2,1-a]isoindol—Z-yl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl (3S,4R)amino—4-fluoropyrrolidine-l -carboxylate (CAS: 1 1740204,
PharmaBlock, Catalog: PB07374) instead of tert—butyl (3R)—3-(hydroxymethyl)piperazine
ylate. Example 30 (46 mg) was obtained. MS: calc’d 443 [(M+H)+], measured 443
[(M+H)+]. 1H NMR (400 MHz, OL-d4) (5 ppm 9.02 (dd, J = 1.6, 4.3 Hz, 1H), 8.76 (dd,
J: 1.6, 8.6 Hz, 1H), 8.16 (d, J: 7.9 Hz,1H), 7.71 (dd, J: 4.3, 8.6 Hz, 1H), 7.37 (d, J: 8.1 Hz,
1H), 7.26 (d, J: 8.3 Hz,1H), 6.92 (d, J: 1.8 Hz, 1H), 6.81 (dd, J: 2.1, 8.3 Hz, 1H), 5.21 - 5.44
(m, 1H), 5.12 (dd, J: 3.9, 11.0 Hz, 1H), 4.82 (d, J= 13.6 Hz, 1H), 4.38 ~ 4.55 (m, 2H), 4.10 -
4.26 (m, 1H), 3.85 =
— 3.97 (m, 1H), 3.56 - 3.84(m, 4H), 3.20-3.30 (m, 2H), 3.12 (dd, J 11.2,
13.1 Hz,1H), 1.51 (d,J= 6.7 Hz, 3H).
Example 3 1
—[(4R,10bS)-8—[[(3S,4S)flu0r0pyrrolidinyl]amino]—4—methyl-3,4,6,10b-tetrahydro-1H-
pyrazino[2,1-a]isoindol~2—yl]quinoline-8—carbonitrile
@531
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl )—3-aminofluoropyrrolidine—1 -carboxylate (CAS: 10090757,
PharmaBlock, Catalog: PB07376) instead of tert-butyl (3R)-3~(hydroxymethyl)piperazine—l-
carboxylate. Example 31 (46 mg) was obtained. MS: calc’d 443 [(M+H)+], ed 443
[(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 6 ppm 9.01 (d, J = 4.03 Hz, 1H), 8.71 (d, J =
8.19 Hz, 1H), 8.17 (d, J: 8.07 Hz, 1H), 7.70 (dd, J= 4.22, 8.62 Hz, 1H), 7.33 (d, J = 7.95 Hz,
1H), 7.03 (d, J: 8.19 Hz, 1H), 6.75 (s, 1H), 6.59 (br d, J: 8.07 Hz, 1H), 4.77 - 5.02 (m, 1H),
4.24 (d, J = 12.23 Hz, 1H), 4.06 (br d, J = 10.27 Hz, 1H), 3.89 - 4.00 (m, 1H), 3.85 (br d, J =
11.13 Hz, 1H), 3.66 (br d, J: 11.86 Hz, 1H), 3.41 - 3.52 (m, 2H), 2.93 - 3.17 (m, 3H), 2.85 (t, J
=11.13 Hz,1H), 2.75 (dd, J: 4.28, 11.98 Hz, 1H), 1.27 (d, J= 6.36 Hz, 3H).
2019/064323
Example 32
-[(4R,10bS)—8-[[(3R,4S)fluoropyrrolidinyl] methyl—3,4,6,l0b-tetrahydro-1H—
pyrazino[2,1-a]isoindol—2-yl]quinoline—S—carbonitrile
. {Ml
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl (3R,4S)—3-aminofluoropyrrolidine—1-carb0xy1ate (CAS: 1009075~48—2,
PharmaBlock, Catalog: PB07375) instead of tert—butyl (3R)-3—(hydroxymethyl)piperazine-1—
carboxylate. Example 32 (26 mg) was obtained. MS: calc’d 443 [(M+H)+], ed 443
[(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 6 ppm 9.00 (dd, J = 1.28, 4.22 Hz, 1H), 8.72
(dd, J: 1.6, 8.6 Hz, 1H), 8.16 (d, J: 8.07 Hz, 1H), 7.69 (dd, .1: 4.28, 8.56 Hz, 1H), 7.32 (d, J:
8.07 Hz, 1H), 7.01 (d, .1: 8.07 Hz, 1H), 6.80 (s, 1H), 6.63 (br d, J: 8.07 Hz, 1H), 5.00—5.22 (1n,
1H), 4.22 (d, J: 12.23 Hz, 1H), 3.89 - 4.09 (in, 2H), 3.84 (br d, J: 11.37 Hz, 1H), 3.64 (br (:1, J
= 11.86 Hz,1H), 3.43 (br d, J: 11.49 Hz,1H), 3.12 (t, J: 13.51 Hz, 1H), 2.94 - 3.04 (m, 1H),
2.84 (t, J: 11.13 Hz,1H), 2.71 (t, J: 10.27 Hz, 1H), 1.25 (d, J: 6.48 Hz, 3H).
WO 33941
Example 33
—[(4R,10bS)—8—[[(3R,4R)fluoropyrrolidinyl]amino]methyl-3,4,6,10b-tetrahydro-1H-
pyrazino[2,1-alis0indolyl]quinoline—8-carbonitrile
The title nd was prepared in analogy to the preparation of Example 10 by using
tert—butyl (3R,4R)—3—a1ninofluoropyrrolidine—1-carboxy1ate (CAS: 14413923,
PharmaBlock, Catalog: P807377) instead of tert-butyl (3R)(hydroxymethyl)piperazine—1-
carboxylate. Example 33 (38 mg) was obtained. MS: calc’d 443 [(M+H)+], measured 443
[(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) (5 ppm 8.99 (dd, J = 1.59, 4.16 Hz, 1H), 8.70
(dd, J: 1.65, 8.62 Hz, 1H), 8.15 (d, J: 7.95 Hz, 1H), 7.68 (dd, J: 4.28, 8.56 Hz, 1H), 7.31 (d, J
= 8.19 Hz, 1H), 7.02 (d, J= 8.19 Hz, 1H), 6.73 (d, J: 1.59 Hz, 1H), 6.57 (dd, J= 1.96, 8.07 Hz,
1H), 4.77 - 5.02 (m, 1H), 4.22 (d, J: 12.35 Hz, 1H), 4.04 (br d, J: 10.39 Hz, 1H), 3.93 (td, .12
.64, 18.43 Hz, 1H), 3.83 (br (1, J= 10.88 Hz,1H), 3.63 (br (1, J: 11.98 Hz,1H), 3.36 — 3.49 (m,
2H), 2.91 - 3.17 (m, 3H), 2.77 - 2.88 (m, 1H), 2.73 (dd, .1: 4.40, 12.10 Hz, 1H), 1.25 (d, J: 6.36
Hz, 3H).
Example 34
-[(4R,10bS)—8-[[(3R,4R)methoxypyrrolidinyl]amino]methyl-3,4,6,10b-tetrahydro—
lH-pyrazino[2,1-a]isoindol—2~yl]quinoline-S-carbonitrile
\ fifql
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl (3R,4R)—3 methoxypyrrolidine-1~carb0xy1ate (CAS: 1400562—12-0,
PharmaBlock, Catalog: PBXA3109) instead of utyl (3R)—3-(hydroxymethy1)piperazine
carboxylate. Example 34 (46 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455
[(M+H)+]. 1H NMR (400 MHz, METHANOL-d4)(5 ppm 8.69 (dd, J = 1.59, 8.56 Hz, 1H), 8.14
(d, J = 7.95 Hz, 1H), 7.67 (dd, J = 4.28, 8.56 Hz, 1H), 7.30 (d, J = 8.07 Hz, 1H), 7.00 (d, J =
8.07 Hz, 1H), 6.71 (d, J: 1.59 Hz, 1H), 6.55 (dd, J: 2.02, 8.13 Hz, 1H), 4.20 (d, J: 12.10 Hz,
1H), 4.03 (br d, J: 10.15 Hz,1H), 3.83 (br (1, J= 11.25 Hz, 1H), 3.74 — 3.79 (m, 1H), 3.66 — 3.71
(m, 1H), 3.63 (br d, J: 11.86 Hz, 1H), 3.39 - 3.46 (m, 1H), 3.35 (s, 3H), 3.27 - 3.31 (m, 1H),
2.90 - 3.04 (m, 3H), 2.82 (dd, J: 10.45, 11.68 Hz, 1H), 2.67 (dd, J: 3.91, 11.98 Hz, 1H), 1.24
(d, J = 6.48 Hz, 3H).
e 35
-[(4R,l0bS)-4—methyl-8—(5-oxa-2,8-diazaspiro[3.5]nonan-Z-yl)-3,4,6,10b-tetrahydro—1H—
pyrazino[2,1-alisoindolyl]quinoline—8—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl 5—oxa-2,8-diazaspiro[3.5]nonanecarboxylate (CAS: 1251005~61-4, PharmaBlock,
Catalog: 11065—5G) instead of tert-butyl (3R)—3-(hydroxymethyl)piperazine~1-
carboxylate. Example 35 (16 mg) was obtained. MS: calc’d 467 [(M+H)+], measured 467
[(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 6 ppm 8.89 (dd, J = 1.7, 4.2 Hz, 1H), 8.61 (dd,
J: 1.6, 8.6 Hz, 1H), 8.06 (d, J: 8.1 Hz, 1H), 7.57 (dd, J= 4.2, 8.5 Hz, 1H), 7.22 (d, J= 8.1 Hz,
1H), 6.98 (d, J: 7.9 Hz, 1H), 6.48 (d, J: 1.3 Hz, 1H), 6.29 (dd, J = 2.0, 7.9 Hz, 1H), 4.15 (d, J
= 12.3 Hz, 1H), 3.97 (br d, J: 10.5 Hz, 1H), 3.69 - 3.84 (m, 3H), 3.44 - 3.61 (1n, 5H), 3.34 (br d,
J: 11.6 Hz, 1H), 3.23 = 6.4
- 2.96 (m, 3H), 2.67 - 2.78 (m, 3H), 1.16 (d, J - 3.28 (m, 1H), 2.84
Hz, 3H).
Example 36
-[(4R,10bS)—8-(2,6—diazaspir0[3.3]heptan-Z-yl)—4—methy1~3,4,6,10b-tetrahydro-1H—
no[2,1—a]isoindol—2-yl]quinoline—8—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl 2,6—diazaspiro[3.3]heptane~2-earboxylate oxalate (CAS: 10410263, Block,
Catalog: PBO3883—1G) instead of tert—butyl ~(hydroxymethyl)piperazine—1»carboxylate.
Example 36 (19.2 mg) was obtained. MS: calc’d 437 [(M+H)+], measured 437 [(M+H)+]. 1H
NMR (400 MHz, METHANOL-d4) 6 ppm 9.01 (dd, J = 1.5, 4.2 Hz, 1H), 8.71 (dd, J= 1.3, 8.6
Hz, 1H), 8.17 (d, J: 7.9 Hz, 1H), 7.70 (dd, J: 4.3, 8.6 Hz, 1H), 7.33 (d, J: 8.1 Hz, 1H), 7.07
(d, J = 8.1 Hz, 1H), 6.55 (s, 1H), 6.37 (dd, J: 1.7, 7.9 Hz, 1H), 4.25 (d, J: 12.3 Hz, 1H), 4.06
(br (1, J: 10.1 Hz, 1H), 3.92 (s, 4H), 3.78 — 3.88 (m, 1H), 3.77 (s, 4H), 3.65 (br d, J: 12.5 Hz,
1H), 3.34 — 3.48 (m, 2H), 2.99 (t, J: 10.9 Hz, 1H), 2.84 (br t, J: 11.1 Hz, 1H), 1.27 (d, J: 6.4
Hz, 3H).
Example 37
-{(4R,10bS)(1,6—diazaspiro[3.3]heptanyl)-4—methyl-3,4,6,10b—tetrahydro-1H-
pyrazino[2,1-a1isoindolyl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl 1,6~diazaspiro[3.3]heptanecarboxylate (CAS: 1330763-95—5, PharmaBlock, Catalog:
PBN2011926-1G) instead of tert—butyl (3R) (hydroxymethyl)piperazineearboxylate.
Example 37 (8.8 mg) was obtained. MS: calc’d 437 +], ed 437 [(M+H)+]. 1H
NMR (400 MHz, METHANOL—d4) 6 ppm 9.03 (dd, J: 1.7, 4.2 Hz, 1H), 8.75 (dd, J== 1.6, 8.6
Hz, 1H), 8.18 (d, J: 8.1 Hz, 1H), 7.71 (dd, J: 4.3, 8.6 Hz, 1H), 7.36 (d, J: 8.1 Hz,1H), 7.22
(d, J: 8.2 Hz, 1H), 6.66 (d, J: 1.7 Hz, 1H), 6.49 (dd, J: 2.1, 8.1 Hz, 1H), 4.50 - 4.64 (m, 2H),
4.35 (d, J: 10.0 Hz, 2H), 4.13 (d, J: 9.7 Hz, 2H), 4.08 (br d, J: 12.7 Hz, 1H), 3.95 - 4.03 (m,
2H), 3.86 - 3.93 (m, 1H), 3.71 — 3.80 (m, 1H), 3.52 — 3.59 (m, 1H), 2.98 — 3.11 (m, 2H), 2.79 -
2.91 (m, 2H), 1.39 (d, J: 6.6 Hz, 3H).
Example 38
-[(4R,10bS)methyl(6-methyl—2,6—diazaspiro[3.3]heptan-Z-yl)—3,4,6,10b-tetrahydro-
1H-pyrazino[2,1-a]isoindol—2—yl] quinoline—S-carbonitrile
.530
The title nd was prepared in analogy to the preparation of Example 10 by using 2-
methyl-2,6-diazaspiro[3.3]heptane (CAS: 12035676, Block, Catalog: PBLJ2831)
instead of tert-butyl (3R)(hydroxymethy1)piperazine—1— carboxylate. Example 38 (16.0 mg)
was obtained. MS: calc’d 451 [(M+H)+], measured 451 [(M+H)+]. 1H NMR (400 MHz,
METHANOL—d4) 5 ppm 9.06 (dd, J = 1.6, 4.3 Hz, 1H), 8.80 (dd, J: 1.5, 8.6 Hz, 1H), 8.21 (d, J
= 7.9 Hz, 1H), 7.75 (dd, J: 4.3, 8.6 Hz, 1H), 7.35 - 7.47 (m, 2H), 7.19 (s, 1H), 7.08 (dd, J: 2.2,
8.4 Hz, 1H), 5.24 = 13.8 Hz, 1H), 4.64 (br
- 5.36 (m, 1H), 4.94 (d, J (:1, J: 13.7 Hz, 1H), 4.26 -
4.41 (m, 1H), 4.15 (s, 2H), 3.78 - 3.86 (m, 2H), 3.55 - 3.73 (m, 3H), 3.26 — 3.32 (m, 5H), 2.78 (s,
3H), 1.56 (d, J= 6.7 Hz, 3H).
Example 39
-[(4R,10bS)-8—(3-amin0-3—methyl—azetidinyl)methyl—3,4,6,10b-tetrahydro—1H—
pyrazino[2,1-a]isoindol—2-yl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl N-(3-methy1azetidinyl)carbamate (CAS: 10184430, PhannaBlock, Catalog:
PB03046) instead of tert-butyl (3R)(hydroxymethyl)~ piperazine-l-carboxylate. Example
39 (30 mg) was obtained. MS: calc’d 425 [(M+H)+], measured 425 [(M+H)+]. 1H NMR (400
MHz, METHANOL-d4) 6 ppm 9.04 (dd, J = 1.6, 4.3 Hz, 1H), 8.76 (dd, J = 1.6, 8.6 Hz, 1H),
8.18 (d, J: 7.9 Hz,1H), 7.71 (dd, J= 4.3, 8.6 Hz, 1H), 7.37 (d, J= 8.1 Hz, 1H), 7.25 (d, J= 8.1
Hz, 1H), 6.66 (d, J: 1.7 Hz, 1H), 6.51 (dd, J: 2.1, 8.1Hz,1H), 4.73 - 4.81 (m, 1H), 4.64 (d, J:
13.2 Hz, 1H), 4.22 (d, J: 13.1 Hz, 1H), 3.99 - 4.09 (m, 2H), 3.87 - 3.97 (m, 4H), 3.53 - 3.65 (m,
1H), 3.02 - 3.16 (m, 2H), 1.70 (s, 3H), 1.43 (d, J: 6.6 Hz, 3H).
Example 40A and 40B
-[(4R,10bS)I(3S,4S)—3-amin0—4-hydr0xy—pyrrolidin-l—yl]-4—methyl—3,4,6,10b—tetrahydro-
1H—pyrazin0[2,1-a]isoindol-Z-yl]quinoline-S-carbonitrile and 5-[(4R,10bS)[(3R,4R)
aminohydroxy-pyrrolidinyl]—4-methyl—3,4,6,10b-tetrahydro-lH—pyrazino[2,1-
a]isoindol—Z—yl]quinolinecarbonitrile
N N
N\ N
/ /
N N
HZN’O H2N““9
OH OH
The title compound was prepared in analogy to the preparation of Example 16A and 16B by
using trans—3—(boc-amino)—4-hydroxypyrrolidine (CAS: 870632—89-6, PharmaBlock, Catalog:
PB07572) instead of 3-(boc—amino)methoxypyrrolidine. Example 40A (38 mg) was
obtained. MS: calc’d 441 [(M+H)+], ed 441 +]. 1H NMR (400 MHZ,
METHANOL-d4) 6 ppm 9.07 (dd, J: 1.3, 4.1 Hz, 1H), 8.79 (d, J: 8.3 Hz, 1H), 8.21 (d, J: 8.2
Hz, 1H), 7.75 (dd, J: 4.3, 8.6 Hz, 1H), 7.30 - 7.48 (m, 2H), 6.82 (s, 1H), 6.71 (dd, J: 1.5, 8.3
Hz, 1H), 5.14 - 5.40 (m, 1H), 4.89 - 4.96 (m, 2H), 4.55 — 4.66 (m, 1H), 4.43 - 4.51 (m, 1H), 4.20
- 3.29 (m, 2H), 1.55 (d, J: 6.7 Hz, - 3.52 (m, 2H), 3.15
- 4.37 (1n, 1H), 3.74 — 3.89 (m, 4H), 3.42
3H). e 408 (40 mg) was obtained. MS: calc’d 441 [(M+H)+], measured 44] [(M+H)+].
1H NMR (400 MHZ, METHANOL-d4) 5 ppm 9.07 (dd, J: 1.3, 4.1 Hz, 1H), 8.79 (d, J: 8.3 Hz,
1H), 8.21 (d, J: 8.2 Hz, 1H), 7.75 (dd, J: 4.3, 8.6 Hz, 1H), 7.30 — 7.48 (m, 2H), 6.82 (s, 1H),
6.71 (dd, J: 1.5, 8.3 Hz, 1H), 5.14 — 5.40 (m, 1H), 4.89 — 4.96 (m, 2H), 4.55 — 4.66 (m, 1H), 4.43
- 3.52 (m, 2H), 3.15 — 3.29 (m, 2H),
- 4.51 (m, 1H), 4.20 — 4.37 (m, 1H), 3.74 - 3.89 (m, 4H), 3.42
1.55 (d, J: 6.7 Hz, 3H).
Example 41
-[(4R,10bS)(3a-methoxy—1,2,3,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol—S-yl)—4—methyl—
3,4,6,10b-tetrahydr0-lH—pyrazino[2,1-a]isoindol—2-yl] quinoline-8—carbonitrile
The title compound was prepared in analogy to the ation of Example 10 by using
tert—butyl 3a—methoxy—1,2,3,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole—5-carboxylate instead of tert-
butyl -(hydroxymethyl)piperazinecarboxylate. Example 41 (8.8 mg) was obtained. MS:
calc’d 481 [(M+H)+], measured 481 [(M+H)+]. 1H NMR (400 MHZ, METHANOL—d4) 65 ppm
9.07 (dd, J: 1.6, 4.3 Hz, 1H), 8.80 (br (1, J: 8.3 Hz, 1H), 8.21 (br d, J: 7.8 Hz, 1H), 7.75 (dd, J
= 4.3, 8.6 Hz, 1H), 7.23 - 7.49 (m, 2H), 6.75 (s, 1H), 6.65 (dd, J: 2.0, 8.4 Hz, 1H), 5.13 — 5.36
(m, 1H), 4.90 - 4.96 (m, 1H), 4.49 - 4.65 (1n, 1H), 4.23 - 4.39 (m, 1H), 3.74 - 3.83 (m, 2H), 3.57
— 3.06 (m, 2H), 1.55 (d, J: 6.7 Hz,
— 3.68 (m, 1H), 3.47 - 3.56 (m, 2H), 3.23
- 3.43 (m, 9H), 2.91
3H).
W0 2019/233941
Example 42
-[(4R,10bS)[(3S,4S)hydr0xy(methylamino)pyrrolidin-l-yl]methyl—3,4,6, 10b-
tetrahydro—lH—pyrazino[2,1-a]isoindolyl]quinoline-S-carbonitrile
HO’Q
The title compound was prepared in analogy to the preparation of Example 10 by using
utyl N-[(3S,4S)hydroxypyrrolidiny1]-N—methy1-carbamate instead of utyl (3R)-
3~(hydroxymethyl)piperazinecarboxy1ate. Example 42 (46 mg) was obtained. MS: calc’d 455
[(M+H)+], measured 455 [(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) 6 ppm 9.04 (dd, J =
1.7, 4.2 Hz, 1H), 8.76 (dd, J: 1.6, 8.6 Hz, 1H), 8.19 (d, J: 7.9 Hz, 1H), 7.72 (dd, J: 4.2, 8.6
Hz, 1H), 7.37 (d, J: 8.1 Hz, 1H), 7.27 (d, J: 8.2 Hz, 1H), 6.79 (d, J: 1.7 Hz, 1H), 6.65 (dd, J
= 2.2, 8.4 Hz, 1H), 4.75 = 13.2 Hz, 1H), 4.55 — 4.62 (m, 1H), 4.26 (d, J
- 4.86 (m, 1H), 4.67 (d, J
= 13.2 Hz, 1H), 3.88 — 4.02 (m, 2H), 3.69 — 3.86 (m, 3H), 3.51 - 3.64 (m, 2H), 3.20 - 3.28 (m,
1H), 3.04 — 3.17 (m, 2H), 2.88 (s, 3H), 1.45 (d, J: 6.6 Hz, 3H).
WO 33941
~81-
Example 43
-[(4R,10bS)—4—methyl[(3R,4R)—3-hydr0xy(methylamino)pyrrolidin-l-yl]—3,4,6,10b-
tetrahydro-lH—pyrazino[2,l—a]isoindol—Z-yl]quinoline—8—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl N—[(3S,4S)hydroxypyrrolidin-3—yl]-N-methy1-carbamate instead of tert-butyl (3R)-
3-(hydroxymethyl)piperazine-1~carboxylate. Example 43 (45 mg) was obtained. MS: calc’d 455
[(M+H)+], measured 455 [(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) 0‘ ppm 9.04 (dd, J=
1.6, 4.3 Hz, 1H), 8.76 (dd, J = 1.6, 8.6 Hz, 1H), 8.18 (d, J: 7.9 Hz, 1H), 7.72 (dd, J = 4.2, 8.6
Hz, 1H), 7.37 (d, J= 7.9 Hz, 1H), 7.28 (d, J: 8.3 Hz, 1H), 6.79 (d, J= 1.8 Hz, 1H), 6.65 (dd, J
= 2.1, 8.4 Hz, 1H), 4.82 — 4.90 (m, 1H), 4.66 — 4.75 (m, 1H), 4.55 — 4.64 (m, 1H), 4.31 (d, J =
13.2 Hz, 1H), 3.95 - 4.09 (m, 1H), 3.88 - 3.94 (m, 1H), 3.69 - 3.86 (m, 3H), 3.52 - 3.63 (m, 2H),
3.22 - 3.28 (m, 1H), 3.04 ~ 3.20 (m, 2H), 2.88 (s, 3H), 1.46 (d, J: 6.7 Hz, 3H).
Example 44
-[(4R,10bS)—4—methyl—8—[(4aR,7aR)—3,4,4a,5,7,7a—hexahydro-2H—pyrrolo[3,4-b] xazin-
6-yl]-3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindol-Z—yl]quinoline—S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl-(4aR,7aR)-3,4a,5,6,7,7a-hexahydro-2H—pyrrolo[3 ,4-b] [1 ,4]oxazinecarboxylate
instead of tert—butyl (3R)(hydroxymethyl)piperazine—1-carboxylate. Example 44 (8.8 mg) was
obtained. MS: calc’d 467 [(M+H)+], measured 467[(M+H)+]. 1H NMR (400 MHz,
METHANOL—d4) 6 ppm 9.03 (dd, J: 1.6, 4.3 Hz, 1H), 8.75 (dd, J: 1.7, 8.6 Hz, 1H), 8.18 (d, J
= 7.9 Hz, 1H), 7.71 (dd, J: 4.2, 8.6 Hz, 1H), 7.36 (d, J: 8.1 Hz, 1H), 7.21 (d, J: 8.3 Hz, 1H),
6.70 (d, J: 1.6 Hz, 1H), 6.54 (dd, J: 2.0, 8.3 Hz, 1H), 4.47 - 4.68 (m, 2H), 4.15 - 4.25 (m, 1H),
4.11 (d, J: 13.2 Hz, 1H), 3.86 - 3.73 (m, 2H), 3.52 - - 3.84 (m, 1H), 3.64
- 4.03 (m, 3H), 3.74
3.60 (m, 1H), 3.38 - 3.12 (m, 2H), 1.40 (d, J: 6.5 Hz,
- 3.47 (m, 1H), 3.23 - 3.37 (m, 4H), 2.95
3H).
e 45
—[(4R,10bS)methyl[trans-(3R,4R)amino-3—hydroxy—3-methyl-pyrrolidin-l-yll-
3,4,6,10b-tetrahydro—lH-pyrazino[2,1-alisoindol—2-yl]quinoline—S-carbonitrile
“02/?
The title compound was prepared in analogy to the ation of Example 10 by using
tert-butyl N—[trans-4—hydroxymethy1-pyrrolidin—3-y1]carbamate instead of tert-butyl (3R)-3—
(hydroxymethyl)piperazine—1~carboxy1ate. e 45 (26 mg) was obtained. MS: calc’d 455
[(M+H)+], measured 455 [(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) (5 ppm 9.04 (dd, J =
1.6, 4.3 Hz, 1H), 8.76 (dd, J== 1.6, 8.6 Hz, 1H), 8.18 (d, J= 8.1 Hz, 1H), 7.72 (dd, J: 4.3, 8.6
Hz, 1H), 7.37 (d, J: 7.9 Hz, 1H), 7.25 (d, J: 8.3 Hz, 1H), 6.73 (d, J: 1.6 Hz, 1H), 6.59 (dd, J
= 2.1, 8.3 Hz, 1H), 4.76 (br d, J = 7.9 Hz, 1H), 4.64 (d, J = 13.1 Hz, 1H), 4.22 (d, J = 13.1 Hz,
1H), 3.81 - 3.51
- 4.02 (m, 3H), 3.67 - 3.75 (m, 1H), 3.54 - 3.63 (1n, 2H), 3.46 (1n, 1H), 3.38 (d, J
= 10.4 Hz, 1H), 3.03 - 3.17 (in, 2H), 1.51 (s, 3H), 1.44 (d, J: 6.6 Hz, 3H).
Example 45A and 45B
-[(4R,10bS)[(3R,4R)-4—amin0hydroxymethyl—pyrrolidinyl]methy1-3,4,6,10b-
tetrahydro-lH—pyrazino[2,1—a]isoindol—2—yl]quinoline~8—carbonitrile and 5-[(4R,10bS)—8-
[(3S,4S)—4-amin0-3—hydroxy—3-methyl—pyrrolidin-l—yl]methyl-3,4,6,lOb-tetrahydro-l H-
no[2,1-a]isoindol—Z-yl]quinoline—S-carbonitrile
N N
I I | |
N\ N\
/ /
N N
H6 H0 5
NH2 NH2
The title compound was prepared in analogy to the preparation of Example 16A and 163
by using tert—butyl N-[trans—4-hydroxy-4—methyl-pyrrolidinyl]carbamate d of trans
(boc-amino)—4-methoxypyrrolidine. Example 45A (18 mg) was obtained. MS: calc’d 455
[(M+H)+], measured 455 [(M+H)+]. ‘H NMR (400 MHZ, METHANOL—ab) 5 ppm lH NMR (400
MHz, CD3OD, 299 K) (5 (ppm) 9.04 (dd, J z 1.6, 4.3 Hz, 1H), 8.76 (dd, J = 1.6, 8.6 Hz, 1H),
8.18 (d, J: 8.1 Hz, 1H), 7.72 (dd, J: 4.3, 8.6 Hz,1H), 7.37 (d, J = 7.9 Hz,1H), 7.25 (d, J: 8.3
Hz, 1H), 6.73 (d, J = 1.6 Hz, 1H), 6.59 (dd, J = 2.1, 8.3 Hz, 1H), 4.76 (br d, J = 7.9 Hz, 1H),
4.64 (d, J: 13.1 Hz, 1H), 4.22 (d, J: 13.1 Hz, 1H), 3.81 - 4.02 (in, 3H), 3.67 - 3.75 (m, 1H),
3.54 - 3.63 (m, 2H), 3.46 — 3.51 (m, 1H), 3.38 (d, J: 10.4 Hz, 1H), 3.03 - 3.17 (m, 51 (s,
3H), 1.44 (d, J = 6.6 Hz, 3H). Example 45B (19 mg) was obtained. MS: calc’d 455 [(M+H)+],
measured 455 [(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) (5 ppm 9.04 (dd, J x 1.6, 4.3 Hz,
1H), 8.76 (dd, J: 1.7, 8.6 Hz, 1H), 8.19 (d, J: 7.9 Hz, 1H), 7.72 (dd, J: 4.3, 8.6 Hz, 1H), 7.37
(d, J: 8.1 Hz, 1H), 7.26 (d, J: 8.3 Hz, 1H), 6.74 (d, J: 1.7 Hz, 1H), 6.59 (dd, J: 2.2, 8.3 Hz,
1H), 4.76 = 13.2 Hz, 1H), 4.25 - 3.98 (m,
- 4.84 (m, 1H), 4.67 (d, J (d, J= 13.2 Hz, 1H), 3.83
3H), 3.65 - 3.73 (m, 1H), 3.55 — 3.64 (m, 2H), 3.46 - 3.53 (m, 1H), 3.38 (d, J = 10.5 Hz, 1H),
3.00 - 3.20 (m, 2H), 1.51 (s, 3H), 1.45 (d, J = 6.6 Hz, 3H).
2019/064323
Example 46
-[(4R,10bS)—8—[(3S,4R)amino-4—fluoro-pyrrolidinyl]methyl—3,4,6,10b-tetrahydro-
1H-pyrazino[2,1-a]isoindol—Z-yl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl N—[(3S,4R)-4—fluoropyrrolidin—3-yl]carbamate (CAS: 1033718-89—6, PharmaBlock,
Catalog: PBO9206) instead of tert—butyl- (3R)(hydroxymethyl)—piperazinecarboxy1ate.
Example 46 (35 mg) was obtained. MS: calc’d 443 +], measured 443 [(M+H)+]. 'H
NMR (400 MHz, METHANOL-d4) 5 ppm 9.05 (dd, J = 1.6, 4.3 Hz, 1H), 8.78 (dd, J: 1.7, 8.6
Hz, 1H), 8.19 (d, J = 8.1 Hz, 1H), 7.73 (dd, J: 4.3, 8.6 Hz, 1H), 7.39 (d, J: 8.1 Hz, 1H), 7.33
(d, J: 8.4 Hz, 1H), 6.80 (d, J: 1.8 Hz, 1H), 6.66 (dd, J: 2.2, 8.4 Hz, 1H), 5.38 - 5.63 (m, 1H),
.05 - 5.16 (m, 1H), 4.83 (d, J= 13.6 Hz, 1H), 4.48 (d, J = 13.6 Hz, 1H), 4.12 - 4.25 (m, 2H),
3.68 - 3.53 (m, 1H), 3.19 - 3.28 (m, 1H), 3.08 — 3.17 (m,
— 3.97 (m, 4H), 3.60 — 3.66 (m, 1H), 3.44
1H), 1.51 (d, J= 6.7 Hz, 3H).
~85-
Example 47
-[(4R,l0bS)—8-[(3R,4S)aminofluor0-pyrrolidinyl]methyl-3,4,6,10b—tetrahydrolH-pyrazino
[2,1-a]isoindol—2—yl]quinoline—S-carbonitrile
The title compound was prepared in analogy to the ation of Example 10 by using
tert—butyl N—[(3R,4S)—4-fluoropyrrolidin—3-y1]carbarnate (CAS: 1033718-91—0, PharmaBlock.
Catalog: PB09204) instead of tert—butyl-(3R)—3-(hydroxymethyl)pipcrazine-1—carboxy1ate.
Example 47 (31 mg) was obtained. MS: calc’d 443 +]. measured 443 [(M+H)+]. 'H
NMR (400 MHz, METHANOL—d4) 6 ppm 9.04 (dd, J = 1.7, 4.2 Hz, 1H), 8.77 (dd, J = 1.7, 8.6
Hz, 1H), 8.19 (d, J: 8.1 Hz, 1H), 7.73 (dd, J: 4.3, 8.6 Hz, 1H), 7.38 (d, J: 7.9 Hz, 1H), 7.30
(d, J: 8.4 Hz, 1H), 6.78 (d, J: 1.8 Hz, 1H), 6.64 (dd, J: 2.2, 8.4 Hz, 1H), 5.38 - 5.61 (m, 1H),
.05 — 5.16 (m, 1H), 4.73 (d, J: 13.3 Hz, 1H), 4.33 (d, J = 13.2 Hz, 1H), 4.09 - 4.23 (m, 1H),
3.97 - 3.53 (m, 1H), 3.04 - 3.22 (m,
— 4.07 (m, 1H), 3.65 - 3.95 (m, 4H), 3.59 - 3.63 (m, 1H), 3.42
2H), 1.47 (d, J: 6.6 Hz, 3H).
Example 48
-[(4R,10bS)—8—[(3R,4R)—3-amino-4—fluor0-pyrrolidin—l—yl]methyl-3,4,6,lOb-tetrahydro-
azin0[2,1-a]isoindol—Z-yl]quinoline—8—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl ((3R,4R)-4—fluoropyrrolidinyl)carbamate hydrochloride (CAS: 20970614,
BePharm, Catalog: BDOO765464) instead of tert—butyl ~ xymethyl)piperazine—1-
carboxylate. Example 48 (8.8 mg) was obtained. MS: calc’d 443 [(M+H)+], measured 443
[(M+H)+]. 1H NMR (400 MHZ, METHANOL—d4) 5 ppm 9.03 (dd, J = 1.6, 4.3 Hz, 1H), 8.75 (dd,
J=1.6, 8.6 Hz, 1H), 8.18 (d, J: 7.9 HZ, 1H), 7.71 (dd, J: 4.3, 8.6 Hz, 1H), 7.36 (d, J: 7.9 Hz,
1H), 7.26 (d, J: 8.2 Hz, 1H), 6.81 (d, J: 1.7 Hz, 1H), 6.66 (dd, J= 2.1, 8.4 Hz, 1H), 5.28 - 5.48
(m, 1H), 4.65 — 4.01 (m, 4H),
— 4.73 (m, 1H), 4.61 (d, J: 13.0 Hz, 1H), 4.06 — 4.23 (m, 2H), 3.75
3.45 - 3.67 (m, 3H), 3.01 — 3.15 (1n, 2H), 1.42 (d, J: 6.5 Hz, 3H).
Example 49
-[(4R,10bS)-8—[(3S,4S)~3-aminofluoro—pyrrolidinyl]—4-methyl—3,4,6,10b-tetrahydro-
1H-pyrazino[2,1—a]isoindol—Z-yl]quinoline—S-carbonitrile
The title compound was prepared in analogy to the ation of Example 10 by using
tert—butyl N—[(3S,4S)—4-fluoropyrrolidiny1]carbamate (CAS: 2133888, PharmaBlock,
Catalog: PB09205) instead of tert-butyl (3R)—3—(hydroxymethyl)piperazine-1—carboxy1ate.
Example 49 (58 mg) was ed. MS: calc’d 443 [(M+H)+], measured 443 [(M+H)+]. 1H
NMR (400 MHz, METHANOL—da) 6 ppm 9.03 (dd, J: 1.6, 4.3 Hz, 1H), 8.75 (dd, J = 1.6, 8.6
Hz, 1H), 8.18 (d, J: 7.9 Hz, 1H), 7.71 (dd, J: 4.3, 8.6 Hz, 1H), 7.36 (d, J= 7.9 Hz, 1H), 7.26
(d, J: 8.2 Hz, 1H), 6.81 (d, J: 1.7 Hz, 1H), 6.66 (dd, J: 2.1, 8.4 Hz, 1H), 5.28 - 5.48 (1n, 1H),
4.65 (d, J = 13.0 Hz, 1H), 4.06 - 4.23 - 4.73 (m, 1H), 4.61 (1n, 2H), 3.75 - 4.01 (m, 4H), 3.45 -
3.67 (m, 3H), 3.01 - 3.15 (m, 2H), 1.42 (d, J: 6.5 Hz, 3H).
Example 50
-[(4R,10bS)-8—[(3R)(methoxymethyl)piperazin—1-yl]methyl-3,4,6,10b-tetrahydro-IH-
pyrazino[2,1-a]isoindol—Z-yl]quinoline—S-carbonitrile
eff”)N
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl (2R)(methoxymethyl)piperazinecarboxy1ate (CAS: 1023301-73—6, PharmaBlock,
Catalog: 78) instead of tert-butyl (3R)(hydroxymethyl)piperazine—1-carboxylate.
Example 50 (5.4 mg) was obtained. MS: calc’d 469 [(M+H)+], measured 469 [(M+H)+]. lH
NMR (400 MHz, METHANOL-d4) 6 ppm 8.91 (dd, J: 1.6, 4.3 Hz, 1H), 8.64 (dd, J: 1.7, 8.6
Hz, 1H), 8.05 (d, J: 7.9 Hz, 1H), 7.60 (dd, J = 4.3, 8.6 Hz, 1H), 7.25 (dd, J = 5.3, 8.2 Hz, 2H),
7.08 (d, J: 1.8 Hz, 1H), 6.94 (dd, J: 2.2, 8.4 Hz, 1H), 4.85 - 4.91 (m, 2H), 4.65 (d, J: 13.4 Hz,
1H), 4.27 (d, J: 13.4 Hz, 1H), 3.89 - 4.01 (m, 1H), 3.78 - 3.86 (1n, 1H), 3.67 — 3.76 (m, 2H),
3.45 - 3.26 (m, 1H), 2.85 - 3.11
- 3.64 (m, 4H), 3.36 - 3.42 (m, 1H), 3.30 - 3.38 (m, 2H), 3.22 (1n,
4H), 1.36 (d, J: 6.7 Hz, 3H).
Example 51
-[(4R,10bS)(4-aminomethylpiperidyl)methyl-3,4,6,10b-tetrahydro-1H-
no[2,1-a]isoindol—Z-yl]quinoline—8-carbonitrile
The title compound was prepared in analogy to the ation of Example 10 by using
tert-butyl N-(4-methylpiperidin-4—yl)carbamate (CAS: 1632717, PharmaBlock, Catalog:
PB02909) instead of tert-butyl (3R)—3~(hydroxymethyl)piperazinecarboxy1ate. Example 51
(40 mg) was obtained. MS: calc’d 453 [(M+H)+], measured 453 [(M+H)+]. 1H NMR (400 MHZ,
METHANOL—d4) 5 ppm 9.05 (dd, J = 1.6, 4.3 Hz, 1H), 8.79 (dd, J: 1.7, 8.6 Hz, 1H), 8.19 (d, J
= 7.9 Hz, 1H), 7.74 (dd, J: 4.3, 8.6 Hz, 1H), 7.38 (dd, J= 8.3,17.4 Hz, 2H), 7.18 (d, J: 1.8 Hz,
1H), 7.06 (dd, J: 2.2, 8.6 Hz, 1H), 6.94 (dd, J: 2.2, 8.4 Hz, 1H), 5.16 — 5.26 (m, 1H), 4.87 (d, J
= 13.6 Hz, 1H), 4.58 (d, J: 13.6 Hz, 1H), 4.23 - 4.34 (m, 1H), 3.87 - 4.00 (m, 1H), 3.55 - 3.69
(m, 3H), 3.24 - 3.31 (m, 1H), 3.07 - 3.21 (m, 3H), 1.79 - 2.04 (m, 4H), 1.54 (d, J: 6.7 Hz, 3H),
1.47 (s, 3H).
-89—
Example 52
-[(4R,10bS)(3,4a,5,6,7,7a-hexahydro-ZH—pyrrolo[3,4-b] [1,4] yl)—4-methyl—
3,4,6,10b-tetrahydro—lH-pyrazino[2,1-a]isoindolyl]quinoline—S-carbonitrile
The title compound was prepared in analogy to the preparation of e 10 by using
tert-butyl octahydropyrrolo[3,4-b]morpholinecarboxylate (CAS: 13603641, PharinaBlock,
Catalog: PBCS1406244) instead of tert—butyl (3R)(hydroxyrnethy1)piperazinecarboxy1ate.
Example 52 (18 mg) was obtained. MS: calc’d 467 [(M+H)+], measured 467 [(M+H)+]. 1H
NMR (400 MHz, METHANOL-d4) (5 ppm 9.03 (dd, J = 1.6, 4.3 Hz, 1H), 8.75 (dd, J = 1.6, 8.6
Hz, 1H), 8.18 (d, J: 7.9 Hz, 1H), 7.71 (dd, J: 4.3, 8.6 Hz, 1H), 7.36 (d, J: 8.1 Hz, 1H), 7.33
(d, J = 8.1 Hz, 1H), 7.25 (s, 1H), 7.09 (dd, J = 1.5, 7.9 Hz, 1H), 4.54 (br d, J: 12.7 Hz, 2H),
4.09 - 4.18 (m, 1H), 4.01 - 3.89 (m, 1H), 3.59 - 3.74 (m,
— 4.08 (m, 1H), 3.89 - 4.00 (m, 2H), 3.79
3H), 3.51 - 3.58 (m, 1H), 3.18 - 3.31 (m, 2H), 2.87 - 3.13 (m, 5H),1.38(d, J: 6.4 Hz, 3H).
2019/064323
Example 53A and 53B
-[(4R,10bS)-8—[(6S)—6-hydroxy-1,4—diazepan-l-yl]methyl-3,4,6,10b-tetrahydro-IH-
pyrazinolZJ~a]isoindolyl]quinoline—S-carbonitrile and 5-[(4R,10bS)—8—[(6R)hydroxy-
1,4-diazepanyl]methyl-3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindol
yl]quinoline—S-carbonitrile
N N
I I | 1
N\ N\
/ /
N N
N N
N N
H H
The title compound was prepared in analogy to the preparation of Example 16A and 16B
by using terz-butyl 6—hydroxy-1,4-diazepanecarboxylate (CAS: 9563171, WUXI
APPTEC, Catalog: WX604354) instead of trans-3—(boc-amino)—4~1nethoxypyrrolidine. Example
53A (19.8 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H NMR (400
MHz, OL-d4) 6 ppm 8.91 (dd, J = 1.6, 4.3 Hz, 1H), 8.66 (dd, J = 1.5, 8.6 Hz, 1H),
8.05 (d, J: 8.1 Hz, 1H), 7.61 (dd, J: 4.3, 8.7 Hz, 1H), 7.36 - 7.17 (m, 2H), 6.94 (d, J= 1.3 Hz,
1H), 6.83 (dd, J: 2.3, 8.6 Hz, 1H), 5.17 (br d, J: 7.7 Hz, 1H), 4.73 - 4.81 (m, 1H), 4.50 (br d, J
= 13.7 Hz, 1H), 4.27 - 4.34 (m, 1H), 4.15 - 4.26 (m, 1H), 3.70 - 3.86 (m, 3H), 3.47 - 3.66 (m,
3H), 3.36 - 3.45 (1n, 1H), 3.13 - 3.28 (m, 5H), 1.44 (d, J: 6.7 Hz, 3H). Example 53B (23.3 mg)
was obtained. MS: calc’d 455 [(M+H)+], ed 455 [(M+H)+]. 1H NMR (400 MHZ,
METHANOL-d4)5 ppm 8.91 (dd, J: 1.6, 4.2 Hz, 1H), 8.66 (dd, J: 1.5, 8.6 Hz, 1H), 8.05 (d, J
= 7.9 Hz, 1H), 7.61 (dd, J: 4.3, 8.6 Hz, 1H), 7.17 - 7.34 (m, 2H), 6.95 (d, J: 1.3 Hz, 1H), 6.83
(dd, J: 2.3, 8.6 Hz, 1H), 5.10 - 5.22 (m, 1H), 4.78 - 4.82 (m, 1H), 4.50 (br d, J: 13.7 Hz, 1H),
4.28 - 3.86 (m, 3H), 3.46 - 3.66 (m, 3H), 3.35 - 3.44 (m,
- 4.35 (m, 1H), 4.14 - 4.27 (m, 1H), 3.70
1H), 3.12 — 3.29 (in, 5H), 1.44 (d, J: 6.7 Hz, 3H).
-91 _
Example 54
-[(4R,10bS)(6-amin0-1,4-oxazepan—4—yl)methyl—3,4,6,10b-tetrahydro-IH-
pyrazino [2,1-a1isoindol-2—yl] quinoline—8-carbonitrile
OJ(—N
The title compound was prepared in y to the preparation of Example 10 by using
tert-butyl N-(l,4-oxazepanyl)carbamate (CAS: 17829168, Block, Catalog:
PB95734) instead of tert-butyl (3R)—3~(hydroxymethyl)piperazine—1—carboxy1ate. Example 54
(8.1 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. ‘H NMR (400 MHZ,
METHANOL-d4) 5 ppm 9.04 (dd, J: 1.6, 4.3 Hz, 1H), 8.77 (dd, J: 1.7, 8.6 Hz, 1H), 8.19 (d, J
= 8.1 Hz, 1H), 7.72 (dd, J= 4.3, 8.6 Hz, 1H), 7.37 (d, J: 8.1 Hz, 1H), 7.28 (d, J: 8.4 Hz, 1H),
7.02 (d, J: 2.0 Hz, 1H), 6.87 (dd, J: 2.3, 8.4 Hz, 1H), 4.80 - 4.87 (m, 1H), 4.69 (d, J: 13.2 Hz,
1H), 4.28 (d, J: 13.1 Hz, 1H), 4.13 - 4.21 (m, 1H), 3.71 - 4.08 (m, 7H), 3.45 - 3.68 (m, 4H), 3.
01 - 3.20 (m, 2H), 1.46 (d, J: 6.6 Hz, 3H).
Example 54A and 54B
-[(4R,10bS)[(6R)amin0-1,4-0xazepan-4—y1]methyl-3,4,6,10b—tetrahydro-1H-
pyrazin0[2,1-a]isoindolyl]quinoline—8-carbonitrile and 5-[(4R,10bS)—8-|(6S)—6—amin0—1,4-
oxazepanyl]methyl—3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindolyl]quinoline-S-
carbonitrile
N N
l | I |
N\ N\
/ /
N N
The title compound was ed in analogy to the ation of Example 16A and 16B
by using terZ-butyl -oxazepany1)carbamate (CAS: 17829168, PharmaBlock,
Catalog: PB95734) instead of trans(boc-amino)-4—methoxypyrrolidine. Example 54A (29 mg)
was obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H NMR (400 MHz,
METHANOL—d4) 6 ppm 9.04 (dd, J: 1.6, 4.3 Hz, 1H), 8.77 (dd, J: 1.7, 8.6 Hz, 1H), 8.19 (d, J
= 8.1 Hz, 1H), 7.72 (dd, J: 4.3, 8.6 Hz, 1H), 7.37 (d, J: 8.1 Hz, 1H), 7.28 (d, J: 8.4 Hz, 1H),
7.02 (d, J: 2.0 Hz, 1H), 6.87 (dd, J: 2.3, 8.4 Hz, 1H), 4.80 — 4.87 (m, 1H), 4.69 (d, J: 13.2 Hz,
1H), 4.28 (d, J = 13.1 Hz, 1H), 4.13 - 4.21 (m, 1H), 3.71 - 4.08 (m, 7H), 3.45 - 3.68 (m, 4H),
3.01 - 3.20 (m, 2H), 1.46 (d, J= 6.6 Hz, 3H). Example 543 (36 mg) was obtained. MS: calc’d
455 [(M+H)+], measured 455 [(M+H)+]. 1H NMR (400 MHZ, METHANOL—d4) 5 ppm 9.04 (dd,
J: 1.6, 4.3 Hz, 1H), 8.77 (dd, J = 1.7, 8.6 Hz, 1H), 8.19 (d, J: 7.9 Hz, 1H), 7.72 (dd, J: 4.2,
8.6 Hz, 1H), 7.38 (d, J: 8.1 Hz, 1H), 7.28 (d, J: 8.4 Hz, 1H), 7.01 (d, J: 2.0 Hz, 1H), 6.86 (dd,
J: 2.4, 8.5 Hz, 1H), 4.74 = 13.2 Hz, 1H),
- 4.83 (m, 1H), 4.66 (d, J: 13.1 Hz, 1H), 4.25 (d, J
4.12 - 3.67 (m, 4H), 3.01 - 3.19 (m, 2H), 1.44 (d, J:
- 4.21 (m, 1H), 3.73 — 4.08 (m, 7H), 3.45
6.6 Hz, 3H).
Example 55
-[(4R,10bS)—8-(6-hydroxymethyl-1,4-diazepanyl)—4—methyl-3,4,6,10b-tetrahydr0-1H-
pyrazino[2,1-alis0indolyl]quinoline-S-carbonitrile
”bk/LW”
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl oxymethyl-1,4-diazepane—1—carboxy1ate (PharmaBlock, Catalog: PB96918)
instead of utyl (3R)—3-(hydroxymethyl)piperazinecarboxy1ate. Example 55 (42 mg) was
obtained. MS: calc’d 469[(M+H)+], measured 469 [(M+H)+]. 1H NMR (400 MHz,
METHANOL—d4) 6 ppm 9.03 (dd, J: 1.7, 4.2 Hz, 1H), 8.73 (dd, J: 1.6, 8.6 Hz, 1H), 8.17 (d, J
= 8.1 Hz, 1H), 7.70 (dd, J= 4.2, 8.6 Hz, 1H), 7.33 (d, J = 8.1 Hz, 1H), 7.18 (d, J: 8.4 Hz, 1H),
7.05 (d, J: 1.8 Hz, 1H), 6.88 (dd, J = 2.3, 8.4 Hz, 1H), 4.48 (br (1, J= 12.6 Hz, 2H), 3.96 — 4.09
(m, 2H), 3.81 - 3.90 (m, 2H), 3.61 - 3.73 (m, 3H), 3.49 - 3.55 (m, 1H), 3.38 - 3.44 (m, 1H), 3.25
- 3.33 (m, 2H), 3.10 — 3.17 (m, 1H), 2.95 - 3.05 (m, 2H), 1.38 (s, 3H),1.38(d, J: 6.7 Hz, 3H).
Example 55A and 55B
-[(4R,10bS)[(6.5')hydroxymethyl—1,4-diazepan—1-yl]—4-methyl-3,4,6,10b-tetrahydro-
lH-pyrazino[2,1-a]isoindolyl]quinoline-S-carbonitrile and 5-[(4R,10b.$')—8—[(6R)—6-
hydroxy—6—methyl-l,4-diazepanyl}methyl-3,4,6,10b-tetrahydro-lH-pyrazino[2,1-
a]isoindol—Z-yl]quinoline—S-carbonitrile
N N
I | I l
N\ N\
/ /
N N
Nj\ Nj\
The title compound was prepared in analogy to the preparation of e 16A and 16B
by using tert—butyl 6-hydroxymethyl-1,4-diazepanecarboxylate (PharmaBlock, Catalog:
P396918) instead of 3~(boc-amino)methoxypyrrolidine. Example 55A (26 mg) was
obtained. MS: calc’d 469 [(M+H)+], measured 469 [(M+H)+]. 1H NMR (400 MHZ,
METHANOL-d4) 6 ppm 9.03 (dd, J: 1.7, 4.2 Hz, 1H), 8.73 (dd, J: 1.6, 8.6 Hz, 1H), 8.17 (d, J
= 8.1Hz,1H), 7.70 (dd, J: 4.2, 8.6 Hz,1H), 7.33 (d, J: 8.1 Hz, 1H), 7.18 (d, J: 8.4 Hz,1H),
7.05 (d, J: 1.8 Hz, 1H), 6.88 (dd, J: 2.3, 8.4 Hz, 1H), 4.48 (br (1, J: 12.6 Hz, 2H), 3.96 — 4.09
(m, 2H), 3.81 — 3.90 (m, 2H), 3.61 ~ 3.73 (m, 3H), 3.49 - 3.55 (m, 1H), 3.38 - 3.44 (m, 1H), 3.25
- 3.32 (m, 2H), 3.10 - 3.17 (m, 1H), 2.95 - 3.05 (m, 2H), 1.38 (s, 3H), 1.38 (d, J: 6.7 Hz, 3H).
e 55B (23.8 mg) was obtained. MS: calc’d 469 [(M+H)+], measured 469 [(M+H)+]. 1H
NMR (400 MHz, METHANOL-d4) 5 ppm 1H NMR (400 MHz, CD3OD, 298 K) (5 (ppm) = 9.05
(dd, J = 1.6, 4.3 Hz, 1H), 8.77 (dd, J: 1.7, 8.6 Hz, 1H), 8.19 (d, J: 7.9 Hz, 1H), 7.73 (dd, J:
4.3, 8.6 Hz, 1H), 7.37 (d, J: 8.1 Hz, 1H), 7.25 (d, J: 8.6 Hz, 1H), 7.07 (d, J: 2.1 Hz, 1H), 6.94
(dd, J: 2.3, 8.5 Hz, 1H), 4.70 (d, J: 13.2 Hz, 1H), 4.32 (d, J: 13.3 Hz, 1H), 3.95 - 4.13 (m,
2H), 3.80 — 3.94 (m, 2H), 3.54 - 3.75 (m, 3H), 3.38 — 3.44 (m, 1H), 3.23 - 3.32 (m,3H), 3.01 -
3.21 (m, 3H), 1.47 (d, J: 6.7 Hz, 3H), 1.38 (s, 3H).
Example 56
-[(4R,10bS)-4—methyl(1,4-oxazepan—6-ylamino)-3,4,6,10b-tetrahydro-lH-pyrazino[2,1-
a]isoindol—Z-yl]quinoline-S-carbonitrile
752:1
HN\~/J
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl 6-amino-1,4-0xazepanecarb0xylate (CAS: 11703901, WUXI , g:
WX601045) instead of tert-butyl (3R)-3—(hydroxymethyl)piperazine—1-carboxy1ate. Example 56
(49.4 mg) was obtained. MS: calc’d 455[(M+H)+], measured 455 [(M+H)+]. 1H NMR (400 MHZ,
METHANOL-d4) 6 ppm 9.03 (dd, J: 1.6, 4.3 Hz, 1H), 8.75 (dd, J = 1.7, 8.6 Hz, 1H), 8.17 (d, J
= 7.9 Hz, 1H), 7.71 (dd, J: 4.3, 8.6 Hz, 1H), 7.36 (d, J: 8.1 Hz, 1H), 7.20 (d, J: 8.3 Hz, 1H),
6.85 (d, J: 1.8 Hz, 1H), 6.72 (dd, J: 2.1, 8.3 Hz, 1H), 4.76 ~ 4.86 (m, 1H), 4.65 (d, J: 13.1 Hz,
1H), 4.25 (d, J=13.1 Hz, 1H), 3.85 - 4.15 (m, 6H), 3.76 - 3.85 (m, 1H), 3.54 - 3.62 (m, 1H),
3.38 - 3.51 (m, 4H), 3.01 - 3.17 (m, 2H),1.45(d,J= 6.6 Hz, 3H).
—96-
Example 56A and 56B
-[(4R,10bS)methyl—8-[{(6R)-1,4-oxazepanyl]amino]-3,4,6,10b-tetrahydro-1H-
pyrazino[2,1-a]isoindolyl]quinoline—S-carbonitrile and 5-[(4R,10bS)—4-methyl{[(6S)-
1,4-oxazepanyl]amino]-3,4,6,10b-tetrahydro-1H—pyrazino[2,1-a]isoindol-Z-yl]quinoline-
8-carbonitrile
N N
I I I |
N N
\ \
/ /
N N
Nj\ Nj\
HN HN
( O ( O
”Nd “Nd
The title compound was ed in analogy to the preparation of Example 16A and 168
by using tert—b‘utyl o-1,4-oxazepaneearboxylate (CAS: 1170390—54-1, WUXI APPTEC,
Catalog: WX601045) instead of trans(boc—amino)—4-methoxypyrrolidine. Example 56A (24
mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455[(M+H)+]. 1H NMR (400 MHz,
METHANOL-d4) 6 ppm 9.03 (dd, J: 1.6, 4.3 Hz, 1H), 8.75 (dd, J: 1.7, 8.6 Hz, 1H), 8.17 (d, J
= 7.9 Hz, 1H), 7.71 (dd, J: 4.3, 8.6 Hz, 1H), 7.36 (d, J: 8.1 Hz, 1H), 7.20 (d, J: 8.3 Hz, 1H),
6.85 (d, J: 1.8 Hz, 1H), 6.72 (dd, J= 2.1, 8.3 Hz,1H), 4.76 - 4.86 (1n, 1H), 4.65 (d, J:13.1 Hz,
1H), 4.25 (d, J: 13.1 Hz, 1H), 3.85 - 4.15 (m, 6H), 3.76 - 3.85 (m, 1H), 3.54 — 3.62 (m, 1H),
3.38 — 3.51 (m, 4H), 3.01 - 3.17 (m, 2H), 1.45 (d, J: 6.6 Hz, 3H). e 56B (28 mg) was
obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H NMR (400 MHZ,
METHANOL-d4) (5 ppm 1H NMR (400 MHz, CD3OD, 298 K) 6 (ppm) 9.03 (dd, J = 1.7, 4.2 Hz,
1H), 8.75 (dd, J: 1.7, 8.6 Hz, 1H), 8.18 (d, J: 8.1 Hz, 1H), 7.71 (dd, J: 4.2, 8.6 Hz, 1H), 7.36
(d, J: 8.1 Hz, 1H), 7.18 (d, J: 8.2 Hz, 1H), 6.83 (d, J2 1.7 Hz, 1H), 6.69 (dd, J: 2.1, 8.3 Hz,
1H), 4.60 — 4.69 (m, 1H), 4.56 (d, J = 13.1 Hz, 1H), 3.94 - 4.15 (m, 5H), 3.74 - 3.92 (m, 3H),
3.52 - 3.59 (m, 1H), 3.39 - 3.48 (1n, 4H), 2.94 — 3.12 (m, 2H), 1.40 (d, J: 6.6 Hz, 3H).
Example 57
-[(4R,10bS)—4-methyl(morph01inylmethylamino)-3,4,6,1Ob-tetrahydro-IH-
pyrazino[2,1-a]is0indol—2-yl]quinoline-S-carbonitrile
jENj\
0 NH
The title nd was prepared in analogy to the preparation of Example 10 by using
tert-butyl 3~(aminomethyl)morpholinecarboxylate (CAS: -18—4, BePharm, Catalog:
BD28817) instead of tert-butyl (3R)—3-(hydroxymethyl)piperazine-l~carboxylate. Example 57
(17.5 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H NMR (400
MHz, METHANOL-d4) d ppm 9.01 (dd, J = 1.6, 4.3 Hz, 1H), 8.75 (dd, J = 1.7, 8.6 Hz, 1H),
8.15 (d, J: 7.9 Hz, 1H), 7.70 (dd, J: 4.3, 8.6 Hz, 1H), 7.35 (d, J: 7.9 Hz, 1H), 7.23 (d, J: 8.3
Hz, 1H), 6.85 (d, J: 1.8 Hz, 1H), 6.73 (dd, J: 2.1, 8.4 Hz, 1H), 5.02 - 5.12 (m, 1H), 4.78 (d, J:
13.6 Hz, 1H), 4.44 (d, J: 13.6 Hz, 1H), 4.15 — 4.21 (m, 1H), 4.07 - 4.14 (m, 1H), 3.96 — 4.03 (m,
1H), 3.86 - 3.92 (m, 1H), 3.73 — 3.82 (m, 1H), 3.50 — 3.67 (m, 3H), 3.40 - 3.45 (m, 2H), 3.32 —
3.38 (m, 1H), 3.16 - 3.26 (m, 2H), 3.05 — 3.14 (m, 1H), 1.49 (d, J= 6.7 Hz, 3H).
Example 58
-[(4R,10bS)methyl[[(2S)-morpholinyl]methylamino]-3,4,6,10b-tetrahydro—1H-
pyrazino[2,1-a]isoindol—2—yl]quinoline—8—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl N—[(2S)-morpholinylmethyl]carbamate (CAS: 875551-59—0, PharmaBlock, Catalog:
PBN20121323) instead of tert-butyl -(hydroxymethyl)piperazinecarboxylate. Example
58 (28 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H NMR (400
MHZ, METHANOL-d4) 5 ppm 8.88 (dd, J = 1.7, 4.2 Hz, 1H), 8.60 (dd, J = 1.6, 8.6 Hz, 1H),
8.05 (d, J: 7.9 Hz, 1H), 7.56 (dd, J: 4.3, 8.6 Hz, 1H), 7.21 (d, J: 8.1 Hz, 1H), 6.89 (d, J: 8.1
Hz,1H), 6.60 (d, J: 1.7 , 6.43 (dd, J: 2.1, 8.1 Hz, 1H), 4.11 (d, J: 12.1 Hz,1H), 3.94
(br d, J: 10.1 Hz, 1H), 3.69 - 3.83 (m, 2H), 3.45 - 3.62 (m, 3H), 3.31 - 3.41 (m, 1H), 3.27 - 3.30
(m, 1H), 2.94 — 3.10 (m, 2H), 2.79 - 2.91 (m, 2H), 2.64 - 2.78 (m, 3H), 2.38 - 2.55 (m, 1H), 1.15
(d, J: 6.4 Hz, 3H).
Example 59
-[(4R,10bS)methyl[[(2R)-morpholinyl]methylamino]-3,4,6, 1 0b—tetrahydro-1H-
pyrazino [2, 1 ~21]isoindol—2-yl] quinoline-8—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl )—morpholiny1methyl]carbamate (CAS: 1862023, PharmaBlock, Catalog:
PBN20121322) instead of tert~butyl (3R)—3-(hydroxymethyl)piperazine~1—carboxylate. Example
59 (8.8 mg) was ed. MS: calc’d 455 [(M+H)+], measured 455 +]. 1H NMR (400
MHz, METHANOL-d4) 5 ppm 8.88 (dd, J = 1.7, 4.2 Hz, 1H), 8.60 (dd, J = 1.6, 8.6 Hz, 1H),
8.05 (d, J: 7.9 Hz, 1H), 7.56 (dd, J: 4.3, 8.6 Hz, 1H), 7.21 (d, J: 8.1 Hz, 1H), 6.89 (d, J: 8.1
Hz, 1H), 6.60 (d, J: 1.7 Hz,1H), 6.43 (dd, J: 2.1, 8.1Hz,1H), 4.11 (d, J: 12.1 Hz, 1H), 3.94
(br d, J: 10.1 Hz, 1H), 3.69 - 3.83 (m, 2H), 3.45 - 3.62 (m, 3H), 3.31 - 3.41 (m, 1H), 3.27 - 3.30
(m, 1H), 2.94 - 3.10 (m, 2H), 2.79 - 2.91 (m, 2H), 2.64 - 2.78 (m, 3H), 2.38 - 2.55 (m, 1H), 1.15
(d, J: 6.4 Hz, 3H).
-l 00-
Example 60
- [(4R, 1 0bS)—8- [ [(3S,4R)methoxypyrrolidinyl] amino] methyl-3,4,6, 1Ob—tetrahydro—
lH-pyrazino[2,1-a]isoindol—2-yl]quinolinecarbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
(3S,4R)—tert-butyl 3-amino~4-methoxypyrrolidine-1—carboxylate (CAS: 1482601, BePharm,
Catalog: BD260807) instead of tert—butyl (3R)(hydroxymethyl)piperazinecarboxy1ate.
Example 60 (70 mg) was obtained. MS: calc’d 455 [(M+H)+], ed 455 [(M+H)+]. 1H
NMR (400 MHZ, OL-d4) 8 ppm 9.03 (dd, J = 1.7, 4.2 Hz, 1H), 8.75 (dd, J: 1.7, 8.6
Hz, 1H), 8.18 (d, J: 8.1 Hz, 1H), 7.71 (dd, J= 4.3, 8.6 Hz,1H), 7.36 (d, J: 8.1 Hz, 1H), 7.19
(d, J: 8.3 Hz, 1H), 6.89 (d, J: 1.7 Hz, 1H), 6.75 (dd, J: 2.1, 8.3 Hz, 1H), 4.68 — 4.77 (m, 1H),
4.61 (d, J: 13.1 Hz, 1H), 4.29 - 4.21 (m, 2H), 3.81 - 3.95 (m, 2H), 3.52 - - 4.39 (m, 1H), 4.11
3.69 (m, 3H), 3.42 - 3.46 (m, 1H), 3.42 (s, 3H), 3.03 - 3.22 (m, 3H), 1.42 (d, J: 6.6 Hz, 3H).
Example 61
,10bS)—8-[[(3R,4S)—4—methoxypyrrolidin—3-yl]amino]methyl—3,4,6,lOb-tetrahydro-
lH—pyrazino[2,1-a]isoindol—Z-yl]quinoline-S-carbonitrile
The title compound was ed in analogy to the preparation of Example 10 by using
(3R,4S)—tert-butyl 3-aminomethoxypyrrolidinecarboxylate (CAS: 1482600, BePharm,
Catalog: BD285562) instead of tert—butyl (3R)-3—(hydroxymethyl)piperazinecarboxylate.
e 61 (61 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H
NMR (400 MHz, METHANOL—d4) 8 ppm 9.03 (dd, J = 1.6, 4.3 Hz, 1H), 8.74 (dd, J: 1.6, 8.6
Hz, 1H), 8.18 (d, J= 7.9 Hz, 1H), 7.70 (dd, J= 4.2, 8.6 Hz, 1H), 7.35 (d, J= 8.1 Hz, 1H), 7.16
(d, J= 8.2 Hz, 1H), 6.88 (d, J: 1.8 Hz, 1H), 6.73 (dd, J= 2.1, 8.2 Hz, 1H), 4.48 - 4.59 (m, 2H),
4.28 - 3.93 (m, 1H), 3.69 -
— 4.38 (m, 1H), 4.10 - 4.17 (m, 1H), 4.05 (d, J = 13.0 Hz, 1H), 3.85
3.79 (m, 1H), 3.58 - 3.67 (m, 2H), 3.51 — 3.57 (m, 1H), 3.41 ~3.45 (m, 1H), 3.42 (s, 3H), 3.13 -
3.22 (m, 1H), 2.96 - 3.09 (m, 2H), 1.39 (d, J: 6.5 Hz, 3H).
Example 62
-[(4R,10bS)—8—[[(3S,4S)methoxypyrrolidinyl]amino]methyl—3,4,6,10b—tetrahydrolH-pyrazino
[2,1-a]isoindol-Z-yl]quinoline-S-carbonitrile
@131
fwd“
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl )aminomethoxypyrrolidinecarboxylate (CAS: 10016353, BePharm,
g: BD260806) instead of tert—butyl (3R)—3—(hydroxymethyl)piperazine~1—carboxy1ate.
Example 62 (58 mg) was obtained. MS: calc’d 455 [(M+H)+], measured 455 [(M+H)+]. 1H
NMR (400 MHz, METHANOL-d4) 5 ppm 9.04 (dd, J = 1.7, 4.2 Hz, 1H), 8.77 (dd, J = 1.7, 8.6
Hz, 1H), 8.19 (d, J: 8.1 Hz, 1H), 7.73 (dd, J: 4.3, 8.6 Hz, 1H), 7.38 (d, J: 8.1 Hz, 1H), 7.25
(d, J= 8.2 Hz, 1H), 6.84 (d, J== 1.8 Hz, 1H), 6.72 (dd, J: 2.1, 8.3 Hz, 1H), 4.93 - 5.03 (m, 1H),
4.74 (d, J: 13.4 Hz, 1H), 4.38 (d, J: 13.3 Hz, 1H), 4.20 (br d, J: 5.4 Hz, 1H), 4.02 - 4.12 (m,
2H), 3.87 - 3.54 (m, 2H), 3.48 (s,
- 3.95 (m, 1H), 3.67 - 3.75 (m, 1H), 3.58 - 3.65 (m, 1H), 3.50
3H), 3.37 (d, J: 2.1 Hz, 1H), 3.06 - 3.24 (m, 2H), 1.48 (d,J= 6.7 Hz, 3H).
—l 02—
Example 63
,10bS)—8-[[(3R,4R)-4—meth0xypyrrolidinyl]amino]-4,9-dimethyl-3,4,6, 10b-
tetrahydro—lH-pyrazino[2,1—a]isoindol—2-yl]quinoline—8-carbonitrile
The title compound was prepared according to the following scheme:
—103—
N N
II II
N\ N
/ / (s 5
NBS I
M M
j\ HOAC N
Pd(dppf)C|2.DCM
Br K2C03 dioxane/water
HN’ HN’
0 O
/ N O / N o
\(il/ Y
H H
N: N:
@l @k
)30-C‘Yo
f+ ,-C‘
Example 63
Step 1: ation of tert—butyl (3R,4R)[[(4R,10bS)-9—bromo (8-cyano
—5-quinolyl)methyl—3,4,6,10b—tetrahydro-1H—pyrazino[2,1—a]isoindol—S-yl]amino]
methoxy—pyrrolidine—l-carboxylate (compound 63b)
To a on of tert—butyl (3R,4R)[[(4R,10bS)(8-cyanoquinoly1)—4-methyl-
3 ,4,6,10b—tetrahydro-1H—pyrazino[2,1-a]isoindol-S—yl]amino]—4-methoxy—pyrrolidine—l-
carboxylate (compound 63a, 200 mg, 361 umol) in Acetic Acid (5 mL) was added NBS (64.2
mg, 361 umol). The resultant mixture was stirred at room temperature for 2 hrs. The reaction
was quenched with aqueous NaHCOg. The aqueous layer was extracted with EtOAc (10 mL) for
three times. The combined organic layers were washed with water, brine, dried over NaZSO4 and
concentrated in vacuo. The residue was purified by flash tography (silica gel, 12 g, 0% to
100% EtOAc in PE) to afford compound 63b (98 mg, 42.9 % yield). MS: calc’d 633 [(M+H)+],
measured 633 [(M+H)+].
Step 2: preparation of tert—butyl (3R,4R)[[(4R,10bS)(8-cyano-S-quinolyl)—4,9-
dimethyl—3,4,6,10b—tetrahydro-lH-pyrazino[2,1-a]isoindol—8-yl]amino]-4—methoxy-
pyrrolidine—l-carboxylate (compound 63c)
To a solution of tert-butyl (3R,4R)-3—[[(4R,10bS)-9—br0mo(8-cyano—5— quinoly1)
methyl-3 0b-tetrahydro-1H—pyrazino[2,1-a]isoindol—8—yl]amino]—4- y—pyrrolidine-l -
carboxylate (compound 63b, 98 mg, 155 umol) in dioxane (5 mL) and water (1 mL) was added
2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (38.8 mg, 309 umol), K2CO3 (42.8 mg, 309 umol)
and Pd(dppf)Cl-CH2C12 adduct (11.3 mg, 15.5 umol). The resultant mixture was stirred at 90 °C
for 2 hrs. Then the e was cooled to room temperature, diluted with water (20 mL) and
extracted with BA (20 mL) for three times. The combined organic layer was washed with brine,
dried over Na2804, filtered and concentrated in vacuo. The residue was purified by flash
chromatography (silica gel, 20 g, 30% to 100% EtOAc in PE) to afford compound 63c (53 mg,
60.3 % yield). MS: calc’d 569 [(M+H)+], measured 569 [(M+H)+].
Step 3: preparation of 5-[(4R,10bS)-8—[[(3R,4R)-4—methoxypyrrolidinyl]amino]—4,9-
dimethyl-3,4,6,1 0b-tetrahydro-lH-pyrazinol2,1-a]isoindol-Z-yl]quinoline-S-carbonitrile
(Example 63)
To a solution of tert—butyl (3R,4R)—3-[[(4R,10bS)—2—(8-cyan0quinolyl)-4,9- dimethyl-
3 ,4,6, 1 0b—tetrahydro- 1 I—I-pyrazino[2, 1 ~a]isoindoly1] amino] hoxy—pyrrolidine- 1 —
carboxylate und 63c, 53 mg, 93.2 pmol) in DCM (10 ml) was added TFA (5 ml). The
reaction e was stirred at room temperature for 2 hrs, then concentrated to afford a crude
product which was purified by pre-HPLC to afford Example 63 (32 mg, 58.9 % yield). MS:
calc’d 469 [(M+H)+], measured 469 +]. 1H NMR (400 MHZ, METHANOL—d4) 5 ppm
9.03 (dd, J: 1.7, 4.2 Hz,1H), 8.75 (dd, J: 1.6, 8.6 Hz,1H), 8.18 (d, J: 8.1 Hz, 1H), 7.71 (dd, J
= 4.3, 8.6 Hz, 1H), 7.36 (d, J: 8.1 Hz, 1H), 7.10 (s, 1H), 6.82 (s, 1H), 4.53 - 4.67 (m, 2H), 4.27
(br (1, J = 5.5 Hz, 1H), 4.08 - 4.17 (1n, 2H), 3.90 (br d, J: 12.1 Hz, 1H), 3.70 - 3.83 (m, 2H),
3.52 - 3.59 (m, 3H), 3.50 (s, 3H), 3.42 - 3.49 (m, 1H), 3.02 - 3.12 (m, 2H), 2.20 (s, 3H), 1.41 (d,
J= 6.6 Hz, 3H).
-105—
Example 64
-[(4R,10bS)[[(3S,4S)methoxypyrrolidin—3-yl]-methyl-amino]methyl-3,4,6,10b-
ydro—lH—pyrazino[2,1-a]isoindol—2-yl]quinoline—S-carbonitrile
\ Mk
9 g 5
HD‘N\
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl (3S,4S)~3-methoxy—4-(methylamino)pyrrolidinecarboxylate (CAS: 9603169,
PharmaBlock, Catalog: 14) instead of tert-butyl (3R)-3—(hydroxymethyl)piperazine
carboxylate. Example 64 (25 mg) was obtained. MS: calc’d 469 [(M+H)+], measured 469
[(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 6 ppm 9.04 (dd, J = 1.7, 4.3 Hz, 1H), 8.77 (dd,
J: 1.7, 8.6 Hz,1H), 8.19 (d, J: 7.9 Hz,1H), 7.73 (dd, J= 4.2, 8.6 Hz,1H), 7.38 (d, J: 7.9 Hz,
1H), 7.33 (d, J: 8.3 Hz,1H), 7.16 (d, J= 1.8 Hz, 1H), 7.03 (dd, J: 2.2, 8.3 Hz, 1H), 4.82 - 4.87
(m,1H), 4.71 (d,J= 13.2 Hz, 1H), 4.40 - 4.47 (m, 1H), 4.31 (d, J = 13.1 Hz, 1H), 4.14 - 4.21 (m,
1H), 3.88 - 3.48 (m, 2H), 3.36 (s, 3H), 3.06 — 3.19 (m,
— 4.04 (m, 2H), 3.51 - 3.69 (m, 3H), 3.37
2H), 2.91 (s, 3H), 1.46 (d, J: 6.7 Hz, 3H).
Example 65
—[(4R,10bS)-4—methyl—8—[[(3R)piperidyl]amino]-3,4,6,10b—tetrahydro-lH—pyrazino[2,1—
a]isoindolyl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
—106—
tert-butyl (3R)aminopiperidine-1~carboxy1ate (CAS: 1881117, m, Catalog:
BDO329) instead of tert-butyl (3R)(hydroxymethyl)piperazine-1—carboxy1ate. e 65
(27 mg) was obtained. MS: calc’d 439 [(M+H)+], measured 439 +]. ‘H NMR (400 MHZ,
METHANOL-d4) 6 ppm 9.05 (dd, J= 1.7, 4.2 Hz, 1H), 8.77 (dd, J= 1.7, 8.6 Hz, 1H), 8.19 (d, J
= 7.9 Hz, 1H), 7.73 (dd, J: 4.3, 8.6 Hz, 1H), 7.38 (d, J: 7.9 Hz, 1H), 7.32 (d, J: 8.4 Hz, 1H),
7.16 (d, J: 1.7 Hz, 1H), 7.03 (dd, J= 2.1, 8.5 Hz, 1H), 4.72 (d, J: 13.3 Hz, 1H), 4.33 (d, J=
13.4 Hz, 1H), 3.96 - 4.06 (m, 1H), 3.90 - 3.96 (m, 1H), 3.46 - 3.66 (m, 3H), 3.25 - 3.31 (m, 2H),
3.06 — 3.20 (m, 4H), 1.93 — 2.14 (m, 2H), 1.70 - 1.86 (m, 2H), 1.46 (d, J= 6.6 Hz, 3H).
Example 66
- [(4R,10bS)—8—| [(3S,4R)—3-methoxy—4-piperidyl]amino]methyl-3,4,6,10b—tetrahydro-1H-
pyrazino[2,1-a]isoindolyl]quinoline—8—carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl (3S,4R)amino-3—methoxypiperidinecarboxy1ate(CAS: 1171125-92—0,
PharmaBlock, Catalog: PBN20120813) instead of tert—butyl (3R)—3~(hydroxymethy1)piperazine-
1—carboxy1ate. Example 66 (28 mg) was ed. MS: calc’d 469 [(M+H)+], measured 469
[(M+H)+]. 1H NMR (400 MHZ, METHA‘NOL-d4) 0‘ ppm 8.87 (dd, J = 1.6, 4.3 Hz, 1H), 8.58 (dd,
J=1.7, 8.6 Hz,1H), 8.02 (d, J: 7.9 Hz,1H), 7.55 (dd, J= 4.3, 8.6 Hz,1H), 7.19 (d, J: 8.1 Hz,
1H), 6.90 (d, J= 8.1 Hz, 1H), 6.67 (d, J: 1.5 Hz, 1H), 6.50 (dd, J = 2.0, 8.1 Hz, 1H), 4.10 (d, J
= 12.1 Hz, 1H), 3.92 (br d, J: 10.4 Hz,1H), 3.73 (br (1, J = 11.0 Hz,1H), 3.52 (br d,J= 11.7 Hz,
1H), 3.42 - 3.20 (m, 2H), 2.81 - 2.96 (m,
- 3.49 (m, 1H), 3.29 — 3.34 (m, 2H), 3.24 (s, 3H), 3.13
2H), 2.65 - 1.67 (1n, 2H), 1.14 (d, J: 6.5 Hz, 3H).
- 2.76 (m, 1H), 2.44 - 2.61 (m, 2H), 1.48
-107—
Example 67
-[(4R,10bS)methyl(2-m0rpholinoethylamino)—3,4,6,10b-tetrahydro-1H-pyrazino[2,l-
a]isoindol—Z—yl]quinoline—S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using 2-
morpholinoethanamine (CAS: 20381, BePharm, Catalog: 7) instead of Iert—butyl
(3R)—3—(hydroxymethyl)piperazinecarboxy1ate. Example 67 (29 mg) was obtained. MS:
calc’d 469 [(M+H)+], measured 469 [(M+H)+]. IH NMR (400 MHz, METHANOL—d4) 6 ppm
8.87 (dd, J= 1.7, 4.2 Hz, 1H), 8.57 (dd, J= 1.7, 8.6 Hz, 1H), 8.02 (d, J: 8.1 Hz, 1H), 7.55 (dd, J
= 4.2, 8.6 Hz, 1H), 7.18 (d, J: 8.1 Hz, 1H), 6.88 (d, J: 8.1 Hz, 1H), 6.59 (d, J: 1.7 Hz, 1H),
6.42 (dd,J= 2.1, 8.1 Hz, 1H), 4.10 (d, J: 12.2 , 3.91 (br d,J= 10.3 Hz,1H),3.68 - 3.76
(m, 1H), 3.57 - 3.64 (m, 4H), 3.51 (br d, J: 11.6 Hz, 1H), 3.31 (br d,J=11.6 Hz, 1H), 3.16 —
3.19 (m, 1H), 3.13 (t, J: 6.5 Hz, 2H), 2.86 (t, J: 10.9 Hz, 1H), 2.67 - 2.74 (m, 1H), 2.50 (t, J:
6.5 Hz, 2H), 2.37 - 2.45 (m, 4H), 1.14 (d, J: 6.4 Hz, 3H).
—108-
Example 68
-[(4R,10bS)—8—[2-[(3S)hydroxypyrrolidin- l-yl]ethylamino]-4—methyl-3,4,6, 10b-
tetrahydro-lH—pyrazino[2,1-a]isoindol—2—yl]quinoline-S-carbonitrile
<1...
The title compound was prepared in analogy to the ation of Example 10 by using
(3S)-1—(2-aminoethy1)pyrrolidinol (CAS: 540787—75—5, BePharm, Catalog: BD45313) instead
of utyl (3R)(hydroxymethyl)piperazinecarboxylate. Example 68 (13 mg) was
obtained. MS: calc’d 469 [(M+H)+], measured 469[(M+H)+]. 1H NMR (400 MHz,
METHANOL-d4) 5 ppm 8.87 (dd, J= 1.6, 4.3 Hz, 1H), 8.58 (dd, J: 1.6, 8.6 Hz, 1H), 8.03 (d, J
= 7.9 Hz, 1H), 7.55 (dd, J= 4.3, 8.6 Hz, 1H), 7.19 (d, J: 8.1 Hz, 1H), 6.89 (d, J: 8.1 Hz, 1H),
6.60 (d, J: 1.6 Hz, 1H), 6.43 (dd, J: 2.0, 8.1 Hz, 1H), 4.20 - 4.31 (m, 1H), 4.10 (d, J: 12.2 Hz,
1H), 3.92 (br d, J: 10.3 Hz, 1H), 3.72 (br (1, J=11.2 Hz,1H), 3.52 (br d, J: 12.0 Hz, 1H), 3.32
(br d, J= 11.6 Hz,1H), 3.16 - 3.20 (m, 1H), 3.13 (t, J: 6.6 Hz, 2H), 2.86 (t, J: 10.9 Hz,1H),
2.59 — 2.77 (m, 5H), 2.38 - 2.51 (m, 2H), 1.99 — 2.12 (m, 1H), 1.59 - 1.72 (m, 1H), 1.14 (d, J=
6.4 Hz, 3H).
—109-
Example 69
-[(4R,10bS)—8-[(3-fluoroazetidinyl)methylamino]methyl-3,4,6,10b-tetrahydro-1H-
pyrazino[2,1-a]isoindol—2-yl]quinolinecarbonitrile
The title compound was prepared in y to the preparation of Example 10 by using
tert-butyl 3~(aminomethyl)—3-fluoroazetidinecarboxylate (CAS: 1083181—23—0, PharmaBlock,
Catalog: PBN20120081) instead of utyl (3R)—3—(hydroxymethyl)piperazine-1~carboxylate.
Example 69 (10 mg) was obtained. MS: calc’d 443 [(M+H)+], measured 443 [(M+~H)+]. ‘H
NMR (400 MHz, METHANOL-d4) 5 ppm 9.04 (dd, J: 1.6, 4.3 Hz, 1H), 8.76 (dd, J z 1.7, 8.6
Hz, 1H), 8.18 (d, J: 7.9 Hz, 1H), 7.72 (dd, J: 4.3, 8.6 Hz, 1H), 7.37 (d, J: 7.9 Hz, 1H), 7.22
(d, J: 8.3 Hz, 1H), 6.90 (d, J: 1.7 Hz, 1H), 6.77 (dd, J: 2.1, 8.3 Hz, 1H), 4.95 - 5.02 (m, 1H),
4.75 (d, J= 13.3 Hz, 1H), 4.24 - 4.46 (m, 5H), 4.06 - 4.18 (m, 1H), 3.86 - 3.95 (111, 1H), 3.69 (d,
J: 19.8 Hz, 2H), 3.55 — 3.64 (m, 1H), 3.16 - 3.25 (m, 1H), 3.04 - 3.13 (m, 1H), 1.49 (d, J: 6.6
Hz, 3H).
Example 70
-[(4R,10bS)—8-[1(2S,4S)-4—fluoropyrrolidin-Z-yl]methylamino]methyl—3,4,6, rahydro
—lH-pyrazino[2,1-a]isoindol-Z-yl]quinoline-S—carbonitrile
“51.4ng
—l l 0-
The title compound was ed in analogy to the preparation of Example 10 by using
tert-butyl (23,4S)(aminomethyl)fluoropyrrolidinecarboxy1ate (CAS: 10332453,
Block, Catalog: PB05325) instead of tert-butyl (3R)-3—(hydroxymethyl)piperazine
ylate. Example 70 (28 mg) was obtained. MS: calc’d 457 [(M+H)+], measured 457
[(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) 6 ppm 9.03 (dd, J = 1.6, 4.3 Hz, 1H), 8.76 (dd,
J=1.7, 8.6 Hz, 1H), 8.17 (d, J= 7.9 Hz, 1H), 7.72 (dd, J: 4.3, 8.6 Hz, 1H), 7.37 (d, J: 7.9 Hz,
1H), 7.24 (d, J: 8.3 Hz,1H), 6.87 (d, J: 1.7 Hz,1H), 6.74 (dd, J2 2.1, 8.3 Hz, 1H), 5.39 - 5.58
(m, 1H), 4.97 - 4.17 (m,
— 5.04 (m, 1H), 4.76 (d, J: 13.4 Hz, 1H), 4.40 (d, J: 13.4 Hz, 1H), 4.04
2H), 3.84 — 3.78 (m, 1H), 3.40 - 3.65 (m, 4H), 3.17 - 3.27 (m, 1H), 3.06 - - 3.96 (m, 1H), 3.68
3.14 (m, 1H), 2.51 - 2.73 (m, 1H), 2.12 - 2.31 (m, 1H), 1.49 (d, J: 6.6 Hz, 3H).
Example 71
-[(4R,10bS)[(8aS)—3-oxo—1,5,6,7,8,82-hexahydr0imidazo[1,5-a]pyrazin-Z-yljmethyl-
3,4,6,10b—tetrahydro-lH-pyrazino[2,1-a]isoindolyl]quinoline—S-carbonitrile
The title nd was prepared in analogy to the preparation of Example 10 by using
tert—butyl (8aR)oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazine carboxylate instead of
tert—butyl (3R)—3—(hydroxymethyl)piperazine—1-carboxylate. Example 71 (38 mg) was obtained.
MS: calc’d 480 [(M+H)+], measured 480 [(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 5
ppm 9.03 (dd, J: 1.7, 4.2 Hz, 1H), 8.77 (dd, J3 1.6, 8.6 Hz, 1H), 8.18 (d, J: 7.9 Hz, 1H), 7.86
(d, J: 1.3 Hz, 1H), 7.72 (dd, J: 4.3, 8.6 Hz, 1H), 7.51 (dd, J: 2.0, 8.4 Hz, 1H), 7.33 - 7.47 (m,
1H), 4.92 = 13.3 Hz, 1H), 4.06
— 4.22 (m,
- 5.01 (m, 1H), 4.77 (d, J: 13.3 Hz, 1H), 4.38 (d, J
3H), 3.93 - 4.06 (m, 2H), 3.68 - 3.74 (m, 1H), 3.54 — 3.65 (m, 2H), 3.41 — 3.47 (m, 1H), 3.29 (br d,
J: 3.3 Hz, 1H), 3.00 - 3.22 (m, 4H), 1.47 (d, J: 6.6 Hz, 3H).
-1 1 1—
Example 72
-[(4R,10bS)[(8aR)-3—0xo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazin-Z-yl]methyl-
3,4,6,10b-tetrahydro—lH-pyrazino[2,1-a]is0indolyl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert—butyl (8aS)oxo-l,2,5,6,8,8a-hexahydroimidazo[l,5-a]pyrazine carboxylate instead of
tert—butyl —(hydroxymethy1)piperazine-1~Carboxylate. Example 72 (8.8 mg) was obtained.
MS: calc’d 480 [(M+H)+], ed 480 [(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 0'
ppm 9.02 (dd, J: 1.6, 4.3 Hz, 1H), 8.74 (dd, J: 1.7, 8.6 Hz, 1H), 8.18 (d, J: 8.1 Hz, 1H), 7.75
(d, J: 1.5 Hz, 1H), 7.70 (dd, J: 4.2, 8.6 Hz, 1H), 7.44 (dd, J: 2.0, 8.3 Hz, 1H), 7.27 - 7.38 (m,
2H), 4.41 - 4.15 (m, 3H), 3.90 — 4.01 (m, 2H), 3.49 - 3.70 (in, 4H), 3.37
- 4.54 (m, 2H), 4.04
3.44 (m, 1H), 3.24 - 3.30 (1n, 1H), 3.03 - 3.14 (m, 3H), 2.87 - 3.01 (m, 1H), 1.36 (d, J: 6.5 Hz,
3H).
Example 73
-[(4R,10bS)[(3S,4S)—4-flu0r0pyrrolidin—3-yl]oxymethyl-3,4,6,10b-tetrahydro-1H—
pyrazino[2,1-a]isoindol—2-yl]quinoline-8—carbonitrile
HNO‘0
The title nd was prepared in analogy to the preparation of Example 10 by using
tert-butyl (3S,4.S')-3 -fluorohydroxypyrrolidinecarboxylate (CAS: 1 1740209,
-1 12-
PharmaBlock, Catalog: PB08192) instead of tert—butyl (3R)—3-(hydroxymethyl)piperazine-lcarboxylate.
Example 73 (18 mg) was obtained. MS: calc’d 444 [(M+H)+], measured 444
[(M+H)+]. 1H NMR (400 MHz, OL-d4) (5 ppm 9.02 (dd, J = 1.5, 4.2 Hz, 1H), 8.73 (dd,
J=1.5, 8.6 Hz, 1H), 8.17 (d, J= 8.1 Hz, 1H), 7.69 (dd, J: 4.2, 8.6 Hz, 1H), 7.34 (d, J= 7.9 Hz,
1H), 7.28 (d, J: 8.1 Hz, 1H), 7.14 (s, 1H), 6.97 (br (1, J: 8.4 Hz, 1H), 5.37 — 5.57 (m, 1H), 5.25
- 5.34 (m, 1H), 4.41 (d, J: 12.6 Hz, 1H), 4.28 (br (1, J= 10.1 Hz, 1H), 3.62 - 3.95 (m, 6H), 3.49
(br d, J: 8.9 Hz, 2H), 3.03 (t, J: 11.1 Hz, 1H), 2.90 (t, J: 11.7 Hz, 1H), 1.32 (d, J= 6.2 Hz,
3H).
1 0 Example 74
-[(4R,10b.S)—8-[[(2S,4S)—4-fluoropyrrolidin-Z—yl]methoxy]methyl-3,4,6,10b-tetrahydro-
1H-pyrazino[2,1-a]isoindol-Z-yl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 10 by using
tert-butyl S)—4-fluoro~2—(hydroxymethyl)pyrrolidinecarboxy1ate (CAS: 3173567,
PharmaBlock, Catalog: PB05324) instead of tert-butyl (3R)(hydroxymethyl)piperazine—1-
carboxylate. Example 74 (12 mg) was obtained. MS: cale’d 458 [(M+H)+], measured 458
[(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 6 ppm 9.02 (dd, J = 1.6, 4.3 Hz, 1H), 8.74 (dd,
J=1.6, 8.6 Hz, 1H), 8.17 (d, J: 8.1 Hz, 1H), 7.70 (dd, J: 4.3, 8.6 Hz,1H), 7.35 (d, J: 8.1Hz,
1H), 7.29 (d, J: 8.3 Hz, 1H), 7.12 (d, J: 2.1 Hz, 1H), 6.96 (dd, J: 2.3, 8.3 Hz, 1H), 5.35 - 5.63
(m, 1H), 4.36 - 3.95 (m, 1H),
- 4.53 (m, 3H), 4.14 — 4.32 (m, 2H), 3.99 (d, J== 12.8 Hz, 1H), 3.88
3.71 - 3.09 (m, 2H), 2.60 - 2.81 (m, 1H), 2.16 - 2.34 (m,
- 3.81 (m, 1H), 3.42 - 3.67 (m, 3H), 2.92
1H), 1.36 (d, J: 6.6 Hz, 3H).
-l 1 3-
Example 75
(4R,1 0bS)—N—[(3S,4R)-4—fluoropyrrolidinyl]methyl-Z-(8-methyl—5-quinolyl)-3,4,6,1 0b-
tetrahydro—lH-pyrazino[2,1-a]isoind01—8—amine
The title compound was prepared ing to the following :
Q 13w Ni Q6
:j\ PdCIH2
XPhos Pd <32 oszco3 MeOH F N O
dioxane, 80 00 F NYC Y
1i 75a 75b
N \/2
N\ j\ N
r TFA/DCM
—-—-—-——> HN —————-———->
RuPhos Pd 62 C52003
dioxane, 90 0c F’t‘ ”N
N o
750 Example 75
Step 1: preparation of tert-butyl (3S,4R)-3—(((4R,10bS)benzyl—4-methyl—
1,2,3,4,6,10b-hexahydropyrazino[2,1-a]is0indol—8—yl)amino)—4-flu0ropyrrolidine-l—
carboxylate (compound 75a)
To a solution of tert-butyl (3S,4R)amino—4-fluoropyrrolidine—l-carhoxy1ate (366 mg, 1.8
mmol) in dioxane (15 mL) was added (4R,lObS)benzyl— 8—bromomethyl-1,2,3,4,6,10b-
hexahydropyrazino[2,1—a]isoindole (compound lj, 640 mg, 1.8 mmol, ), CsZCO3 (1.7 g, 5.4
mmol) and XPhos Pd G2 (152 mg, 179 mmol). The reaction mixture was stirred at 85 0C
overnight. The mixture was cooled to room temperature, d with water (50 mL) and
extracted with EA (80 mL) for three times. The combined organic layer was washed with brine,
dried over NaZSO4, filtered and concentrated in vacuo. The residue was purified by flash
chromatography a gel, 40 g, 0% to 100% EtOAc in DCM) to afford compound 75a (710 mg,
82.5 % yield). MS: calc’d 481 [(M+H)+], measured 481 [(M+H)+].
Step 2: preparation of tert-butyl (3R,4S)fluoro—4-(((4R,10bS)methyl-
1,2,3,4,6,10b-hexahydropyrazino[2,1—a]isoindolyl)amino)pyrrolidinecarboxylate
(compound 75b)
A mixture of utyl (3S,4R)-3—(((4R,10bS)—2-benzyl—4—methyl—l,2,3,4,6,10b—
dropyrazino[2,1-a]isoindoly1)amino)fluoropyrrolidinecarboxy1ate (compound
7521, 710 mg, 1.5 mmol) and Pd-C (100 mg) in MeOH (80 mL) was hydrogenated by a hydrogen
balloon at room temperature for 5 hrs. After the catalyst was filtered off, the filtrate was
concentrated in vacuo to afford compound 75b (490 mg, 84.9 % yield) which was used directly
for the next step without further purification. MS: calc’d 391 [(M+H)+], measured 39] [(M+H)+].
Step 3: preparation of tert-butyl )fluoro—4-(((4R,10bS)methyl-2— (8-
methquuinolin-S-yl)—1,2,3,4,6,lOb-hexahydropyrazino[2,1-a]isoindol-S-yl)—amino)—
pyrrolidine-l-carboxylate (compound 75c)
To a solution of 5-bromomethquuinoline (CAS: 74316—55—5, BePharm, Catalog:
BD239383, 34.1 mg, 154 umol) in e (5 mL) was added tert—butyl (3R,4S)-3—fluoro
10bS)—4-methyl-l ,2,3 ,4,6,10b-hexahydropyrazino[2,l-a]isoindol—8-yl)amino)pyrrolidine—l —
carboxylate (compound 75b, 60 mg, 154 pmol), RuPhos Pd G2 (11.9 mg, 15.4 umol) and
CszC03 (150 mg, 461 umol). The reaction mixture was stirred at 90 °C for 20 hrs. The mixture
was cooled to room temperature, diluted with water (20 mL) and extracted with EA (20 mL) for
three times. The combined organic layer was washed with brine, dried over Na2804, filtered and
concentrated in vacuo. The residue was purified by flash tography (silica gel, 20 g, 0% to
100% EtOAc in PE) to afford compound 75c (39 mg, 47.7 % yield). MS: calc’d 532 [(M+H)+],
measured 532 [(M+H)+].
Step 4: (412,10bS)—N—[(3S,4R)—4—flu0ropyrrolid'myl]methyl(8-methyl-
-quinolyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-alisoindol-8—amine (Example 75)
To a solution of utyl (3R,4S)—3-fluoro(((4R,10bS)—4—methyl—2— (8-methquuinolin-5—
y1)-l ,6,10b-hexahydropyrazino[2,l—a]isoindol-8—yl)amino)pyrrolidinecarboxylate
(compound 75c, 39 mg, 73.4 umol) in DCM (8 mL) was added TFA (2 mL). The reaction
-1 15-
mixture was d at room temperature for 2 hrs, then concentrated to afford a crude product,
which was purified by pre—HPLC to afford Example 75 (10 mg, 32% yield). MS: calc’d 432
[(M+H)+], measured 432 [(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 6 ppm 8.80 (dd, J =
1.7, 4.3 Hz, 1H), 8.68 (dd, J= 1.5, 8.5 Hz, 1H), 7.50 (dd, J: 4.3, 8.4 Hz, 1H), 7.45 (dd, J: 0.7,
7.7 Hz,1H), 7.16 (d, J: 7.6 Hz,1H), 7.13 (d, J: 8.4 Hz, 1H), 6.83 (d, J: 1.7 Hz, 1H), 6.70 (dd,
J= 2.1, 8.4 Hz, 1H), 5.15 - 5.34 (m, 1H), 4.99 — 5.08 (m, 1H), 4.75 (d, J= 13.7 Hz, 1H), 4.31 -
4.47 (m, 2H), 4.06 - 4.19 (m, 1H), 3.54 — 3.74 (m, 4H), 3.31 (br d, J: 12.3 Hz, 1H), 3.03 - 3.18
(m, 2H), 2.85 - 2.98 (m, 1H), 2.61 (s, 3H), 1.40 (d, J= 6.7 Hz, 3H).
Example 76
(4R,10bS)—N-[(3S,4R)—4-fluoropyrrolidinyl]methyl(8-methquuinoxalin-5—yl)-
3,4,6,10b—tetrahydro—1H-pyrazino[2,1-a]isoindol—S-amine
($21“
F NH
The title compound was prepared in analogy to the preparation of Example 75 by using 5-
Bromo-8—methquuinoxa1ine (CAS: 13605994, BePharm, Catalog: BD00771201) instead of
~bromo-8—methquuinoline. Example 76 (11 mg) was obtained. MS: calc’d 433 +],
ed 433 [(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) (5 ppm 8.84 - 8.98 (m, 2H), 7.53
- 7.69 (m, 1H), 7.31 (d, J: 7.8 Hz, 1H), 7.22 (d, J: 8.3 Hz, 1H), 6.92 (d, J: 1.6 Hz,1H), 6.80
(dd, J: 2.1, 8.2 Hz, 1H), 5.25 - 5.45 (m, 1H), 4.81 — 4.87 (m, 1H), 4.68 (d, J: 13.3 Hz, 1H),
4.40 — 4.56 (m, 1H), 4.18 - 4.33 (m, 2H), 3.88 — 4.03 (m, 2H), 3.62 ~ 3.83 (m, 3H), 3.25 (t, J:
11.2 Hz, 1H), 2.95 - 3.10 (m, 2H), 2.71 (s, 3H), 1.45 (d, J: 6.5 Hz, 3H).
WO 33941
-1 l 6-
Example 77
(4R,l 0bS)-N- [(3S,4R)fluoropyrrolidinyl]methyl [8-(trifluoromethyl)quinoxalin
yl] -3,4,6,10b-tetrahydro-1H—pyrazino[2,1-a]isoindolamine
{5.1x
F’GH
The title compound was prepared in analogy to the preparation of Example 75 by using 5—
bromo(trifluoromethyl)quinoxaline instead of 5-bromo1nethy1quinoline. Example 77 (21.2
mg) was obtained. MS: calc’d 487 [(M+H)+], measured 487 [(M+H)+]. IH NMR (400 MHz,
METHANOL-d4) (5 ppm 8.86 - 9.04 (m, 2H), 8.11 (d, J = 8.4 Hz, 1H), 7.37 (d, J: 8.2 Hz, 1H),
7.24 (d, J: 8.3 Hz, 1H), 6.91 (d, J: 1.7 Hz, 1H), 6.79 (dd, J: 2.1, 8.3 Hz, 1H), 5.20 - 5.44 (m,
1H), 4.69 — 4.75 (m, 1H), 4.64 (d, J= 13.2 Hz, 1H), 4.38 - 4.59 (m, 2H), 4.17 - 4.29 (m, 2H),
3.84 - 3.94 (m, 1H), 3.65 - 3.83 (m, 3H), 3.25 (t, J: 11.2 Hz, 1H), 3.09 - 3.20 (m, 2H),1.45(d, J
= 6.6 Hz, 3H).
Example 78
7—[(4R,10bS)[[(3S,4R)fluoropyrrolidin—yl]amino]methyl-3,4,6,10b-tetrahydro-1H-
pyrazino[2,1-a]isoindol—Z-yl]—1,3-benzothiazolecarbonitrile
. 6.3x
The title compound was ed according to the following scheme:
Nj\ N N
Nl N S)
F TFA/DCM
D!EA,DMSO
F'tr‘q
7513 Example 78
Step 1: preparation of tert-butyl (3S,4R)[[(4R,10bS)(4-cyano-l,3- benzothiazol
yl)-4—methyl—3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindol—S-yll—amino]fluoro—
pyrrolidinecarboxylate (compound 78a)
To a solution of 7-fluorobenzo[d]thiazolecarbonitrile (27.4 mg, 154 umol) in DMSO (2
ml) was added tert—butyl )—3-[[(4R,10bS)—4-methyl-l ,2,3 , 4,6,10b—
dropyrazino[2,l -a]isoindolyl]amino]—4-fluoro-pyrrolidine-1 -carboxylate (compound
75b, 60 mg, 154 umol) and DIEA (99.3 mg, 768 umol). The resultant mixture was stirred at 120
°C ght. After cooled to room temperature, the reaction was quenched with water (20 mL)
and extracted with BA (20 mL) twice. The combined organic layer was washed with brine, dried
over NaZSO4, filtered and concentrated in vacuo. The residue was purified by flash
chromatography (silica gel, 20 g, 0% to 100% EtOAc in PE) to afford nd 78a (29 mg,
34.4 % yield). MS: calc’d 549 [(M+H)+], measured 549 [(M+H)+].
Step 2: preparation of 7—[(4R,10bS)—8-[[(3S,4R)flu0ropyrrolidin—3-yl]-
amino]methyl-3,4,6,10b—tetrahydro-lH—pyrazino[2,1-a]isoindol—Z-yl]-1,3-benzothiazole—
4-carbonitrile le 78)
To a solution of tert—butyl (3S,4R)—3—[[(4R,l0bS)(4-cyano-1,3-benzothiazol—7-yl)—4-
methyl-3 ,4,6, l Ob-tetrahydro- 1H—pyrazino[2, 1 -a]isoindol-8—y1]amino]fluoro-pyrrolidine- l -
carboxylate (compound 78a, 20 mg, 36.5 umol) in DCM (8 mL) was added TFA (2 mL). The
reaction mixture was stirred at room ature for 2 hrs, then concentrated to afford a crude
product, which was purified by pre-HPLC to afford Example 78 (11mg, 67% yield). MS: calc’d
449 [(M+H)+], measured 449 +]. ‘H NMR (400 MHz, METHANOL-d4) 0‘ ppm 9.33 (s,
1H), 7.81 (d, J: 8.2 Hz, 1H), 7.13 (dd, J: 4.0, 8.2 Hz, 2H), 6.81 (d, J: 1.6 Hz, 1H), 6.68 (dd, J
= 2.0, 8.3 Hz, 1H), 5.11 - 4.45 (m, 1H), 4.02
- 5.34 (1n, 1H), 4.46 - 4.57 (m, 2H), 4.29
- 4.15 (m,
2H), 3.77 (br d, J = 12.7 Hz, 1H), 3.52 - 3.71 H), 2.96 — 3.16 (m, 3H), 1.35 (d, J: 6.5 Hz,
311).
Example 79
bS)(8-chloro—5—quinolyl)-N-[(3S,4R)fluoropyrrolidin—3-yl]-4—methyl—3,4,6,10b-
tetrahydro—lH—pyrazino[2,1—a]isoindol-8—amine
32:1
The title compound was prepared in analogy to the preparation of Example 75 by using 5-
Bromo-S-Chloroquinoline (CAS: 927800-41—7, BePharm, Catalog: BD3 8263) instead of 5-
bromo-S-methquuinoline. Example 79 (12 mg) was obtained. MS: calc’d 452 [(M+H)+],
measured 452 [(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) (5 ppm 8.99 (dd, J = 1.6, 4.3 Hz,
1H), 8.78 — 8.88 (m, 1H), 7.87 (d, J: 8.1 Hz, 1H), 7.71 (dd, J= 4.2, 8.5 Hz, 1H), 7.34 (d, J: 8.2
Hz, 1H), 7.23 (d, J: 8.2 Hz, 1H), 6.93 (d, J: 1.7 Hz, 1H), 6.80 (dd, J: 2.1, 8.3 Hz, 1H), 5.22 -
.44 (m, 1H), 4.94 - 5.02 (m, 1H), 4.76 (d, J: 13.4 Hz, 1H), 4.32 - 4.55 (m, 2H), 4.08 (br d, J:
7.0 Hz, 1H), 3.61 - 3.85 (m, 4H), 3.45 (br d, J: 12.0 Hz, 1H), 3.25 (t, J: 11.2 Hz,1H), 3.00 -
3.18 (m, 2H), 1.48 (d, J: 6.7 Hz, 3H).
-1 1 9-
e 80
-[(4R,10bS)[2-[(3S)hydroxypyrrolidin-l-yl]ethylamino]methyl-3,4,6,10b-
tetrahydro-lH—pyrazino[2,1-a]isoindolyl]quinoline-S-carbonitrile
”KRIS/OH
The title compound was prepared in analogy to the preparation of Example 68. Example
80 (12 mg) was obtained. MS: calc’d 469 [(M+H)+], ed 469 [(M+H)+]. 1H NMR (400
MHz, METHANOL-d4) 6 ppm 8.97 - 9.05 (m, 1H), 8.73 — 8.78 (m, 1H), 8.17 (d, J: 8.1 Hz, 1H),
7.71 (dd, J: 4.3, 8.6 Hz, 1H), 7.37 (d, J: 8.1 Hz, 1H), 7.28 (t, J: 7.8 Hz, 1H), 6.70 - 6.83 (m,
2H), 4.96 — 5.01 (m, 1H), 4.56 - 4.69 (m, 2H), 4.31 (br (1, J= 13.0 Hz, 1H), 4.02 - 4.14 (m, 1H),
3.92 (br .1 Hz, 1H), 3.41 - 3.76 (m, 9H), 3.07 - 3.22 (m, 2H), 2.24 - 2.36 (m, 1H), 2.03 -
2.15 (m, 1H), 1.49 (d, J: 6.6 Hz, 3H).
Example 81
-[(4R,10bS)[[(3S,4R)—4-fluoropyrrolidin—3-yl]amino]-4—methyl—3,4,6,10b-tetrahydr0-1H-
1 5 pyrazino [2,1-a]isoindol-Z-yl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 30. Example
81 (10 mg) was obtained. MS: calc’d 443 [(M+H)+], measured 443 [(M+H)+]. 1H NMR (400
MHZ, METHANOL—d4) 6 ppm 9.02 (dd, J = 1.6, 4.3 Hz, 1H), 8.74 (dd, J = 1.7, 8.6 Hz, 1H),
-1 20—
8J6QLJ=T9HL1HL7JOM¢J=43,&6HL1HL736MHF=&1H;1HL727flJé78
&M¢J=82HL1HL6&(¢J=75H;1HL529¢J=29HL1HL484®r¢J
=3IIHLZHD,464(dHI=13J.HA1fD,422(d“/=13JQHLllD,388—4Dl(nLZLD,368—
3.84 (m, 3H), 3.59 (br d, J= 12.5 Hz, 1H), 3.43 (t, J: 11.2 Hz, 1H), 3.02 — 3.19 (m, 2H), 1.45 (d,
J: 6.6 Hz, 3H).
Example 82
-[(4R,10bS)I(3R,4R)—4-aminohydroxy—3-methyl—pyrrolidin-l-yl}—9—fluor0methyl-
3,4,6,10b-tetrahydro—lH-pyrazino[2,l-a]isoindol—Z-yl]quinoline-S-carbonitrile
The title compound was prepared according to the following scheme:
— l 21 -
0 OH
H_______*__3______.so4NBS con (33200 Mel NBS BPO
0014
0 do Nvé’i:
[|r(dtbbpy)(ppy)2]PFe
AgNoa Z/
——-——> F
-PrOHIWa_—T—.er 4A molecular sieves, 0\ ACN/TFE (9:1)
CHSCN blue light
82e 82f 829
I | m
N\ N\
H /
BHBITHF 1)ACE--c: DCE N
F DIEA, DMSO Nj\
2) MeOH
82i 82]
H N H
N | I
HO,,,_ N\
NH /
o=( A<
_....._—_. :i TFA/DCM Nj\
tBuXPhos Pd GS, t-BuONa
dioxane
0* 82k Example 82
Step 1: preparation of 5-bromofluoro-2—methyl-benzoic acid (compound 82b)
To the solution of 4-fluoromethylbenzoic acid (compound 82a, 50.0 g, 324.38 mmol) in
Con. H2SO4 (250.0 lnL) was added NBS (58.0 g, 325.88 mmol) in portions at 0 OC. Then the
reaction mixture was stirred at 0-5 °C for 1 hr. The resultant mixture was poured into 2.5 L ice-
water. The solid was collected by filtration. The collected solid was dried in air and then in
vacuo to afford nd 82b (67 g, 88.6% . MS: calc’d 231, 233[(M-H)‘], measured 231,
233[(M—H)'].
~122—
Step 2: preparation of methyl 5-bromo—4-fluoro—2-methyl-benzoate (compound 82c)
To the stirred solution of 5-bromofluoromethyl-benzoic acid (compound 82b, 35.0 g,
150.2 mmol) in DMF (350 mL) was added cesium ate (73.5 g, 225.6 mmol) The resultant
mixture was stirred for 30 minutes, followed by the addition of iodomethane (22.0 g, 155 mmol).
Then the e was d at 40 °C for 15 hrs. After cooled to room temperature, the on
was quenched with water (1.5 L) and extracted with EA (800 mL) for three times. The ed
organic layer was washed with brine, dried over Na2804, filtered and concentrated in vacuo to
afford compound 82c (35 g, crude) which was used directly for the next step without further
purification. MS: calc’d 247, 249[(M+H)+], measured 247, 249[(M+H)+].
Step 3: preparation of methyl 5-bromo-Z—(dibromomethyl)fluoro-benzoate
und 82d)
To the on of methyl 5-bromofluoro—2-methyl-benzoate (compound 82c, 35.0 g,
crude) in carbon tetrachloride (200 mL) was added benzoylperoxide (3.43 g, 14.2 mmol) and
NBS (77.0 g, 432.6 mmol). The resultant mixture was stirred at reflux for 18 hrs. The reaction
mixture was d through Celite and washed with CC14. The filtrate was washed with the
mixed solution of aq. NaHCO3/aq. Nazszo3 aq. (1:1, 200 mL) and brine (200 mL) subsequently,
dried over Na2804, filtered and concentrated in vacuo afford compound 82d (51 g, crude). MS:
calc’d 405, 407[(M+H)+], measured 325, 327[(M- Br)+].
Step 4: preparation of methyl 5-bromo-4—fluoro—2-formyl-benzoate (compound 82c)
To a suspension of methyl 5—bromo—2-(dibromomethyl)~4~fluoro-benzoate (compound 82d,
.0 g, crude) in 2-propanol (150 mL) was added a solution of silver nitrate (9.2 g, 54.16 mmol)
in deionized water (20 mL) at room temperature in the absence of light under the protection of
N2 over about 30 mins. The resultant mixture was stirred at room temperature for another 3 hrs
in the absence of light. The reaction was quenched with 5 mL brine, the resultant mixture was
filtered through Celite, and the filtrate was trated in vacuo. The residue was re—dissolved
with DCM (500 mL), washed with aq.NaHCO3 (200 mL) and brine (300 mL) subsequently,
dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by flash
chromatography (silica gel, 120 g, 0% to 10% EtOAc in PE) to afford compound 82c (2.5 g,
31.9% yield for total three steps). MS: calc’d 261, 263[(M+H)+], measured 261,263[(M+H)+].
Step 5: preparation of (4R,10bS)benzyl—8-bromofluoro—4—methyl—1,3,4,10b-
ydropyrazino[1,2-b]isoindolone (compound 82g)
A mixture of the (2R)-N1-benzy1-N1~(trimethylsilylmethyl)propane—l,2-diamine
(compound 1g, 1.0 g, 2.0 g, 8.0 mmol), methyl 5-bromofluoro—2-formyl-benzoate (compound
82c, 2.5 g, 7.6 mmol), and 4A MS (4.5 g) in MeCN (50 mL) under N2 was stirred overnight at
WO 33941 2019/064323
room temperature. The reaction mixture was filtered through Celite and washed with DCM. The
filtrate was concentrated in vacuo to afford the ediate compound 82f, and the residue was
re-dissolved in MeCN/TFE (18 mL/2 mL), followed by the on of
[1r(dtbbpy)(ppy)2][PF6] (CAS: 676525—77-2, TCI, Catalog: D4887, 120 mg, 130 umol). The
reaction was stirred at room temperature under the exposure of blue LEDs (synLED-16 A
Discover, 12 W, wavelength 465-470 nm, purchased from SYNLED corp.) for 24 hrs. After the
solvents were removed in vacuo, the residue was purified by flash tography (silica gel, 40
g, 20% to 80% EA in PE) to afford compound 82g (0.9 g, 28.5 % . The stereochemistry
was confirmed by NOESY. MS: calc’d 389 and 391 [(M+H)+], measured 389,391[(M+H)+].'H
NMR (400 MHz, CHLOROFORM-a’) 5 ppm 7.97 (d, J: 6.0 Hz, 1H), 7.40 - 7.30 (m, 5H), 7.10 -
7.06 (m, 1H), 4.39 (dd, J: 3.2, 10.8 Hz, 1H), 3.86 - 3.75 (m, 1H), 3.66 - 3.55 (m, 2H), 3.34 ~—
3.30 (m, 1H), 2.89 - 2.85 (m, 1H), 1.98 (t, J: 11.0 Hz, 1H), 1.79 (d, J: 6.8 Hz, 3H), 1.76 — 1.73
(m, 1H).
Step 6: preparation of (4R,10bS)benzyl—8-bromofluoromethyl-3,4,6, 10b-
tetrahydro—lH—pyrazino[2,1-a]isoindole (compound 82h)
A mixture of (4R,10bS)—2-benzy1-8—bromo—9—fluoromethy1—1,3 ,4,10b-
tetrahydropyrazino[1,2-b]isoindol—6-one (compound 82g, 0.9 g, 2.31 mmol) and BH3 solution
(1M in THF, 40 mL, 40 mmol) was heated at 80 °C with stirring on for 15 hrs. HCl solution (6 Nu
mL) was added slowly to the reaction mixture at 0 °C. The resultant mixture was stirred at
room temperature overnight, then the mixture was basified with a NaOH on (2 N) to pH 10.
The mixture was extracted with EtOAc twice. The organic phases were combined and dried over
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash
chromatography a gel, 40 g, 30% to 100% EtOAc in PE) to afford compound 82h (0.5 g,
57.6 % yield). MS: calc’d 375,377 [(M+H)+], measured 375,377[(M+H)+].
Step 7: preparation of (4R,10bS)br0mo—9—fluoro—4-methyl—1,2,3,4,6,10b
-hexahydropyrazino[2,1-a]isoindole (compound 82i)
To a stirred solution of (4R,10bS)—2-benzy1br0mo—9-fluoromethy1—3,4,6,10b-
tetrahydro-lH—pyrazino[2,1-a]isoindole (compound 82g, 0.5 g, 1.3 mmol) in DCE (15 mL) at
room temperature was added 1—ch10roethy1 ochloridate (0.9 g, 6.6 mmol). The on
mixture was heated under reflux overnight and cooled to room temperature before concentrated
in vacuo. The residue was dissolved in MeOH (30 mL) and the resultant mixture was heated
under reflux for additional 2 hrs. The mixture was cooled to room temperature and concentrated
in vacuo. The residue was diluted with water (10 mL), and the solution was basified with aq.
NaHCOg. The ant mixture was extracted with EtOAc (50 mL) twice. The combined organic
WO 33941
layer was washed with brine, dried over Na2804, d and concentrated in vacuo to afford
compound 82i (290 mg, 77.6% yield) which used directly to the next step. MS: calc’d 285, 287
+], measured 285,287[(M+H)+].
Step 8: preparation of 5-[(4R,10bS)—8-brom0fluoro—4-methyl-3,4,6,10b -
tetrahydro-lH-pyrazino[2,1—a]isoindol—2—yl]quinoline—8-carbonitrile (compound 82j)
To a solution of 5-fluoroquinolinecarbonitrile (compound lo, 186 mg, 1.1 mmol) in
DMSO (5 mL) was added (4R,l0bS)—8-bromofluoro—4-methyl-1,2,3,4, 6,10b-
hexahydropyrazino[2,1-a]isoindole und 82i, 280 mg, 1.0 mmol) and (381 mg, 3.0 mmol).
The reaction mixture was stirred at 120 0C for 5 hrs. The mixture was cooled to room
temperature, quenched with water (50 mL), and extracted with BA (60 mL) twice. The ed
organic layer was washed with brine, dried over NaZSO4, filtered and concentrated in vacuo. The
residue was purified by flash chromatography to afford compound 82j (150 mg, 32 % yield). MS:
calc’d 437 and 439 [(M+H)+], measured 437 and 439 [(M+H)+].
Step 9: preparation of tert-butyl N-[(3R,4R)—l-[(4R,10b.”—2-(8-cyanoquinolyl)
fluoro—4-methyl-3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindol—8-yl]hydroxy—4-
methyl-pyrrolidinyl]carbamate (compound 82k)
To a solution of 5—[(4R,10bS)—8-bromofluoromethyl—3,4,6,lOb—tetrahydro —1H—
no[2,1-a]isoindolyl]quinolinecarbonit1ile (compound 82j, 60.0 mg, 140 umol) in
dioxane (5 mL) was added tert-butyl ,4R)hydroxy-4—methyl -pyrrolidin—3-
y1]carbamate (45.0 mg, 210 umol), Cesium carbonate (90.0 mg, 280 umol) and tBuXPhos Pd G3
(CAS: 1447963—75—8, Sigma—Aldrich, Catalog: 762229, 24 mg, 30 umol). The reaction mixture
was stirred at 90 OC overnight. The mixture was cooled to room temperature, diluted with water
(10 mL) and extracted with EA (15 mL) for three times. The combined organic layer was washed
with brine, dried over NaZSO4, filtered and trated in vacuo. The residue was purified by
flash chromatography (silica gel, 12 g, 30% to 100% EtOAc in PE) to afford compound 82k (50
mg, 62% yield). MS: calc’d 573 [(M+H)+], measured 573 [(M+H)+].
Step 10: preparation of 5-[(4R,10bS)[(3R,4R)—4-aminohydroxy—3-methyl-
pyrrolidinyl]-9—fluoromethyl—3,4,6,10b-tetrahydr0-lH-pyrazino[2,1-a]isoindol—2-
yl]quinolinecarbonitrile (Example 82)
To a solution of tert-butyl N—[(3R,4R)—l—[(4R,10bS)—2-(8-cyanoquinolyl)— 9-fluoro—4-
methyl-3 ,4,6,1 rahydro—lH—pyrazino[2,1-a]isoindol—S-yl]~4—hydroxymethy1-pyrrolidin—3-
yl]carbamate (compound 82k, 50.0 mg, 87 umol) in DCM (5 mL) was added TFA (2 mL). The
reaction mixture was stirred at room temperature for 2 hrs, then concentrated to afford a crude
t, which was purified by pre-HPLC to afford Example 82 (5.9 mg, 14% yield). MS:
—125—
calc’d 473 [(M+H)*], measured 473 [(M+H)*]. 1H NMR (400 MHz, DMSO—d,) (5 ppm 9.05 (d, J
= 3.2 Hz, 1 H), 8.60 (d, J: 8.8 Hz, 1 H), 8.23 (d, J= 8.4 Hz, 1 H), 7.70 (dd, J: 8.0, 4.0 Hz, 1 H),
7.28 (br 01, J = 8.0 Hz, 1 H) 7.00 (, J = 13.6 Hz, 1 H), 6.62 (d, J = 8.8 Hz, 1 H), 4.72 (s, 1 H),
4.05 — 4.12 (m, 2 H), 3.89 - 3.92 (m, 1 H), 3.87 (br d, J = 10.4 Hz, 1 H), 3.61 - 3.67 (m, 1 H),
3.50 - 3.53 (1n, 2 H), 3.16 — 3.20 (m, 2 H), 3.09 (br s, 1 H), 2.96 — 1, 1 H), 2.87 (t, J = 10.8
Hz, 1 H), 2.69 - 2.74 (m, 1 H), 1.20 (s, 3 H), 1.13 (br d, J = 6.0 Hz, 3 H).
Example 83
-[(4R,10bS)-8—{(3S,4S)—4—aminohydroxy—3~methyl-pyrrolidin-l—yl]fluoromethyl-
3,4,6, 1 Ob-tetrahydro-lH-pyrazino [2, l-a] isoindol—Z-yl] quinoline-S-carbonitrile
F ”1‘
HO N
The title compound was prepared in analogy to the preparation of Example 82 by using
tert-butyl N—[(3S,4S)—4—hydroxymethyl -pyrrolidiny1]carbamate instead of utyl N—
[(3R,4R)hydroxy—4-methy1-pyrrolidiny1]carbamate. Example 83 (8.1 mg) was ed.
MS: calc’d 473 [(M+H)+], measured 473 [(M+H)+]. 1H NMR (400 MHZ, DMSO'dé) 5 ppm 9.06
(dd, J: 1.6, 4.0 Hz, 1H), 8.61 (dd, J== 1.6, 8.4 Hz, 1H), 8.24 (d, J: 8.0 Hz, 1H), 7.70 (dd, J:
4.0, 8.4 Hz, 1H), 7.28 (d, J: 8.4 Hz, 1H), 7.01 (d, J = 13.6 Hz, 1H), 6.62 (d, J: 8.4 Hz, 1H),
4.70 (s, 1H), 4.11 (d, J: 12.0 Hz, 1H), 3.87 (br d, J: 9.2 Hz, 2H), 3.64 — 3.68 (m, 1H), 3.52 (br
d, J: 11.6 Hz,1H), 3.36 - 3.43 (m, 2H), 3.16 (br dd, J= 2.8, 9.6 Hz, 2H), 3.06 - 3.11 (m, 1H),
2.97 - 3.00 (m, 1H), 2.86 (t, J: 11.2 Hz, 1H), 2.69 — 2.75 (m, 1H), 1.48 - 1.79 (m, 2H), 1.21 (s,
3H), 1.14 (d, J: 6.4 Hz, 3H).
-126—
Example 84
—[(412,10bS)(2,6-diazaspiro[3.3]heptan-Z-yl)fluoromethyl-3,4,6,10b-tetrahydro-1H—
pyrazino[2,1-a]isoindolyl}quinolinecarbonitrile
The title compound was prepared in y to the preparation of e 82 by using
tert-butyl 2,6-diazaspiro[3.3]heptanecarboxylate instead of utyl N—[(3R,4R)hydroxy-
yl~pyrrolidiny1]carbamate. Example 84 (10.4 mg) was obtained. MS: calc’d 455
[(M+H)+], measured 455 [(M+H)+]. 1H NMR (400 MHz, DMSO-d6) (5 ppm 9.12 (br d, J = 2.8
Hz, 1H), 8.68 (br s, 2H), 8.28 (br d, J: 8.0 Hz, 1H), 7.73 (dd, J: 4.0, 8.4 Hz, 1H), 7.25 —7.33
(m, 2H), 6.67 (br s, 1H), 4.75 - 5.25 (m, 1H), 4.31 - 4.60 (m, 1H), 4.17 (br 1, J: 5.6 Hz, 4H),
4.09 (br s, 4H), 3.68 - 3.92 (m, 1H), 3.45 — 3.59 (m, 2H), 3.19 - 3.27 (m, 2H), 2.86 ~2.96 (m, 1H),
1.33 (br s, 3H).
Example 85
5-[(4R,10bS)—9-fluoro—4—methyl-8—(9-oxa—3,7-diazabicyclo[3.3.1]nonan—3-yl)—3,4,6,10b—
tetrahydro-lH—pyrazino[2,1-a]isoindol-Z—yl]quinoline-S-carbonitrile
The title compound was prepared in analogy to the preparation of Example 82 by using
tert—butyl 9-oxa—3,7-diazabicyclo[3.3.1]nonanecarboxylate instead of tert—butyl N-[(3R,4R)-4—
hydroxy—4-methyl-pyrrolidinyl]carbamate. Example 85 (10.4 mg) was obtained. MS: calc’d
485 [(M+H)+], measured 485 [(M+H)+]. lH NMR (400 MHZ, DMSO'dé) (5 ppm 9.30 (br d, J =
.8 Hz, 1H), 9.10 (dd, J: 1.3, 4.2 Hz, 1H), 8.73 (br d, J: 8.8 Hz, 1H), 8.30 (br d, J: 8.0 Hz,
2H), 7.75 (dd, J: 4.2, 8.6 Hz, 1H), 7.44 (br (1, J = 11.6 Hz, 1H), 7.34 (br (1, J: 7.2 Hz, 1H), 7.26
~127-
(br d, J: 7.6 Hz, 1H), 5.22 - 5.38 (m, 1H), 4.79 -. 4.91 (m, 1H), 4.43 - 4.59 (m, 1H), 4.10 - 4.28
(m, 4H), 3.64 - 3.10 (m, 1H), 1.37
- 4.00 (m, 2H), 3.37 - 3.43 (m, 6H), 3.19
— 3.27 (m, 2H), 2.93
(br (1, J= 6.0 Hz, 3H).
e 86
5-[(4R,10bS)-4—methyl(piperazine—l-carbonyl)—3,4,6,l(lb-tetrahydro-lH-pyrazino[2,1—
a] isoindol-Z-yl]quinoline-S-carbonitrile
The title compound was prepared according to the following scheme:
N N >1/
II // 0 0
N\ oven N
/ \
CI 01 0
N _
___.___.__.
_.________.
Pd(OAc)2,Xan1Phos, 0
CI N TEA,DMAP,THF
N TEA, PhCFS
10b 86a
N II
IN\ N\
:j\ N
TFA/DCM
______.___.
> (>le \N HN
o \——/ o
86b Example86
Step 1: preparation of (2,4,6-trichlorophenyl) bS)(8-cyano-S-quinolyl)
methyl-3,4,6,1{lb-tetrahydro-lH-pyrazino[2,1-a]isoindole-S-carboxylate (compound 86a)
The mixture of 5-[(4R,10bS)—8—bromo-4~methy1-3,4,6,10b-tetrahydro-1H- pyrazino[2,1—
a]isoindolyl]quinoline—8-carbonitrile (compound 10b, 500 mg, 1.2 mmol), -
trichlorophenyl) formate (1.6 g, 7.1 mmol), XantPhos (140 mg, 240 umol), Pd(OAc)2 (30.0 mg,
—128-
0.130 mmol) and triethylamine (300 mg, 3.0 mmol) in PhCF3 (6.0 mL) was degassed and purged
with N2 for 3 times. The resultant mixture was stirred at 60 °C for 16 hrs under N2 atmosphere.
The reaction mixture was diluted with DCM/MeOH (80 mL/10 mL), filtered, and the filtrate was
trated in vacuo. The residue was purified by Prep-TLC (PE: EA=1 :1) to afford compound
86a (480 mg, 70.0% yield). MS calc’d 563 [(M+H) +1; ed 563 [(M+H) +].
Step 2: preparation of tert-butyl 4-[(4R,10bS)(8-cyanoquinolyl)methyl-
3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindole-8—carbonyl]piperazine-l-carboxylatea
(compound 86b)
To a solution of (2,4,6-trichlorophenyl) (4R,l0bS)(8-cyanoquinolyl)—4-methyl-
3,4,6,lOb-tetrahydro-1H-pyrazino[2,1-a]isoindolecarboxylate (compound 86a, 120.0 mg, 210
umol) in THF (3 mL) was added DMAP (5.0 mg, 40umol), triethylamine (44.0 mg, 430 umol)
and tert-butyl piperazine—l-carboxylate (60.0 mg, 320 umol). The resultant e was stirred
at 50 °C for 16 hrs, then the mixture was concentrated in vacuo. The residue was purified by
Prep-TLC to afford compound 86b (80 mg, 64.0% yield). MS calc’d 553 [(M+H) Jr]; measured
553 [(M+H) t]
Step 3: preparation of 5-[(4R,l0bS)methyl(piperazinecarbonyl)—3,4,6,10b-
tetrahydro-1H-pyrazino[2,1-a]isoindol-Z—yl]quinolinecarbonitrile (Example 86)
To a solution of tert—butyl 4-[(4R,10bS)(8-cyanoquinolyl)methy1-3,4,6,10b-
tetrahydro-1H—pyrazino[2,1—a]isoindolecarbony1]piperazinecarboxylate und 86b,
80.0 mg, 140 pmol) in DCM (5 mL) was added TFA (2 mL). The on mixture was stirred at
room temperature for 2 hrs, then concentrated to afford a crude product, which was purified by
pre-HPLC to afford Example 86 (34.5 mg, 51.0 % yield). MS: calc’d 453 [(M+H)+], ed
453 [(M+H)+]. 1H NMR (400 MHz, DMSO-dé) 6 ppm 9.06 (dd, J = 4.0, 1.6 Hz, 1H), 8.64 (dd, J
= 8.8, 1.6 Hz, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.71 (dd, J = 8.8, 4.0 Hz, 1H), 7.30 — 7.36 (m, 3H),
7.21 (d, J = 8.0 Hz, 1H), 4.25 (d, J = 12.4 Hz, 1H), 3.94 - 4.01 (m, 2H), 3.63 (dd, J = 12.4, 1.6
Hz, 1H), 3.50 — 3.57 (m, 1H), 3.39 - 3.49 (m, 2H), 3.23 - 3.26 (m, 1H), 3.14 - 3.23 (m, 2H), 2.97
(t, J = 11.2 Hz, 1H), 2.70 — 2.76 (m, 2H), 2.65 — 2.70 (m, 2H), 2.52 (d, J = 2.0 Hz, 2H), 1.16 (d, J
= 6.4 Hz, 3H).
Example 87
,10bS)[(1S,4S)-2,5-diazabicyclo[2.2.1]heptane-z-carbonyl]methyl-3,4,6,10b-
tetrahydro-lH—pyrazino[2,1-a]isoindol-Z-yl]quinoline—S-carbonitrile
H N
H O
The title compound was prepared in analogy to the preparation of Example 86 by using
utyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptanecarboxylate instead of tert-butyl piperazine—
l—carboxylate. Example 87 (46.1 mg) was ed. MS: calc’d 465 [(M+H)+], measured 465
[(M+H)+]. 1H NMR (400 MHz, DMSO-a’é) 6 ppm 9.07 (dd, J = 4.0, 1.6 Hz, 1H), 8.64 (dd, J =
8.4, 1.2 Hz, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.71 (dd, J = 8.4, 4.0 Hz, 1H), 7.46 - 7.54 (m, 1H),
7.34 = 8.0 Hz, 1H), 4.33 - 4.76 (m, 1H), 4.24 - 4.32 (m, 1H), 4.12 -
- 7.43 (m, 2H), 7.32 (d, J
4.22 (m, 1H), 3.99 (d, J = 8.8 Hz, 2H), 3.60 - 3.67 (m, 2H), 3.54 - 3.59 (m, 1H), 3.42 - 3.43 (m,
1H), 3.23 = 11.2 Hz, 1H), 2.73 (t,J= 11.2 Hz,1H),
- 3.26 (m, 1H), 3.10 — 3.16 (m, 1H), 2.97 (t,J
2.51 = 6.4 Hz, 3H).
- 2.53 (m, 2H), 1.92 — 2.06 (m, 1H), 1.67 — 1.84 (m, 1H), 1.17 (d, J
Example 88
-[(4R,10bS)(4-aminomethy1-piperidinecarbonyl)methyl-3,4,6,10b-tetrahydro-
lH-pyrazino[2,1-a]isoindol—2—yl]quinoline-S-carbonitrile
fl 4
The title compound was prepared in analogy to the preparation of e 86 by using
tert—butyl N—(4—methyl—4-piperidyl)carbamate instead of tert—butyl piperazine-l-carboxy1ate.
Example 88 (56.1 mg) was obtained. MS: calc’d 481 [(M+H)+], measured 481 [(M+H)+]. lH
- 1 3 0—
NMR (400 MHz, DMSO—a’b) (5 ppm 9.06 (d, J = 3.2 Hz, 1H), 8.64 (d, J = 8.0 Hz, 1H), 8.26 (d, J
= 8.0 Hz, 1H), 7.71 (dd, J = 8.8, 4.0 Hz, 1H), 7.30 - 7.36 (m, 3 H), 7.20 (d, J = 8.0 Hz, 1H),
4.25 (d, J = 12.4 Hz, 1H), 3.95 — 4.03 (m, 2H), 3.67 — 3.76 (m, 1H), 3.60 - 3.66 (m, 1H), 3.53 —
3.59 (m, 1H), 3.44 (d, J = 11.6 Hz, 2H), 3.15 — 3.24 (m, 2H), 2.97 (1, J = 11.2 Hz, 1H), 2.73 (t, J
= 10.8 Hz, 1H), 2.54 — 2.61 (m, 2H), 1.37 - 1.54 (m, 4H), 1.16 (d, J = 6.4 Hz, 3H), 1.14 (s, 3H).
e 89
-[(4R,10bS)(3,8—diazabicyclo[3.2.1]octanecarbonyl)—4-methyl—3,4,6,10b-tetrahydro-
1H-pyrazino[2,1-a]is0indol—2-yl]quinoline—S-carbonitrile
<2) 8
The title compound was prepared in analogy to the preparation of Example 86 by using
d of tert—butyl piperazine-l-carboxylate. Example 89 (34.3 mg) was obtained. MS: calc’d
479 [(M+H)+], measured 479 [(M+H)+]. 1H NMR (400 MHz, DMSO—dé) 6‘ ppm 9.07 (dd, J = 4.0m
1.6 Hz, 1H), 8.64 (dd, J = 8.4, 1.2 Hz, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.71 (dd, J = 8.4, 4.0 Hz,
1H), 7.45 (s, 1H), 7.30 = 12.4 Hz, 1H), 3.95
- 7.37 (n1, 3H), 4.44 — 4.59 (m, 1H), 4.27 (d, J — 4.03
(m, 2H), 3.85 = 11.2 Hz, 1H), 3.15
- 3.94 (m, 1H), 3.59 - 3.67 (m, 1H), 3.45 (d, J — 3.28 (1n, 2H),
2.95 - 3.01 (m, 1H), 2.84 ~ 2.93 (m, 1H), 2.69 - 2.79 (m, 2H), 2.51 - 2.53 (m, 2H), 1.86 (s, 4H),
1.16 (d, J = 6.4 Hz, 3H).
2019/064323
-13 1—
Example 90
-[(4R,10bS)—4-methyl(5-oxa—2,8-diazaspiro[3.5]n0nanyl)—3,4,6,10b-tetrahydro-IH-
pyrazino[2,1-a]isoindolyl]deuterio—quinoline-S-carbonitrile
HN/_©o
\__/
The title compound was prepared according to the following scheme:
-1 3 2-
O O—
/ —<_< H
NH2 N O
0— H2804 con
--—----—>
NaHMDS /
90a 90c
N N
Pd(PPh3)4 H H H
H {228 pd/C
Zn(<:N)2 "”e
N o N o ,9 02 N D
——-—-—p —> \ :8 F —D \
DOM 0 EF
DMF,100°C / / /
90e 90f
H H
Nj\ N D N
/ %O o
L/N‘(
os Pd G3, t—BuONa
DIEA, DMSO dioxane
N D
\ H
/ TFA/DCM N D
w———.
#0 {in Example 90
)V 90h
-l33-
Step 1: Preparation of N—(Z—bromo—S-fluoro-phenyl)-3,3-dimethoxy-propanamide
(compound 90b)
To a solution of 2-bromofluoroaniline (50 g, 263 mmol) and methyl 3,3-
dimethoxypropionate, (45 mL, 316 mmol) in THF (150 mL) was added NaHMDS in THF (394
mL, 394 mmol) dropwise at 0°C. The mixture was stirred at the temperature for 10 minutes, and
then it was warmed up to 15 °C and stirred for 18 hrs. The reaction was quenched with sat.
aqueous solution of NH4Cl and concentrated to about 300 mL. The solution was diluted with
water and extracted with EtOAc. The organic layer was dried over NaQSO4 and concentrated to
afford nd 90b (100 g, 90% yield). MS: calc’d 306 [(M+H)+], measured 306 [(M+H)+].
Step 2: Preparation of 8-bromofluoro-IH-quinolin-Z-one (compound 90c)
A solution of N—(2—bromo~5—fluoro-phenyl)—3,3—dimethoxy-propanamide (compound 90b,
100 g, 238 mmol) in DCM (500 mL) was added to concentrated sulfuric acid (300 mL) at 0°C.
The mixture was stirred at 15 °C for 2 hrs. The mixture was poured slowly into 2000 mL ice-
water, and a yellow precipitate appeared. The mixture was filtered, and the wet—cake was washed
with 500 mL water, 200 mL isopropyl l and 300 mL PB. The solid was dried by sucking
in vacuum to afford compound 90c (50 g, 86.5% yield). MS: calc’d 242 [(M+H)+], measured 242
[(M+H)+].
Step 3: Preparation of o—Z-oxo-lH-quinoline—8—carb0nitrile (compound 90d)
A solution of 8-bromofluoro-lH-quinolin-Z-one und 90c, 50 g, 206 mmol), zinc
cyanide (4820 mg, 412 mmol), Pd(PPh3)4 (2428 mg, 21 mmol) in DMF was stirred at 120 °C for
hrs. The reaction mixture was diluted with water and extracted with DCM. The organic layer
was dried and concentrated to give the crude product, which was d by flash column to
afford compound 90d (29 g, 74.5% . MS: calc’d 189 [(M+H)+], measured 189 [(M+H)+].
Step 4: Preparation of (8-cyano-S-fluoro—Z-quinolyl) trifluoromethanesulfonate
(compound 90e)
To a solution of 5—fluorooxo-1H-quinolinecarbonitrile (compound 90d, 17 g, 90 mmol)
and 2,6—dimethylpyridine (39 g, 361 mmol) in DCM was added trifluoromethanesulfonic
ide (5] g, 181 mmol) se at 0 °C. The mixture was stirred at 0 °C for 1 hr, and then
the reaction was diluted with water, extracted with DCM. The c layer was dried and
concentrated. The residue was purified by flash column to give compound 90c (23.0 g, 80%
yield). MS: calc’d 321 [(M+H)+], measured 321 [(M+H)+].
Step 5: Preparation of eriofluoro-quinoline-8—carbonitrile (compound 901)
To a solution of nofluoro-2—quinolyl) trifluoromethanesulfonate (compound 90e,
23 g, 72 mmol) in THF (230 mL) and deuterium oxide (100 mL) was added potassium carbonate
-l34-
(20 g, 144 mmol) and Pd/C (6 g). The mixture was stirred at 40 °C for 5 hrs under deuterium
atmosphere (balloon). The mixture was filtered, and the filtrate was concentrated and purified by
flash column to afford compound 90f (11 g, 87.8% yield) which was used directly for the next
step without further ation. MS: calc’d 174 [(M+H)+], measured 174 [(M+H)+].
Step 6: preparation of 5—[(4R,10bS)-8—bromo—4-methyl—3,4,6,10b—tetrahydro
-1H-pyrazino[2,l-a]isoindol-Z-yl]deuterio-quinoline-8—carbonitrile und 90g)
To a solution of (4R,10bS)bromo-4—methyl-1,2,3,4,6,lOb—hexahydropyrazino
a]isoindole (compound 1021, 660 mg, 2.8 mmol) in DMSO (20 mL) was added 2-deuterio-
~fluoro-quinolinecarbonitrile (compound 90f, 350 mg, 2.0 mmol) and DIEA (1.3 g, 10.1
mmol). The resultant e was stirred at 120 °C overnight. After being cooled to room
temperature, the reaction was quenched with water (50 mL) and extracted with BA (80 mL)
twice. The combined organic layer was washed with brine, dried over Na2SO4, filtered and
concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 0% to
100% EtOAc in PE) to afford compound 90g (810 mg, 95.3 % yield). MS: calc’d 420,
422[(M+H)+], measured 420, 422[(M+H)+].
Step 2: preparation of tert-butyl 2-[(4R,10bS)—2-(8-cyan0deuterio-S-quinolyl)
methyl-3,4,6,10b-tetrahydro-1H—pyrazino[2,1-a]isoindol—8-yl]oxa-2,8—
diazaspiro[3.5]nonane—S—carboxylate (compound 90h)
To a solution of 5-[(4R,10bS)bromo—4—methyl-3,4,6,10b~tetrahydro~lH~ no-[2,l~
a]isoindolyl]deuterio-quinolinecarbonitrile (compound 90g, 100 mg, 238 umol) in
dioxane (15 mL) was added t—BuONa (45.7 mg, 476 umol), utyl 5-oxa—2,8-
diazaspiro[3.5]nonanecarboxylate (65.2 mg, 285 umol) and tBuXPhos Pd G3 (9.4 mg, 11.9
umol). The reaction e was stirred at 900C overnight. The mixture was cooled to room
temperature, diluted with water (50 ml) and extracted with BA (50 mL) for three times. The
combined organic layer was washed with brine, dried over Na2804 and concentrated in vacuo.
The residue was purified by flash chromatography (silica gel, 20 g, 0% to 100% EtOAc in PE) to
afford compound 90h (80 mg, 59.2 % . MS: calc’d 568[(M+H)+], measured 568[(M+H)+].
Step 3: preparation of 5-[(4R,10bS)methyl—8-(5-oxa-2,8-diazaspiro[3.5]-
nonan-Z—yl)—3,4,6,10b-tetrahydro-lH-pyrazino[2,1-a]isoindol-Z-yl]deuterio—quinoline
carbonitrile (Example 90)
To a solution of tert—butyl 2-[(4R,l0bS)—2-(8—cyano~2-deuterio—5-quinolyl)-4~methyl-
3,4,6,l0b-tetrahydro—1H—pyrazino[2,l -a]isoindolyl]oxa~2,8—diazaspiro[3.5]nonane—8—
ylate (compound 90h, 80 mg, 141 umol) in DCM (8 mL) was added TFA (4 mL).The
mixture was stirred at room temperature for 2 hrs. The reaction mixture was stirred at room
temperature for 2 hrs, then concentrated to afford a crude product, which was purified by pre-
HPLC to afford Example 90 (42 mg, ). MS: calc’d 468 [(M+H)+], measured 468 [(M+H)+]. 'H
NMR (400 MHz, METHANOL-d4) (5 ppm 8.76 (d, J = 8.6 Hz, 1H), 8.18 (d, J = 7.9 Hz, 1H),
7.72 (d, J: 8.6 Hz, 1H), 7.37 (d, J: 7.9 Hz, 1H), 7.25 (d, J= 8.2 Hz, 1H), 6.66 (d, J: 1.8 Hz,
1H), 6.51 (dd, J: 2.1, 8.2 Hz, 1H), 4.77 — 4.84 (m, 1H), 4.66 (d, J: 13.2 Hz, 1H), 4.25 (d, J:
13.2 Hz, 1H), 4.06 (d, J= 8.6 Hz, 2H), 3.86 - 3.98 (m, 4H), 3.79 (d, J: 8.4 Hz, 2H), 3.58 (br d, J
= 12.2 Hz, 1H), 3.54 (s, 2H), 3.23 - 3.29 (m, 2H), 3.01 — 3.17 (m, 2H), 1.44 (d, J: 6.6 Hz, 3H).
Example 91
5-[(4R,10bS)[[(3S,4R)—4-flu0r0pyrrolidin—3-yl]amino]methyl-3,4,6,10b—tetrahydro-1H—
pyrazino[2,1-a]isoindol—2-yl]~2-deuterio—quinoline—8-carbonitrile
N D
Q5:1
The title nd was prepared in analogy to the preparation of e 90 by using
tert—butyl (3S,4R)aminofluoropyrrolidinecarboxylate instead of tert—butyl 5-oxa-2,8-
diazaspiro[3.5]nonanecarboxylate. e 91 (21.2 mg) was obtained. MS: calc’d 444
[(M+H)+], measured 444 [(M+H)+]. ‘H NMR (400 MHz, METHANOL-d4) 6 ppm 8.66 (d, J =
8.7 Hz, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.61 (d, J== 8.6 Hz, 1H), 7.27 (d, J: 8.1 Hz, 1H), 7.14 (d,
J = 8.3 Hz, 1H), 6.84 (d, J: 1.8 Hz, 1H), 6.70 (dd, J: 2.2, 8.3 Hz, 1H), 5.14 - 5.36 (m, 1H),
4.88 - 4.48 (m, 2H), 3.95 - 4.10 (m, 1H), 3.74 —
- 4.97 (m, 1H), 4.67 (d, J: 13.4 Hz, 1H), 4.28
3.84 (m, 1H), 3.45 - 3.72 (m, 4H), 3.07 - 3.18 (m, 2H), 2.95 - 3.05 (m, 1H), 1.39 (d, J: 6.7 Hz,
3H).
-l 36—
Example 92
—[(4R,10bS)(3-amino—3—methyl-azetidinyl)methyl-3,4,6,l rahydro-1H-
pyrazino[2,1-a]isoindol—Z-yl]deuterio—quinolinecarbonitrile
N D
The title compound was prepared in analogy to the preparation of e 90 by using
tert-butyl N—(3-methylazetidin-3—yl)carbamate instead of tert—butyl 2,8-
diazaspiro[3.5]nonaneearboxylate. Example 92 (21.2 mg) was obtained. MS: ealc’d 426
[(M+H)+], measured 426 [(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) 5 ppm 8.77 (d, J =
8.6 Hz, 1H), 8.19 (d, J: 8.1 Hz, 1H), 7.72 (d, J= 8.6 Hz,1H), 7.38 (d, J: 8.1 Hz, 1H), 7.27 (d,
J: 8.2 Hz, 1H), 6.67 (d, J: 1.8 Hz, 1H), 6.53 (dd, J = 2.1, 8.2 Hz, 1H), 4.78 - 4.87 (m, 1H),
4.68 (d, J: 13.3 Hz, 1H), 4.27 (d, J: 13.3 Hz, 1H), 3.85 - 4.06 (m, 6H), 3.56 - 3.65 (m, 1H),
3.03 - 3.19 (m, 2H), 1.70 (s, 3H), 1.45 (d, J: 6.6 Hz, 3H).
Example 93
1 5 5-[(4R,10bS)methyl(9-oxa-3,7-diazabicyclo[3.3.1]nonanyl)—3,4,6,10b-tetrahydro-
1H-pyrazino[2,1-a]isoindol-Z-yl]-2—deuterio-quinoline—8-carb0nitrile
The title compound was prepared in analogy to the preparation of Example 90 by using
-137—
tert-butyl 9-oxa-3,7-diazabicyclo[3.3.1]nonanecarboxylate instead of tert-butyl 5~oxa—2,8~
diazaspiro[3.5]nonane—8-carboxylate. Example 93 (21.2 mg) was obtained. MS: calc’d 468
[(M+H)+], measured 468 +]. 1H NMR (400 MHz, METHANOL—d4) 8 ppm 8.77 (d, J =
8.7 Hz, 1H), 8.19 (d, J: 7.9 Hz, 1H), 7.72 (d, J: 8.6 Hz, 1H), 7.37 (d, J= 7.9 Hz, 1H), 7.31 (d,
J = 8.3 Hz, 1H), 7.27 (d, J = 1.7 Hz, 1H), 7.11 (dd, J = 2.2, 8.3 Hz, 1H), 4.54 - 4.65 (m, 2H),
4.23 - 3.98 (m, 1H), 3.71 - 3.86
- 4.31 (m, 1H), 4.28 (br s, 1H), 4.12 (br (1, J= 12.7 Hz, 1H), 3.88
(m, 3H), 3.51 - 3.66 (m, 5H), 3.20 - 3.28 (111,211), 3.01 ~ 3.14 (m, 2H), 1.41 (d, J: 6.5 Hz, 3H).
Example 94
1 O 4-[(4R,10bS)-8—[(3R,4R)—3-aminometh0xy—pyrrolidinyl]-4—methyl—3,4,6,l 0b-
tetrahydro-lH-pyrazino[2,1-a]isoindolyl]pyrazolo[1,5-a]pyridinecarbonitrile
/ N,N
The title compound was prepared ing to the following scheme:
-138—
F / \ Br
O“ N
perchloric acid 0‘ — / N+ ‘8
V0 N‘ ,8. ,‘s —’ I
O d——-—- H2N\ “s
.0 onane Q «0 DCM \ '0'“
94a 94b 94°
R Br ”0 §
/ N,N\ N
Conc. H RWCNZZ” Pd()OAC / N’N\
—""—"
\ \ Xantphos DMA \ \
\ \ water
Br’< b NH
N 0° N4
10a \ H O
—-———-——-——————.
DIEA, DMSO WW os Pd G3. 082003
dioxane
N\ ""
N l
TFA/DCM \
O N
/ N N ——————-------D
HN 0., N
k H2N
94h Example 94
Step 1: preparation of amino 2,4,6-trimethylbenzenesulfonate (compound 94b)
A solution of ethyl (1E)~N—(2,4,6—trimethylphenyl)sulfonyloxyethanimidate (compound 94a,
200 g, 700 mmol) in 1,4-dioxane (500 mL) was added perchloric acid (110 mL) dropwise in 30
min and stirred for 1 hr at 0 °C. 1000 mL ice-water was added and the mixture was filtered. The
filter cake was dissolved in 1.5 L EtOAc, then stirred for 30 minutes. The organic layer was
concentrated (keep the temperature below 25 0C) to afford crude product. The crude product
was recrystallized (petroleum/EtOAc=10/ 1) to afford compound 94b (110 g, 73% yield). MS:
calc’d 216 +], measured 216 [(M+H)+].
- l 3 9-
Step 2: preparation of 2-bromo—5-fluoro-pyridinium—1-amine 2,4,6—
trimethylbenzenesulfonate (compound 94c)
A solution of amino 2,4,6—trimethy1benzenesulfonate (compound 94b, 110 g, 511 mmol)
and 2—bromofluoropyridine (60 g, 341 mmol) in DCM (1800 mL) was stirred at 10°C for 18
hrs. The mixture was concentrated, the residue was recrystallized in EtOAc to afford compound
94c (90 g, 92% yield). MS: calc’d 191 [(M+H)+], measured 191 [(M+H)+].
Step 3: preparation of ethyl 7-bromofluoro-pyrazolo[1,S—a]pyridine—3—carboxylate
(compound 94d)
A solution of 2-bromofluoro—pyridinium—1—amine; 2,4,6-trimethylbenzenesulfonate
(compound 94c, 90 g, 230 mmol), K2CO3 (64 g, 460 mmol) and ethyl late (28 mL, 276
mmol) in DMF (1300 mL) was stirred at 10 °C for 18 hrs. The reaction was diluted with water,
extracted with EtOAc. The organic layer was dried over Na2804, filtered and the filtrate was
concentrated in vacuo. The e was purified by chromatography column to afford compound
94d (11 g, 16.7% yield). MS: calc’d 287 [(M+H)+], measured 287 [(M+H)+].
Step 4: preparation of 7—bromo—4-i'luoro-pyrazolo[1,5—a]pyridine (compound 94c)
To a e of ethyl 7—bromo-4—fluoro-pyrazolo[l,5—a]pyridinecarboxylate und
94d, 8.0 g, 26.7 mmol) in acetic acid (48 mL) and water (48 mL) was added conc. HCl (36 mL,
432 mmol). The mixture was stirred at 100 °C for 18 hrs. The mixture was diluted with water
(200 mL), basified with aq. NaOH (IN) to pH = 8, extracted with EA (200 mL) for three times.
The combined organic layers were washed with brine, dried over Na2804 and concentrated in
vacuo to afford compound 94c (5 g, 86.9% yield) which was used directly for the next step.
MS: calc’d 215 [(M+H)+], measured 215 [(M+H)+].
Step 5: preparation of 4-fluoropyrazolo[1,5-a]pyridine-7—carbonitrile (compound 941)
A mixture of 7-bromo-4—fluoro-pyrazolo[1,5-a]pyridine (compound 94e, 1000 mg, 4.6
mmol), zinc cyanide (880 mg, 7.5 mmol), zinc (31 mg, 0.5 mmol), XantPhos (1076 mg, 1.8
mmol) and Pd(OAc)2 (209 mg, 0.9 mmol) in DMA (10 mL) was degassed and purged with Ar
for 3 times, and then the mixture was stirred at 120°C for 1 h under Ar here. The mixture
was d with EA (150 mL), filtered and the filtrate was washed with water (50 mL), brine (50
mL x 3), dried over NaZSO4 and trated in vacuo. The residue was purified by LC
(PE: EA=3:1) to afford nd 94f (600 mg, 68 % yield). MS: calc’d 162 [(M+H)+],
measured 162 [(M+H)+].
-140—
Step 6: preparation of 4—((4,R,10bS)bromo—4-methyl-3,4,6,10b- tetrahydropyrazino—
]isoindol—2(1H)-yl)pyrazolo[1,5-a]pyridine—7-carbonitrile (compound 94g)
To a solution of 4-fluoropyrazolo[1 ,5—a]pyridinecarbonitrile und 94f, 750 mg, 4.6
mmol) in DMSO (30 mL) was added (4R,lObS)-8—bromomethy1-1,2,3,4,6,10b-
hexahydropyrazino[2,l-a]isoindole (compound 103, 1.2 g, 4.6 mmol) and DIEA (3.0 g, 23.3
mmol). The reaction mixture was stirred at 100 0C for 20 hrs. After cooled to room temperature,
the reaction was quenched with water (50 mL) and extracted with EA (100 mL) twice. The
combined organic layer was washed with brine, dried over NaZSO4, filtered and concentrated in
vacuo. The e was d by flash chromatography (silica gel, 80 g, 0% to 100% EtOAc in
PE) to afford compound 94g (870 mg, 45.8 % yield). MS: calc’d 408, 410 [(M+H)+], measured
408, 410[(M+H)+].
Step 7: preparation of tert—butyl ((3R,4R)((4R,10bS)-2—(7—cyanopyrazolo- [1,5-
a] pyridinyl)—4-methyl—1,2,3,4,6,10b-hexahydr0pyrazino[2,1-a]isoindolyl)—4-
methoxypyrrolidinyl)carbamate (compound 94h)
To a solution of 4-((4R,10bS)~8—bromomethyl-3,4,6,10b—tetr-ahydropyrazino [2,1-
a]isoindol—2(lH)—yl)pyrazolo[1,5-a]pyridine-7—carbonitrile (compound 94g, 40 mg, 98 umol) in
dioxane (6 mL) was added tert-butyl ((3R,4R)methoxypyrrolidin—3~yl)—carbamate (25.4 mg,
118 umol), C52C03 (95.8 mg, 294 umol) and tBuXPhos Pd G3 (7.8 mg, 9.8 umol). The on
mixture was stirred at 90 0C overnight. The mixture was cooled to room temperature, diluted
with water (30 mL) and extracted with BA (30 mL) for three times. The combined organic layer
was washed with brine, dried over Na2804, filtered and concentrated in vacuo. The residue was
purified by flash chromatography (silica gel, 12 g, 30% to 100% EtOAc in PE) to afford
compound 94h (22 mg, 41.3 % yield). MS: calc’d 544[(M+H)+], ed 544[(M+H)+].
Step 3: preparation of 4-[(4R,10bS)—8-[(3R,4R)—3-aminomethoxy—pyrrolidinyl]
methyl-3,4,6,10b-tetrahydro-lH—pyrazino[2,1-a]isoindol-Z-yl]-pyrazolo[l,5-a]pyridine-7—
carbonitrile(Example 94)
To a solution of tert—butyl ((3R,4R)-l-((4R,l0bS)~2-(7—cyanopyrazolo[1,5—a]— pyridiny1)-
4-methy1-1,2,3,4,6,10b—hexahydropyrazino[2,1-a]isoindol-S-y1)~4—meth-oxypyrrolidin-3 —
bamate (compound 94h, 22 mg, 40.5 umol) in DCM (10 mL) was added TFA (3 mL). The
e was stirred at room temperature for 2 hrs. The reaction mixture was stirred at room
temperature for 2 hrs, then concentrated to afford a crude product, which was purified by pre—
HPLC to afford Example 94 (12 mg, 66% yield). MS: calc’d 444[(M+H)+], measured
444[(M+H)+]. ]H NMR (400 MHz, METHANOL—d4) 8 ppm 8.08 (d, J = 2.4 Hz, 1H), 7.49 (d, J
= 7.9 Hz, 1H), 7.23 (d, J: 8.2 Hz, 1H), 6.95 (d, J= 2.4 Hz, 1H), 6.74 (d, J: 1.7 Hz, 1H), 6.69
—141—
(d, J: 8.1 Hz, 1H), 6.60 (dd, J: 2.1, 8.3 Hz, 1H), 4.33 — 4.41 (m, 1H), 4.24 — 4.31 (m, 1H), 4.07
- 4.16 (1n, 2H), 3.78 — 3.94 (m, 4H), 3.63
- 3.71 (m, 1H), 3.41 - 3.52 (1n, 1H), 3.48 (s, 3H), 3.24 -
3.33 (m, 2H), 2.98 - 3.06 (m, 1H), 2.86 - 2.96 (m, 1H), 1.34 (d, J: 6.5 Hz, 3H).
Example 95
4-[(4R,10bS)[(3S,4S)aminomethoxy-pyrrolidin-l—yl]methyl-3,4,6,10b-
tetrahydro-lH—pyrazino[2,1-a]isoindol—Z-yl}pyrazolo[1,5-a]pyridinecarbonitrile
/ N,N
The title compound was ed in analogy to the preparation of e 94 by using
tert—butyl ((3S,4S)methoxypyrrolidin—3-y1)-carbamate instead of tert—butyl ((3R,4R)
methoxypyrrolidin—3-y1)-carbamate. Example 95 (18 mg) was obtained. MS: calc’d 444
[(M+H)+], measured 444 [(M+H)+]. 1H NMR (400 MHZ, METHANOL-d4) 8 ppm 8.06 - 8.09 (m,
1H), 7.50 (d, J = 8.1 Hz, 1H), 7.26 (d, J = 8.3 Hz, 1H), 6.96 (d, J = 2.4 Hz, 1H), 6.75 (s, 1H),
6.70 (s, 1H), 6.57 = 12.7 Hz, 1H), 4.25 - 4.32 (m, 2H), 4.10 - 4.17 (m,
- 6.65 (m, 1H), 4.46 (d, J
1H), 3.85 - 3.71 (m, 1H), 3.42 - 3.49 (m, 2H), 3.48 (s, 3H), 2.92 - 3.10 (m, — 3.97 (m, 5H), 3.63
2H), 1.37 (d, J: 6.5 Hz, 3H).
Example 96
4-[(4R,10bS)—8—[(3R)-3—aminopyrrolidinyl]methyl-3,4,6,10b—tetrahydr0-1H-
pyrazino[2,1-a]isoindol—Z—yl]pyrazolo[1,5-a]pyridinecarbonitrile
/ ,N
The title compound was prepared in analogy to the preparation of Example 94 by using
tert-butyl N-[(3R)-pyrrolidiny1]carbamate instead of tert-butyl R)methoxypyrrolidin
—carbamate. Example 96 (5.2 mg) was obtained. MS: calc’d 414 [(M+H)+], ed 414
[(M+H)+]. ‘H NMR (400 MHz, METHANOL-d4) 5 ppm 8.12 (d, J : 2.4 Hz, 1H), 7.54 (d, J :
7.9 Hz, 1H), 7.41 (br d, J: 8.2 Hz, 1H), 7.03 (d, J: 2.4 Hz, 1H), 6.70 - 6.84 (m, 3H), 4.54 -
4.64 (m, 1H), 4.04 - 4.23 (m, 3H), 3.58 - 3.72 (m, 2H), 3.40 - 3.53 (m, 2H), 2.43 - 2.64 (m, 1H),
2.13 - 2.28 (m, 1H), 1.56 (d, J: 6.7 Hz, 3H).
e 97
4-[(4R,10bS)—4—methyl—8—[(3R)-3—methylpiperazin-1—yl]-3,4,6,10b-tetrahydr0-1H—
1 5 pyrazino [2, 1—a]isoindolyl] pyrazolo[1,5-a]pyridinecarbonitrile
/ N,N
The title compound was prepared in analogy to the preparation of Example 94 by using
tert—butyl (2R)—2-methylpiperazine—1-carboxylate instead of tert-butyl ((3R,4R)—4—
methoxypyrrolidin yl)-carbamate. Example 97 (6.0 mg) was obtained. MS: calc’d 428
[(M+H)+], measured 428 [(M+H)+]. 'H NMR (400 MHz, METHANOL-d4) (5 ppm 8.08 (d, J =
2.4 Hz, 1H), 7.50 (d, J = 8.1 Hz, 1H), 7.26 (d, J: 8.6 Hz, 1H), 7.12 (d, J = 1.6 Hz, 1H), 6.93 -
7.00 (m, 2H), 6.70 (d, J: 8.1 Hz, 1H), 4.25 = 11.5 Hz, 1H), 3.69
— 4.36 (m, 2H), 4.00 (br d, J -
3.91 (m, 4H), 3.47 - 3.58 (111, 3H), 3.20 — 3.27 (m, 1H), 2.96 - 3.09 (m, 2H), 2.74 — 2.91 (m, 2H),
1.42 (d, J: 6.6 Hz, 3H), 1.31 (d, J: 6.5 Hz, 3H).
Example 98
4-[(4R,10bS)[[(3S,4R)—4-fluoropyrrolidinyl]amino]—4-methyI-3,4,6,l0b-tetrahydro—1H—
pyrazino[2,1-a]is0indolyl]pyrazolo[1,5-a]pyridine-7—carbonitrile
/ N,N
The title compound was ed in analogy to the preparation of Example 94 by using
tert—butyl (3S,4R)amin0fluoro—pyrrolidine-l—carboxylate instead of tert—butyl ((3R,4R)-4—
methoxypyrrolidin —3-yl)-carbamate. Example 98 (17 mg) was obtained. MS: calc’d 432
[(M+H)+], measured 432 [(M+H)+]. 1H NMR (400 MHz, OL—d4) 0‘ ppm 8.09 (d, J =
2.3 Hz, 1H), 7.51 (d, J: 7.9 Hz, 1H), 7.21 (d, J= 8.1 Hz, 1H), 6.97 (d, J= 2.4 Hz, 1H), 6.87 (d,
J: 1.8 Hz, 1H), 6.76 (dd, J: 2.2, 8.3 Hz, 1H), 6.72 (d, J=~= 8.1 Hz, 1H), 5.24 - 5.45 (m, 1H),
4.47 (d, J: 13.0 Hz, 1H), 4.39 - 4.55 (m, 1H), 4.24 - 4.38 (m, 2H), 3.89 - 4.02 (m, 2H), 3.64 -
3.84 (m, 3H), 3.52 - 3.63 (rn, 1H), 3.24 (t, J=11.1_Hz, 1H), 2.96 - 3.11 (m, 2H), 1.39 (d, J: 6.5
Hz, 3H).
Example 99
4-[(4R,10bS)[(3R,4S)aminoflu0ro-pyrrolidinyl]methyl-3,4,6,10b-tetrahydro-
lH-pyrazino[2,1-a]isoindol—Z-yl]pyrazolo[1,5-a]pyridinecarbonitrile
The title nd was ed in analogy to the preparation of Example 94 by using
tert—butyl N—[(3R,4S)fluoropyrrolidin—3—y1]carbamate instead of tert—butyl R)
methoxypyrrolidin yl)-carbamate. Example 99 (17 mg) was obtained. MS: calc’d 432
[(M+H)+], measured 432 [(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 5 ppm 8.08 (d, J =
2.4 Hz, 1H), 7.50 (d, J: 8.1 Hz, 1H), 7.22 (d, J = 8.3 Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.66 —
6.73 (m, 2H), 6.56 (dd, J: 2.3, 8.1 Hz, 1H), 5.33 - 5.55 (m, 1H), 4.24 - 4.39 (m, 2H), 4.02 — 4.08
(m, 1H), 3.62 — 3.93 (m, 5H), 3.39 — 3.46 (m, 2H), 2.97 — 3.07 (m, 1H), 2.84 - 2.96 (m, 1H), 2.21
(t, J: 7.5 Hz, 1H), 1.32 (d, J: 6.5 Hz, 3H).
Example 100
4-[(4R,10bS)(4-aminomethyl—1-piperidyl)-4—methyl-3,4,6,10b-tetrahydro-1H-
pyrazino[2,1-a]isoindolyl]pyrazolo[1,5-a]pyridine-7—carbonitrile
/N\,N
The title compound was prepared in analogy to the preparation of Example 94 by using
tert—butylN—(4-methy1piperidyl)carbamate instead of tert-butyl ((3R,4R)-4—methoxypyrrolidin
-145—
-carbamate. Example 100 (9.0 mg) was obtained. MS: calc’d 442 +], measured 442
[(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) (5 ppm 8.09 (d, J = 2.4 Hz, 1H), 7.50 (d, J =
7.9 Hz, 1H), 7.30 (d, J: 8.4 Hz, 1H), 7.12 (d, J: 1.7 Hz, 1H), 7.00 ( (dd, J: 2.2, 8.2 Hz, 1H),
6.98 (d, J= 2.4 Hz, 1H), 6.73 (d, J: 7.9 Hz, 1H), 4.53 - 4.60 (m, 1H), 4.40 - 4.51 (m, 1H), 4.22 -
4.34 (m, 1H), 4.09 (d, J: 12.7 Hz, 1H), 3.90 - 3.99 (m, 1H), 3.61 - 3.70 (m, 1H), 3.52 - 3.60 (m,
2H), 2.98 - 3.17 (1n, 4H), 1.88 - 2.03 (m, 4H), 1.47 (s, 3H), 1.42 (d, J: 6.6 Hz, 3H).
Example 101
4-[(4R,10bS)-8—[(6R)—6-amino-1 ,4-oxazepanyl]methyl—3,4,6,lOb—tetrahydro—IH-
pyrazino[2,1-a]isoindol—Z-yl}pyrazolo[1,5-a]pyridinecarbonitrile
/N’\
The title compound was prepared in analogy to the preparation of Example 94 by using
tert—butyl N—[(6R)-1,4—oxazepan—6-y1]carbamate instead of tert—butyl ((3R,4R)
methoxypyrrolidin—3—y1)-carbamate. Example 101 (10.0 mg) was obtained. MS: calc’d 444
+], measured 444 [(M+H)+]. 1H NMR (400 MHZ, METHANOL—d4) (5 ppm 8.09 (d, J =
2.3 Hz, 1H), 7.50 (d, J: 7.9 Hz, 1H), 7.27 (d, J: 8.3 Hz, 1H), 6.92 - 7.03 (m, 2H), 6.84 (dd, J:
2.3, 8.3 Hz, 1H), 6.72 (d, J: 8.1 Hz, 1H), 4.48 (d, J = 12.6 Hz, 1H), 4.24 — 4.38 (m, 2H), 4.16
(dd, J: 5.7, 15.5 Hz, 1H), 4.01 — 4.09 (m, 1H), 3.89 — 4.00 (m, 4H), 3.74 — 3.87 (m, 2H), 3.46 —
3.68(m, 4H), 2.95 — 3.09 (m, 2H), 1.39 (d, J: 6.5 Hz, 3H).
Example 102
4-[(4R,10bS)methyl(5-oxa-2,8-diazaspirol3.5]nonanyl)—3,4,6,10b-tetrahydro-1H—
pyrazino[2,1-a]isoindolyl]pyrazolo[1,5-a]pyridine-7—carbonitrile
/ N,N
The title compound was prepared in analogy to the preparation of Example 94 by using
tert-butyl 5-oxa—2,8-diazaspiro[3.5]nonanecarboxylate instead of terI—butyl ((3R,4R)
methoxypyrrolidin y1)-carbamate. Example 102 (20.2 mg) was obtained. MS: calc’d 456
[(M+H)+], measured 456 +]. IH NMR (400 MHz, METI-IANOL-d4) 5 ppm 8.09 (d, J =
2.4 Hz, 1H), 7.51 (d, J: 7.9 Hz, 1H), 7.28 (d, J: 8.1 Hz, 1H), 6.98 (d, J: 2.4 Hz, 1H), 6.73 (d,
J: 7.9 Hz, 1H), 6.64 (d, J: 1.7 , 6.52 (dd, J: 2.1, 8.2 Hz, 1H), 4.58 (d, J: 13.1 Hz,
1H), 4.50 - 4.54 (in, 1H), 4.24 — 4.34 (m, 1H), 4.12 (d, J: 13.0 Hz, 1H), 4.06 (d, J: 8.4 Hz, 2H),
3.90 = 8.4 Hz, 2H), 3.63 - 3.73
- 3.98 (m, 3H), 3.79 (d, J (1n, 1H), 3.54 (s, 2H), 3.23 — 3.29 (m,
2H), 3.04 - 3.11 (m, 2H), 1.43 (d, J: 6.5 Hz, 3H).
Example 103
4-[(4R,10bS)[(3R)—3-aminomethyl-pyrrolidin-l-yl]methyl-3,4,6,10b-tetrahydr0-1H-
pyrazino[2,1-a]isoindol—2-yl]pyrazolo[1,5-a]pyridine-7—carbonitrile
/ N’N\
—l47-
The title nd was prepared in y to the preparation of Example 94 by using
tert—butyl N—[(3R)methylpyrrolidiny1]carbamate (CAS: —15-5, PharmaBlock,
Catalog: PBXA3113) instead of tert-butyl ((3R,4R)methoxy~ pyrrolidinyl)-carbamate.
Example 103 (20 mg) was obtained. MS: calc’d 428 [(M+H)+], measured 428 [(M+H)+]. 1H
NMR (400 MHz, METHANOL-d4) 6 ppm 8.08 (d, J = 2.3 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H),
7.20 (d, J= 7.9 Hz, 1H), 6.94 (d, J= 2.4 Hz, 1H), 6.71 (d, J: 1.8 Hz, 1H), 6.68 (d, J: 8.1 Hz,
1H), 6.57 (dd, J: 2.1, 8.3 Hz, 1H), 4.22 - 4.35 (m, 2H), 4.01 (br d, J: 10.8 Hz, 1H), 3.87 (br d,
J: 12.3 Hz, 1H), 3.64 - 3.76 (m, 2H), 3.57 (d, J: 10.6 Hz, 1H), 3.39 - 3.47 (m, 2H), 3.22 - 3.31
(m, 1H), 2.95 - 3.05 (m, 1H), 2.84 ~ 2.91 (m, 1H), 2.18 — 2.33 (m, 2H), 1.60 (s, 3H), 1.31 (d, J:
6.5 Hz, 3H).
Example 104
,10bS)—8—[(3R,4R)aminometh0xy—l-piperidyl]methyl—3,4,6,10b—tetrahydro—
1H—pyrazino[2,1-a]isoindol—Z-yllpyrazolo[1,5-a]pyridinecarbonitrile
/ N,N
HZN 0‘
The title compound was prepared in analogy to the preparation of Example 94 by using tert—
butyl N—[(3R,4R)—3-methoxypiperidinyl]carbamate (CAS: 9075447, PharmaBlock,
Catalog: PB07428) instead of tert-butyl ((3R,4R)-4—methoxypyrrolidin ~3—yl)—carbamate.
Example 104 (10 mg) was obtained. MS: calc’d 458 [(M+H)+], measured 458 [(M+H)+]. 1H
NMR (400 MHz, METHANOL—d4) 6 ppm 8.07 (d, J = 2.4 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H),
7.20 (d, J: 8.1 Hz, 1H), 7.07 (d, J: 1.6 Hz, 1H), 6.88 — 6.97 (m, 2H), 6.69 (d, J: 7.9 Hz, 1H),
4.27 (br d, J: 11.9 Hz, 2H), 3.95 - 4.04 (m, 1H), 3.81 - 3.93 (m, 2H), 3.59 - 3.70 (m, 2H), 3.52
(s, 3H), 3.13 — 2.88 (m, 3H), 2.41 - 2.53 (m, 1H), 1.97 -
- 3.23 (m, 3H), 2.94 - 3.05 (m, 1H), 2.68
2.04 (m, 1H), 1.29 (d, J: 6.5 Hz, 3H).
-148—
Example 105
4-[(4R,10bS)—8—[(3R,4S)amin0methoxypiperidyl}methyl-3,4,6,10b-tetrahydro-
1H—pyrazino[2,1—a]isoindol—Z-yIIpyrazolo[1,5—a]pyridinecarbonitrile
H2N 0‘
The title compound was prepared in analogy to the preparation of Example 94 by using
bis(tert-butyl N—[(3R,4S)—3-methoxypiperidinyl]carbamate) oxalic acid (PharmaBlock,
Catalog: PB97963-l) instead of tert-butyl R)-4—methoxypyrrolidin —carbamate.
Example 105 (10 mg) was obtained. MS: calc’d 458 [(M+H)+], measured 458 [(M+H)+]. 1H
NMR (400 MHz, METHANOL-d4) 5 ppm 8.10 (d, J = 2.3 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H),
7.34 (d, J= 8.4 Hz, 1H), 7.13 (d, J: 1.6 Hz, 1H), 6.92 - 7.05 (m, 2H), 6.75 (d, J = 7.9 Hz, 1H),
4.61 = 13.2 Hz, 2H), 4.09 — 4.19 (m, 1H), 3.98 (br d, J = 12.7 Hz,
— 4.79 (m, 2H), 4.30 (br d, J
1H), 3.84 - 3.91 (rn, 1H), 3.73 — 3.55 (m, 1H), 3.48
- 3.80 (m, 1H), 3.68 (br s, 1H), 3.47 (s, 3H),
3.9 — 1.96 (m, 1H), 1.48 (d, J: 6.6
~ 3.21 (m, 2H), 2.85 - 2.99 (m, 2H), 2.05 - 2.18 (m, 1H), 1.86
Hz, 3H).
-149—
Example 106
,10bS)[(3R,4S)aminometh0xypiperidyl]methyl-3,4,6,l 0b-tetrahydro-
1H-pyrazin0 [2,l-a]isoindol—Z—yl]pyrazolo[1,S-a]pyridine—7—carbonitrile
H2Nm...ON
The title compound was prepared in analogy to the preparation of Example 94 by using
tert—butyl N—[(3R,4S)—4-methoxy-3~piperidyl]carbamate (CAS: 7—47—7, PharmaBlock,
Catalog: PBZ5288—1) instead of tert—butyl ((3R,4R)-4—methoxypyrrolidinyl)-Carbamate.
Example 106 (10 mg) was obtained. MS: calc’d 458 [(M+H)+], measured 458 [(M+H)+]. 1H
NMR (400 MHz, METHANOL-d4) 5 ppm 8.08 (d, J = 2.4 Hz, 1H), 7.51 (d, J = 7.9 Hz, 1H),
7.28 (d, J: 8.2 Hz, 1H), 7.12 (d, J: 1.7 Hz, 1H), 6.99 (dd, J: 2.3, 8.4 Hz, 1H), 6.96 (d, J: 2.4
Hz, 1H), 6.71 (d, J = 7.9 Hz, 1H), 4.43 (d, J: 12.6 Hz, 1H), 4.27 — 4.33 (m. 1H), 4.22 (br d, J:
.9 Hz, 1H), 3.86 — 3.96 (m, 2H), 3.59 - 3.75 (m, 2H), 3.36 - 3.49 (m, 3H), 3.48 (s, 3H), 3.23 -
3.30 (m, 1H), 3.00 - 3.12 (m, 2H), 2.89 — 2.98 (m, 1H), 1.96 - 2.09 (m, 2H), 1.36 (d, J: 6.5 Hz,
3H).
-1 50—
Example 107
4-[(4R,10bS)—4—methyl(9-0xa-3,7-diazabicyclo[3.3.1]nonanyl)-3,4,6,10b-tetrahydro-
lH-pyrazino[2,1-a]isoindol—Z-yl]pyrazolo[1,5—a]pyridine—7—carb0nitrile
/ ,N
The title compound was prepared in analogy to the preparation of Example 94 by using
tert-butyl 9-0xa—3,7—diazabicyclo[3.3.1]nonanecarboxylate instead of tert-butyl ((3R,4R)
methoxypyrrolidinyl)-carbamate. Example 107 (10 mg) was obtained. MS: calc’d 456
[(M+H)+], ed 456 [(M+1—1)+]. 1H NMR (400 MHZ, OL-d4) 5 ppm 8.08 (d, J =
2.3 Hz, 1H), 7.50 (d, J: 7.9 Hz, 1H), 7.29 (d, J: 8.2 Hz, 1H), 7.21 (d, J: 1.8 Hz, 1H), 7.06 (dd,
J: 2.1, 8.3 Hz, 1H), 6.96 (d, J: 2.4 Hz,1H), 6.71 (d, J: 8.1 Hz,1H), 4.37 (d, J=12.5 Hz, 1H),
4.23 — 3.94 (m, 1H), 3.75 - 3.82 (m, 3H), 3.52 -
- 4.33 (m, 3H), 4.08 (br d, J: 10.4 Hz, 1H), 3.87
3.64 (m, 5H), 3.19 — 3.28 (m, 2H), 2.99 - 3.06 (m, 1H), 2.84 - 2.94 (m, 1H), 1.33 (d, J: 6.4 Hz,
3H).
1 5 Example 108
4-[(4R,1 0bS)[(3R,4R)aminohydroxymethyl-pyrrolidinyl]methyl-3,4,6,1 0b-
tetrahydro-lH-pyrazino[2,1-a]isoindol—2—yl]pyrazolo[1,5—a]pyridine-7—carbonitrile
-1 51—
The title nd was prepared in analogy to the preparation of Example 94 by using
tert—butyl N-[(3R,4R)—4—hydroxymethyl-pyrrolidin-3~yl]carbamate instead of tert-butyl
((3R,4R)methoxypyrrolidin—3-y1)-carbamate. e 108 (10 mg) was obtained. MS: calc’d
444 [(M+H)+], measured 444 [(M+H)+]. 1H NMR (400 MHz, METHANOL-d4) 6 ppm 8.08 (d, J
= 2.4 Hz, 1H), 7.50 (d, J= 7.9 Hz, 1H), 7.24 (d, J= 8.3 Hz, 1H), 6.96 (d, J = 2.4 Hz, 1H), 6.66 -
6.76 (m, 2H), 6.56 (dd, J = 2.1, 8.3 Hz, 1H), 4.45 (d, J = 12.7 Hz, 1H), 4.28 (br (1, J = 9.4 Hz,
2H), 3.78 = 10.4 Hz,
- 3.98 (m, 3H), 3.63 - 3.74 (m, 1H), 3.59 (d, J 1H), 3.46 - 3.53 (m, 2H),
3.37 (d, J: 10.5 Hz, 1H), 2.92 - 3.10 (m, 2H), 1.51 (s, 3H), 1.37 (d, J: 6.6 Hz, 3H).
Example 109
4-[(4R,l0bS)[(3S,4S)aminohydroxymethyl-pyrrolidin-l-yl]methyl-3,4,6,10b-
ydro—lH—pyrazino[2,l-a]isoindol-Z—yl]pyrazolo[1,5-a]pyridinecarbonitrile
The title compound was prepared in analogy to the preparation of Example 94 by using
tert-butyl N-[(3S,4S)-4—hydroxymethyl-pyrrolidinyl]carbamate instead of tert-butyl
((3R,4R)—4-methoxypyrrolidin-3~yl)-carbamate. Example 109 (27 mg) was obtained. MS: calc’d
444 [(M+H)+], measured 444 [(M+H)+]. 1H NMR (400 MHz, METHANOL—d4) 5 ppm 8.08 (d, J
= 2.3 Hz, 1H), 7.50 (d, J: 8.1 Hz, 1H), 7.24 (d, J: 8.2 Hz, 1H), 6.96 (d, J: 2.4 Hz, 1H), 6.64 -
6.74 (m, 2H), 6.56 (dd, .1 = 2.1, 8.3 Hz, 1H), 4.47 (d, J = 12.6 Hz, 1H), 4.24 — 4.33 (m, 2H), 3.81
= 10.4 Hz, 1H), 3.46 - 3.54 (m, 2H), 3.37 (d, J:
— 3.99 (m, 3H), 3.66 - 3.71 (m, 1H), 3.59 (d, J
.4 Hz, 1H), 2.91 - 3.10 (m, 2H), 1.51 (s, 3H), 1.38 (d, J: 6.6 Hz, 3H).
Example 1 10
4-[(4R,10bS)[(3R,4R)aminohydroxy—pyrrolidinyl]methyl-3,4,6,10b-
tetrahydro—lH—pyrazino[2,1-a]isoindol-Z-pryrazolo[1,5-a}pyridine—7—carbonitrile
/ ,N
The title compound was prepared in analogy to the preparation of Example 94 by using
utyl N—[(3R,4R)—4-methy1-pyrrolidin-3—yl]carbamate (CAS: 18205759, BePhann,
Catalog: BD761646) instead of tert-butyl ((3R,4R)—4-methoxypyrrolidinyl)-carbamate.
Example 110 (40 mg) was obtained. MS: calc’d 430 +], measured 43o [(M+H)+]. 'H
NMR (400 MHz, METHANOL-d4) 5 ppm 8.07 — 8.12 (m, 1H), 7.51 (d, J: 8.1 Hz, 1H), 7.30 (d,
J = 8.3 Hz, 1H), 6.99 (d, J = 2.4 Hz, 1H), 6.71 — 6.76 (m, 2H), 6.64 (dd, J = 2.1, 8.3 Hz, 1H),
4.46 - 4.63 (m, 3H), 4.25 - 4.33 (in, 1H), 4.15 (d, J: 13.1 Hz, 1H), 3.96 (br d, J: 12.5 Hz, 1H),
3.67 - 3.12 (m, 2H), 1.43 (d, J
— 3.88 (m, 4H), 3.46 (d, .1: 6.6 Hz, 1H), 3.25 - 3.29 (m, 1H), 3.03
= 6.6 Hz, 3H).
Example 1 1 1
4- [(4R,l 0bS)[(3S,4S)—3-aminohydroxy—pyrrolidin-l-yl]-4—methyl-3,4,6,10b-tetrahydro-
lH—pyrazino[2,1-a]isoindol—Z-yl]pyrazolo[1,5-a]pyridine—7-carbonitrile
/ ,N
WO 33941
—1 53—
The title compound was prepared in analogy to the preparation of Example 94 by using
tert-butyl N—[(3S,4S)—4—hydroxy-pyrrolidin—3-yl]ca1'bamate (CAS: 8706320, BePharm,
Catalog: BD447697 ) instead of tert-butyl ((3R,4R)—4—methoxypyrrolidinyl)-carbamate.
Example 111 (42 mg) was obtained. MS: calc’d 43o [(M+H)+], ed 430 [(M+H)+]. 1H
NMR (400 MHz, METHANOL—d4) 5 ppm 8.09 (d, J: 2.3 Hz, 1H), 7.51 (d, J3 7.9 Hz, 1H),
7.28 (d, J= 8.3 Hz, 1H), 6.98 (d, J: 2.6 Hz, 1H), 6.70 - 6.76 (m, 2H), 6.62 (dd, J: 2.], 8.3 Hz,
1H), 4.36 - 4.58 (m, 3H), 4.30 (br d, J: 12.5 Hz, 1H), 4.04 (d, J: 13.0 Hz, 1H), 3.94 (br d, J:
12.8 Hz, 1H), 3.72 - 3.86 (m, 3H), 3.56 - 3.64 (m, 1H), 3.45 (d, J: 6.7 Hz, 1H), 3.24 - 3.29 (m,
1H), 3.00 — 3.10 (m, 2H), 1.41 (d, J: 6.5 Hz, 3H).
Example 112
4-[(4R,10bS)[(3S,4S)—4-aminohydroxymethyl—pyrrolidin-l-yl]methy1-3,4,6,10b-
tetrahydro-lH-pyrazino[2,1-a]isoindol—2-yl]fluoro—pyrazolo[1,5—a]pyridine
carbonitrile
\ N\N
HzN‘s
The title nd was prepared according to the following scheme:
-154—
fluor, KF / N’N\ Zn(CN)2,
-——-——> _—__.
Pd PPh( 3)4
F F
112b
l l HN’BOC
/ N’ HNm8“ 10a (3,0 H,,,
\ HN
\ \ RuPhos Pd GZ
DIEA DMA
F F CsZCO3 dioxane
112C
112e Example 112
Step 1:preparation of 7-bromofluoro-pyrazolo[1,5-a]pyridine-3—carboxylic acid
(compound 112a)
The mixture of ethyl 7-bromofluoro—pyrazolo[1,5-a]pyridine-3—carboxylate (compound
94d, 5.2 g, 18.1 mmol), NaOH (2.1 g, 54.3 mmol) in EtOH (90.0 mL) and water (70.0 mL) was
stirred at 60°C for 2 hrs. The reaction mixture was trated and then d with water.
After adjusting pH to 4 with 1 N HCl, grey solid was precipitated, which was collected by
filtration to afford compound 112a (4.0 g, 85.6% . MS: calc’d 259 [(M+H)+], ed
259 [(M+H)+].
Step 2: preparation of 7—bromo—3,4-difluoro—pyrazolo[1,5—a]pyridine (compound 112b)
To a solution of 7-bromo-4—fluoro-pyrazolo[1,5-a]pyridine—3-carboxylic acid (compound
112a, 4.0 g, 15.4 mmol) and KP (3.6 g, 61.8 mmol) in DCE (60.0 mL) and water (50.0 mL) was
added Selectfluor (10.9 g, 30.9 mmol). The reaction was stirred at 70°C for 18 hrs. The reaction
was quenched with water, extracted with DCM twice. The combined organic layers were dried
over NaQSO4, filtered and the filtrate was concentrated in vacuo to afford crude compound 112b
(2.8 g, 78% yield). MS: calc’d 233 [(M+H)+], measured 233 [(M+H)+].
-1 55-
Step 3: preparation of 3,4-difluoropyrazolo[1,5-a}pyridine—7—carbonitrile (compound
112e)
A on of 7-bromo-3,4-difluoro—pyrazolo[1,5-a]pyridine (compound 112b, 2.8 g, 12.0
mmol) and zinc cyanide (5.6 g, 48.0 mmol) in DMF (70.0 mL) was added
tetrakis(tripheny1phosphine)palladium (1.4 g, 1.2 mmol). The reaction mixture was stirred at 120
°C for 18 hrs under N2 atmosphere. The mixture was quenched with water and ted with
EtOAc twice. The combined organic layers were dried over , filtered and the filtrate was
trated in vacuo. The residue was purified by column chromatography to afford compound
112c (810.0 mg, ) as a white solid. MS: calc’d 180 [(M+H)+], measured 180 [(M+H)+]. 1H NMR
(400MHz, CHLOROFORM-d) (5 ppm 8.00 (d, J: 3.6 Hz, 1H), 7.31 (dd, J = 4.7, 8.0 Hz, 1H),
6.83 (t, J: 8.4 Hz, 1H).
Step 4: preparation of 4—[(4R,10bS)—8—bromomethyl—3,4,6,10b—tetrahydro-1H-
pyrazino [2,1-a]isoindolyl]fluoro-pyrazolo[1,5—a]pyridine—7—carbonitrile (compound
1 12d)
A mixture of 3,4—difluoropyrazolo[1,5~a]pyridinecarbonitrile (compound 112e, 200.0 mg,
1.12 mmol), (4R,10bS)—8—bromomethy1—1,2,3,4,6,10b-hexahydropyrazino [2,1-a]isoindole
(compound 10a, 351.1 mg, 1.32 mmol) and DIEA (800.0 mg, 6.19 mmol) in DMA (20 mL) was
stirred at 130 0C for 15 hrs. The reaction mixture was quenched with H20 (50 mL), extracted
with EtOAc (50 mL) for three times. The combined organic layers were washed with brine,
dried over Na2S04, filtered and the filtrate was concentrated in vacuo. The residue was purified
by LC (PE: EA=1:1) to afford compound 112d (224.4 mg, 49.2% yield). MS: calc’d 426
and 428 [(M+H)+], measured 426 and 428 +].
Step 5: preparation of tert-butyl N—[(3S,4S)-l-[(4R,10bS)~2-(7-cyanofluoropyrazolo
I 1 ,S—a] pyridinyl)-4—methyl-3,4,6,10b—tetrahydro-1H-pyrazino[2,1-a]isoindol-S-
yl]hydroxy-4—methyl-pyrrolidinyl]carbamate (compound 112e)
A mixture of tert-butyl N-[(3S,4S)-4—hydroxymethyl-pyrrolidin—3~yl]carbamate (31.0 mg,
140 umol), 4-[(4R,10bS)bromo-4—methyl—3,4,6,10b- tetrahydro—1H—pyrazino[2,1-a]isoindol-2—
fluoro-pyrazolo[l,5—a]pyridinecarbonitrile und 112d, 50.0 mg, 120 umol),
RuPhos Pd G2 (20.0 mg, 20 umol) and cesium carbonate (115.0 mg, 3501111101) in 1,4-dioxane (5
mL) was degassed and purged with Ar for 3 times, and then the mixture was stirred at 100 0C for
16 hrs under Ar atmosphere. The mixture was diluted with DCM (80 mL), filtered and the
filtrate was concentrated in vacuo. The residue was purified by Prep—TLC (PE: EA=1 :2) to afford
nd 112e (40 mg, 37 % yield). MS: calc’d 562 [(M+H)+], measured 562 [(M+H)+].
-1 5 6-
Step 6: preparation of ,10bS)—8-[(3S,4S)-4—aminohydroxy—3-methylpyrrolidin-l
—yl] methyl-3,4,6,10b-tetrahydro—1H-pyrazino[2,1-a]isoindol-Z-yl]fluoro-
pyrazolo[1,S—a]pyridine—7—carbonitrile; 2,2,2-triflu0roacetic acid (Example 112)
To a solution of tert-butyl ,4S)[(4R,l0b5)(7-cyanofluoro-pyrazolo [1 ,5-
a]pyridinyl)—4-methyl-3 ,4,6,lOb-tetrahydro—1H—pyrazino[2,1-a]isoindolyl]hydroxy—4—
methyl-pyrrolidinyl]carbamate (compound 112e, 40.0 mg, 70 umol) in DCM (10 mL) was
added TFA (3 mL). The mixture was stirred at room temperature for 2 hrs. The reaction mixture
was stirred at room temperature for 2 hrs, then concentrated to afford a crude t, which was
purified by pre—HPLC to afford Example 112 (5.5 mg, 17% yield). MS calc’d 462 [(M+H)+],
measured 462.4 +]. 1H NMR (400 MHZ, DMSO-db) (5 ppm 8.31 (d, J = 3.6 Hz, 1H), 8.20
= 8.0 Hz, 1H), 7.28 (d, J: 6.8 Hz, 1H), 6.76 (d, J: 8.0 Hz, 1H), 6.63
- 8.24 (m, 3H), 7.73 (d, J
(br s, 1H), 6.49 — 6.58 (m, 1H), 5.54 — 5.63 (m, 1H), 4.85 - 5.07 (s, 1H), 4.40 — 4.51 (1n, 1H), 3.85
- 4.06 (m, 1H), 3.71 (dd, J: 5.2, 10.8 Hz, 1H), 3.58 — 3.60 (1n, 1H), 3.45 — 3.49 (1n, 2H), 3.28 —
3.29 (m, 2H), 3.23 (d, J: 10.0 Hz, 2H), 2.95 - 3.10 (m, 2H), 1.36 -1.35 (m, 6H).
Example 1 13
4-[(4R,10bS)—8—[(3R,4R)aminomethoxy-pyrrolidin-l-yl]methyl—3,4,6,10btetrahydro-lH
—pyrazino[2,1-a]isoindolyl]fluoro-pyrazolo[1,5-a]pyridine—7-
carbonitrile
The title compound was prepared in analogy to the preparation of Example 112 by using
tert—butyl N~[(3R,4R)rnethoxypyrrolidinyl]carbamate instead of tert—butyl N—[(3S,4S)-4—
hydroxy—4~methyl-pyrrolidin-3~yl]carbamate. Example 113 (70 mg) was obtained. MS: calc’d
462 [(M+H)+], measured 462 [(M+H)+]. 1H NMR (400 MHZ, OL-a’4) 5 ppm 8.06 (d, J
= 3.5 Hz, 1H), 7.46 (d, J: 7.9 Hz, 1H), 7.22 (d, J: 8.3 Hz, 1H), 6.76 (d, J: 1.8 Hz,1H), 6.63
(d, J: 8.1 Hz, 2H), 4.48 (d, J: 12.6 Hz, 1H), 4.30 (br d, J: 10.0 Hz, 1H), 4.07 - 4.16 (m, 2H),
3.98 (br d, J: 12.6 Hz, 1H), 3.84 - 3.94 (m, 2H), 3.63 — 3.74 (m, 2H), 3.41 - 3.55 (m, 5H), 3.30
(br d, J: 3.5 Hz, 1H), 2.90 - 3.07 (m, 2H), 1.37 (d, J: 6.6 Hz, 3H).
-l 57~
Example 1 14
The following tests were carried out in order to ine the activity of the nds of
formula (I), (la) or (lb) in HEK293-Blue-hTLR—7/8/9 cells assay.
HEK293-Blue-hTLR—7 cells assay:
A stable HEK293-Blue-hTLR-7 cell line was purchased from InVivoGen (Cat.#: hkb—htlr7,
San Diego, California, USA). These cells were originally designed for studying the stimulation
ofhuman TLR7 by monitoring the activation ofNF-KB. A SEAP (secreted embryonic alkaline
phosphatase) reporter gene was placed under the control of the IFN-B minimal promoter fused to
five NF-KB and inding sites. The SEAP was induced by activating NF—KB and AP-l via
stimulating HEK-Blue hTLR7 cells with TLR7 ligands. Therefore the reporter expression was
declined by TLR7 antagonist under the stimulation of a ligand, such as R848 (Resiquimod), for
incubation of 20 hrs. The cell culture supernatant SEAP er activity was determined using
-BlueTM kit (Cat.#: rep-qbl, Invivogen, San Diego, Ca, USA) at a wavelength of 640
nm, a detection medium that turns purple or blue in the presence of alkaline phosphatase.
HEK293-Blue—hTLR7 cells were incubated at a density of 250,000~450,000 cells/mL in a
volume of 170 uL in a 96-well plate in Dulbecco's Modified Eagle's medium (DMEM)
ning 4.5 g/L glucose, 50 U/mL penicillin, 50 mg/mL omycin, 100 mg/mL Normocin,
2 mM L—glutamine, 10% (v/V) heat-inactivated fetal bovine serum with addition of 20 uL test
compound in a serial dilution in the presence of final DMSO at 1% and 10 uL of 20uM R848 in
above DMEM, perform incubation under 37 0C in a C02 tor for 20 hrs. Then 20 uL of the
supernatant from each well was incubated with 180 uL Quanti-blue substrate solution at 37 0C
for 2 hrs and the absorbance was read at 620~655 nm using a spectrophotometer. The signaling
pathway that TLR7 activation leads to downstream NF-KB tion has been widely accepted,
and therefore similar reporter assay was modified for evaluating TLR7 antagonist.
HEK293-Blue-hTLR-8 cells assay:
A stable HEK293—Blue-hTLR~8 cell line was purchased from Gen (Cat.#: hkb—htlr8,
San Diego, California, USA). These cells were originally designed for studying the stimulation
of human TLR8 by monitoring the activation of NF-KB. A SEAP (secreted embryonic alkaline
phosphatase) reporter gene was placed under the control of the IFN-B minimal promoter fused to
five NF-KB and AP—l-binding sites. The SEAP was induced by activating NF-KB and AP-
1 via stimulating HEK—Blue hTLR8 cells with TLR8 ligands. Therefore the reporter expression
was declined by TLR8 nist under the ation of a ligand, such as R848, for incubation
of 20 hrs. The cell culture supernatant SEAP reporter activity was ined using QUANTI-
—l 5 8-
BlueTM kit (Cat.#: rep-qbl, gen, San Diego, Ca, USA) at a wavelength of 640 nm, a
detection medium that turns purple or blue in the presence of alkaline phosphatase.
HEK293—Blue—hTLR8 cells were incubated at a density of 250,000~450,000 cells/mL in a
volume of 170 ML in a l plate in Dulbecco's Modified Eagle's medium (DMEM)
containing 4.5 g/L glucose, 50 U/mL llin, 50 mg/mL streptomycin, 100 mg/mL Normocin,
2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum with addition of 20 uL test
compound in a serial dilution in the presence of final DMSO at 1% and 10 uL of 60uM R848 in
above DMEM, perform incubation under 37 °C in a C02 incubator for 20 hrs. Then 20 uL of the
supernatant from each well was incubated with 180 uL Quanti~blue substrate solution at 37°C for
2 hrs and the absorbance was read at 620~655 nm using a spectrophotometer. The signaling
y that TLR8 activation leads to downstream NF-KB activation has been widely accepted,
and therefore similar reporter assay was modified for evaluating TLR8 antagonist.
HEK293-Blue-hTLR-9 cells assay:
A stable HEK293-Blue—hTLR-9 cell line was purchased from Gen (Cat.#: hkb-htlr9,
San Diego, California, USA). These cells were originally ed for studying the stimulation
ofhuman TLR9 by monitoring the activation of NF—KB. A SEAP (sccrctcd embryonic alkaline
phosphatase) reporter gene was placed under the control of the lFN-B minimal promoter fused to
five NF~KB and AP-l -binding sites. The SEAP was induced by activating NF—KB and AP-
1 via stimulating HEK-Blue hTLR9 cells with TLR9 ligands. Therefore the reporter expression
was declined by TLR9 antagonist under the stimulation of a ligand, such as ODN2006 (Cat.#:
tlrl-2006—l, Invivogen, San Diego, California, USA), for incubation of 20 hrs. The cell culture
supernatant SEAP reporter activity was determined using QUANTl-BlueTM kit (Cat.#: rep~qbl,
gen, San Diego, California, USA) at a wavelength of 640 nm, a ion medium that
turns purple or blue in the presence of alkaline phosphatase.
HEK293-Blue-hTLR9 cells were incubated at a density of 0~450,000 cells/mL in a
volume of 170 uL in a 96—well plate in Dulbecco’s Modified Eagle's medium (DMEM)
containing 4.5 g/L glucose, 50 U/mL penicillin, 50 mg/mL streptomycin, 100 mgmL in,
2 mM L—glutamine, l0% (v/v) heat-inactivated fetal bovine serum with addition of 20 uL test
compound in a serial dilution in the presence of final DMSO at 1% and 10 uL of 20uM
ODN2006 in above DMEM, perform incubation under 37 °C in a C02 tor for 20 hrs. Then
uL of the supernatant fi‘om each well was incubated with 180 ML -blue substrate
on at 37 0C for 2 h and the absorbance was read at 620~655 nm using a spectrophotometer.
The signaling pathway that TLR9 activation leads to ream NF—KB activation has been
2019/064323
-159~
widely accepted, and therefore similar reporter assay was modified for evaluating TLR9
antagonist.
The nds of formula (I) have TLR7 and/or TLR8 inhibitory activities (IC50 value)
<0.1 uM. Moreover, most compounds also have TLR9 inhibitory activity <0.3 uM. ty data
of the compounds of the present invention were shown in Table 1.
Table 1: The activity of the compounds of present invention in HEK293—Blue-hTLR-7/8/9
cells assays
HEK/hTLR7 HEK/hTLR8 HEK/hTLR9
Example No
1C50 (HM) IC50 (HM) ICSO (HM)
<3.2 <3.2 106.0
\J u—a kl} /\5”N 125.0
. 87.7
101.0
132.7
156.3
99.2
150.3
130.2
92.5
92.0
71.2
81.1
83.2
95.2
113.4
97.5
81.0
114.1
65.3
86.9
56.1
103.7
92.4
90.5
115.7
55.8
.6 83.4
43.3
96.6
|._. 93.7
89.2
100.1
66.6
111.4
100.3
1 102.9
WO 33941
I *
38 1.7 <0.3 66.8
39 3.0 <0.3 122.6
41 . .
42 <32 <32 65.4
43 4.0 I <32 55.5
44 19.1 0.4 102.0
46 . 143.8
47 4.8 0.6 146.2
- . —
. .
4.5 <32
543 5.7 <32 87.3
55A 7.7 <32 111.2
5513 16.1 <32 156.1
6.9 <3.2 103.4
11.1 <3.2 ‘1 83.0
563 4.5 <32 92.1
59 <32 <32 73.5
62 5.9 <32 84.5
64 <32 <32 125.3
65 4.4 <32 95.8
66 <32 <32 141.2
68 3.3 <3.2 73.5
69 18-2 <32
77 12.6 <3.2 140.7
78 1.2 0.4 83.6
79 7.6 2.8 113.4
~16] -
63.6
126.0
Example 113
Human Microsomal Stability Assay
Human liver microsomes (Cat.NO.: 452117, Corning, USA) were preincubated with test
compound for 10 minutes at 370C in 100 mM potassium phosphate buffer, pH 7.4. The reactions
were initiated by adding NADPH regenerating system. The final tion es contained 1
uM test compound, 0.5 mg/mL liver microsomal protein, 1 mM MgC12, 1 mM NADP, 1 unit/mL
isocitric dehydrogenase and 6 mM isocitric acid in 100 mM potassium ate buffer, pH 7.4.
After incubation times of O, 3, 6, 9, 15 and 30 minutes at 37°C, 300 uL of cold ACN (including
internal standard) was added to 100 uL incubation mixture to terminate the reaction. ing
precipitation and centrifugation, IOOuL supernatant will be taken out and added 300uL water.
The amount of compound remaining in the samples was ined by MS. Controls of
no NADPH regenerating system at zero and 30 minutes were also prepared and analyzed. The
results were categorized as: low (<7.0 mL/min/kg), medium (7.0-16.2 mL/min/kg) and high
(16.2—23.2 mL/min/kg). Test results were summarized in Table 2.
2019/064323
~162—
Table 2: Human microsomal stability results
CL (h)
(mL/min/kg)
21 6.2
27 7.7
28 8.7
8.8
32 8.7
36 6.2
37 6.5
38 6.2
39 6.2
40A 7.0
403 7.6
45 6.2
45A 6.2
4513 6.2
46 8.8
48 8.9
52 8.1
54 8.9
54A 7.5
54B 7.0
60 7.4
61 7.3
62 7.5
65 T 6 2 :]
-l 63—
86 7.7 T
Example 114
hERG Channel Inhibition Assay
The hERG channel inhibition assay is a highly sensitive measurement that identifies
compounds exhibiting hERG tion d to cardiotoxicity in vivo. The hERG KJr channels
were cloned in humans and stably expressed in a CHO ( Chinese hamster ovary) cell line.
CHOhERG cells were used for clamp (voltage—clamp, Whole-cell) experiments. Cells were
stimulated by a voltage pattern to activate hERG channels and conduct IKhERG currents (rapid
delayed outward rectifier ium current of the hERG channel). After the cells were stabilized
for a few minutes, the amplitude and kinetics of IKIIERG were recorded at a stimulation frequency
of 0.1 Hz (6 bpm). Thereafter, the test compound was added to the ation at increasing
concentrations. For each concentration, an t was made to reach a steady-state effect,
usually, this was achieved within 3-10 min at which time the next highest concentration was
applied. The amplitude and kinetics of lKhERG are recorded in each tration of the drug
which were compared to the control values (taken as 100%). (references: Redfern WS, Carlsson
L, Davis AS, Lynch WG, MacKenzie l, Palethorpe S, Siegl PK, Strang I, an AT, Wallis R,
Camm AJ, Hammond TG. 2003; Relationships between preclinical cardiac electrophysiology,
clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for
a provisional safety margin in drug development. Cardiovasc. Res. 58:32-45, netti MC,
Tristani-Firouzi M. 2006; hERG potassium channels and cardiac arrhythmia. Nature 4402463-
469, Webster R, an D, Walker D. 2002; Towards a drug concentration effect relationship
for QT prolongation and torsades de pointes. Curr. Opin. Drug Discov. Devel. 5:116-26). Results
of hERG are given in Table 3.
Table 3: hERG results
Example No
1 >10 >20
16 >10 >20
21 >10 >20
22 5.0 >20
-0 >20
>10 >20
>10 >20
37 8.6 >20
38 >10 >20
39 >10 >20
4013 >10 >20
>10 >20
6.7 >20
.2 >20
6.4 >20
45A >20
453 >10 >20
53A 6.6 >20
>10 >20
>10 >20
“ >10 >20
Example 115
3T3 in Vitro phototoxicity assay
Phototoxicity is defined as a toxic response that is elicited after the first exposure of the
skin to certain chemicals and subsequent exposure to 1ight, or that is d similarly by skin
irradiation after systemic administration of a chemical substance. The assay used in this study is
designed to detect the phototoxic potential of a chemical by using a simple in Vitro xicity
assay with Balb/c 3T3 mouse asts. The principle of this test is a comparison of the
cytotoxicity of a chemical when tested with and without exposure to a non-toxic dose of UVA-
light. Cytotoxicity is expressed as a dose dependent reduction of the growth rate of cells as
determined by uptake of the Vital dye Neutral Red one day after treatment.
Method
Preparation of stock solution and dosage of test item
A small amount of substance was d and formulated freshly in DMSO just before the
start of the exposure of the cells. This stock solution or appropriate dilutions with DMSO were
added to the cell suspensions to obtain the required final concentrations. All solutions were
generally prepared in Eppendorf caps and discarded after use.
Reference substance
Chlorpromazine (HCL) (Sigma, Batch/Lot No.2 120M1328V) test concentration: 300 ug/mL,
Solvent: PBS / 3% DMSO
Measurement of UV absorption spectrum
The absorption spectra as such or with UV-A or with UV-B pro-irradiation were recorded
between 240 nm and 400 nm with a Lambda-2 spectral photometer n Elmer).
UV radiation sources: for UV-A: Sol 500 with filter H1
Main um: 315—690 nm
Irradiance: . 1.67 mW/cm2
Radiation dose : approx. 5 J/cm2
for UV-B: Philips TL 20W/ 12
Main um: 290—320 nm
ance: approx. 0.083 mW/cm2
Radiation dose: approx. 0.05 J/cm2
Determination of oxicity
For this study the Neutral Red uptake (NRU) assay of Borenfreund and Puerner
(Borenfreund, E, Puerner JA. Toxicity determined in Vitro by morphological alterations and
l Red absorption. Toxicology Lett. 1985; 24:119—124.) modified according to INVITTOX
protocol No 78 (ERGATT/FRAME data bank of in Vitro techniques in toxicology. INVITTOX
PROTOCOL No 78. 3T3 NRU oxicity Assay. March 1994) has been adapted to examine a
possible phototoxic ial of the test item. This assay is based on the active uptake of the
Neutral Red dye into the lysosomes of cultured murine fibroblasts. Because lysosomal
membranes are known to be a site of action of many phototoxic compounds, this assay can
provide a measure of potential for phototoxic injury.
Preparation of cell culture
A murine fibroblasts clone A 31 (ATCC no. CCL 163 — passage No. 108) were cultured
in 175 01112 tissue culture grade flasks, containing sDMEM cco’s Minimal Essential
WO 33941
Medium, supplemented with 10% fetal calf serum, 2 mM L—glutamine, 100 ml Penicillin
and 100 pig/ml streptomycin) at 37°C in a humidified atmosphere of 6% C02. Before cells
approach confluence they were removed from flasks by trypsinisation. Prior to use in an assay,
the cells were transferred to l microtiter plates at a tration of 1x 104 cells/well in
100 pl volumes of sDMEM and d to attach for 24 h.
Exposure to test item
For incubation with murine fibroblasts, the test item was diluted in PBS / 3% DMSO
(detailed concentrations see in results).
Culture medium (Dulbecco's Modified Eagle Medium(DMEM), GlutaMAX (Gibco Ref
21885-025), 10% Fetal Bovine Serum (FBS) (Gibco Ref 10270-106), lOOIU/ml Penicillin and
100 ug/ml Streptomycin (Gibco Ref 15140-122» was removed from the wells and murine
asts were washed with PBS. Afterwards 100 uL ofPBS / 3% DMSO containing the test
item was added and target cells were incubated for l h at 37°C with 6% CO2.
UV exposure
For each test item the microtiter plates were prepared according to Table 4. “UVA plates”
were exposed to approx. 5 J/cm2 UVA light, the “Dark plates” were kept in the dark and served
as cytotoxicity control. Plates with chlorpromazine hydrochloride served as positive control. UV
flux was measured with a UV-meter (Dr. Grobel RM2l).
Following UV irradiation, the test item was removed from the wells (one g step
with PBS) and replaced with sDMEM. Target cells were then incubated overnight at 37°C in 6%
C02.
Table 4. 96-well microtiter plate setup
1.0 ~
_ -_,
U01 U02 U03 U04 U05 U06 U07
96-well microtiter plates were prepared as follows:
- l 67—
Each plate contained wells with cells and solvent but without test item which were either
not incubated with Neutral Red on (0% standard - $1) or were stained with Neutral Red
(100% standard —SZ) for calculation of the standard cell viability curve. Wells labeled with U01-
U08 ned the different test item concentrations.
Neutral Red uptake
The ready to use Neutral Red (NR) staining solution was freshly prepared as follows:
' 0.4% aqueous stock solution was shielded from light and filtered before use to remove
NR crystals.
0 1:40 dilution of the stock solution was then prepared in sDMEM and added to the cells.
After the incubation the wells to be assayed were filled with 100 uL of the sDMEM
containing Neutral Red. The target cells were incubated with the NR for 3 h at 37°C in 6% C02.
Measurement of Neutral Red uptake
Unincorporated Neutral Red was removed from the target cells and the wells washed
with at least 100 uL of PBS. 150 uL of l Red desorb solution (1% glacial acetic acid, 50%
ethanol in aqua bidest) was then added to quantitatively t the incorporated dye. After at
least 10 mins of vigorous shaking of the plates on a microtiter plate shaker until Neutral Red has
been extracted from the cells and formed a homogeneous solution, the absorption of the resulting
colored on was measured with a SPECTRAmaX PLUS microtiter plate reader (Molecular
Devices) at 540 nm.
Calculation of cell ity
Cell viability was calculated with the x Pro software package (Molecular
Devices). First a two-point standard curve (0% and 100% viability) was calculated with the
linear curve fit option of the m based on the following formula:
Y = A + ( B >< X)
(A = y-intercept of the line; B = slope of the line;
0% cell viability = cells with solvent, but t test item and l Red;
100% cell viability = cells with solvent and Neutral Red, but without test item)
By this means the ity of the cells incubated with increasing concentrations of the
test chemical was calculated. Chlorpromazine (HCl) served as positive control in the experiment.
Calculation of IC50 values
All calculations were performed with the SOFTmax Pro analysis software package
WO 33941
-1 68—
(Molecular Devices ~ for details see:
http://www.mbl.edu/jbpc/files/ZO14/05/SoftMax_Pro_User_Guide.pdf)
Calculation of discrimination factor for phototoxicity
For evaluation of phototoxic potential, the IC50 values determined with and without UV
exposure were compared.
Factor = IC50 (-UV) / ICso (+UV)
For discrimination between phototoxic and non—phototoxic test chemicals a cut-off factor
of >5 was applied (Liebsch M, Spielmann H, Balls M, Brand M, Doring B, Dupuis J, Holzhfiter
HG, Klecak G, L.Eplattenier H, Lovell W, Maurer T, hauer F, Moore L, Pape W,
Pfannenbecker U, Potthast JM, De Silva O, Steiling W, Willshaw A. First results of the
EC/COLIPA Validation Project. In Vitro Phototoxicity Testing. In: In Vitro Skin Toxicology:
Irritation, Phototoxicity, Sensitization; Vol. 10. Alternative Methods in logy,-Eds.
Rougier A, Maibach HI, Goldberg AM; Mary Ann Liebert Pub1.: New York, USA 1994, pp.
243-251).
Test items which are not xic to murine fibroblasts even at the highest concentrations
tested, but ShOW a strong dose dependent decrease in cell viability after UV exposure are
considered also phototoxic (Spielmann H, Balls M, Dupuis J, Pape WJW, Pechovitch G, Silva
DeO, Holzhfitter, HG, Clothier R, Desolle P, Gerberick F, Liebsch M, Lowell WW, Maurer T,
Pfannenbecker U, Potthast JM, Csato M, Sladowski D, Steiling W, Brantom P. The international
EU/COLIPA in vitro phototoxicity validation study: Results of phase II (blind . Part 1: The
3T3 NRU phototoxicity test. Toxicology in Vitro 1998, 12: 305—327).
The test s were shown below, the compounds of this invention showed very good
phototoxicity profile.
Table 5. The 3T3 test results for the nd of this invention
Example No oxicity factor IC50 (UV-A) (pg/inL)
14 1.00 >100
so >19
39 1.00 >100
54B 1.00
Claims (3)
1. A compound of a (I), (R n R4 (R )m (I), wherein R7 R7 R7 R7 N R8 N R8 N R8 N R8 \ N/ \ / \ / \ / N\ / N/j:Re R] is , a 9 9 R7 R7 R7 R7 \ \ \ \N s 0 , , ; wherein R7 is C1_6alkyl, C1_6alkoxy, haloC1_6alkyl, n, nitro or cyano; R8 is H or deuterium; R9 is H, deuterium or C1_6alkyl; R10 is H or halogen; R2 is H or C1_6alkyl; 10 R3 is H; R4 is H; R5 is H, piperazinyl, halogen, C1_6alky1, halopyrrolidinylamino or hydroxypy1‘rolidinle1_ balkylamino; R6 is H; 15 (Cl-(,alky1)2aminoC1-6alkoxy; (C1-éalky1)2aminoC1-6alkylamino; l,2,3,4,6,6a-hexahydropyrrolo[3,4-C]pyr1‘olyl substituted by C1_6alkoxy; -l 70- 1,4-diazepany1 substituted by one or two substituents independently selected from y and C1_6alky1; 1,4~oxazepanyl substituted by amino; 1,4-oxazepanylamino; 5 l,6-diazaspiro [3 .3]heptany1; 2,5-diazabicyclo[2.2. l ]heptanylcarbonyl; azaspiro[3.3]heptanyl unsubstituted or tuted by C1_6a1ky1; 2-oxaazaspiro[3.4]octany1 substituted by amino; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3 ,4—b] [1 ,4]oxazinyl; 10 3,4a,5,6,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxaziny1; 3,8-diazabicyclo[3 .2. l ]octanylcarbonyl; 3-oxa-7,9-diazabicyclo[3 .3 . 1 ]nonany1; 3-oxo—l ,5,6,7,8,8a—hexahydroimidazo[ 1 ,5-a]pyraziny1; 5-oxa-2,8-diazaspiro[3.5]nonanyl; 15 9-oxa—3 ,7—diazabicyclo[3 .3. 1 ]nonany1; a1nino(C1-6alkyl)piperidinylcarbonyl; inyl unsubstituted or substituted by one or two substituents independently selected from amino and C1-6a1kyl; inylamino; 20 inyloxy; C1-6alkoxypiperidiny1amino; C1-6alkoxypyrrolidinyl(C1-6a1kyl)amino; C1-6alkoxypyrrolidiny1a1nino; haloazetidinyl(C1.6alky1)amino; 25 halopyrrolidinylamino; halopyrrolidinleI-6alkoxy; halopyrrolidinle1-6alky1amino; halopyrrolidinyloxy; hydroxypyrrolidinlel.6alky1amino; 30 morpholinylcl-6alkylamino; piperazinyl unsubstituted or substituted by C1-6alkoxyC1-6a1ky1, hydroxyC1_6alkyl or C1- 6alkyl; piperazinylcarbonyl; -l 71 - piperidinyl unsubstituted or tuted by one or two substituents independently selected from amino, C1_6alkoxy and C1_6alkyl; piperidinylamino; or pyrrolidinyl substituted by one, two or three substituents independently selected from 5 amino, C1_6alkoxy, C1_6alkyl, C1-6alkylamino, halogen, hydroxy and hydroxyC1_6alkyl; m is 0,1, 2, or3; nis 1,2, 3 or4; m+ns4; with the proviso that R5 and R6 are not H simultaneously; 10 or a pharmaceutically acceptable salt thereof.
2. A nd of formula (Ia), (Ia), wherein R7 R7 R7 N R8 N R8 N j: N \ / N’ \ \> / N/ R9 \ \ 8 15 R1 is or ; wherein R7 is C1_6alkyl, haloCl_(,alkyl, halogen or cyano; R8 is H or deuterium; R9 is H or deuterium; R10 is H or halogen; R2 is H or C1_6alkyl; R3 is H; 20 R4 is H; R5 is H, zinyl, rrolidinylamino or hydroxypyrrolidinle1-6alkylamino; R6 is H; (C1-6alkyl)2aminoC1-6alkoxy; (C1_6alky1)2aminoC 1 -6a1ky1amino; l,2,3,4,6,6a—hexahydropyrrolo[3,4—c]pyrroly1 substituted by C._6alkoxy; 1,4-diazepanyl substituted by one or two substituents independently ed from hydroxy and C]_6alkyl; 5 1,4—oxazepanyl substituted by amino; 1 ,4-oxazepanylamino; 1,6-diazaspiro[3 .3]heptanyl; 2,5 -diazabicyclo [2 .2. 1 ]heptanylcarbonyl; 2,6—diazaspiro[3.3]heptanyl unsubstituted or substituted by C1_6alky1; 10 2-oxa—7—azaspiro[3.4]octanyl substituted by amino; 3,4,4a,5,7,7a-hexahydro-2H—pyrrolo[3,4-b] [ l ,4]oxazinyl; 3,4a,5,6,7,7a-hexahydro-ZH-pyrrolo[3,4-b] [ l ,4]oxazinyl; 3,8-diazabicyelo[3.2.1 ylcarbonyl;
3-0xa-7,9-diazabicyclo[3.3.1]nonanyl; 15 3-oxo—1,5,6,7,8,8a-hexahydroi1nidazo[1 ,5-a]pyrazinyl; 5-oxa-2,8-diazaspiro[3.5]nonanyl; 9-oxa-3 ,7—diazabicyclo[3 .3.l ]nonanyl; amino(C1.6alkyl)piperidinylcarbonyl; azetidinyl unsubstituted or substituted by one or two substituents independently selected 20 from amino and Cmalkyl; inylamino; inyloxy; C1-6alkoxypiperidinylamino; C1-6alkoxypyrrolidiny1(C1-6alkyl)amino; 25 C1-6alkoxypyrrolidinylamino; haloazetidinyl(C1-6a1ky1)amino; halopyrrolidinylamino; halopyrrolidinle1-6alk0xy; halopyrrolidinle1.6alkylamino; 30 halopyrrolidinyloxy; hydroxypyrrolidinle.6alkyla1nino; morpholinle1-6alkylamino; piperazinyl unsubstituted or substituted by C1_6alkoxyC1_6alkyl, yC1-6alkyl or CL 6alky1;
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2018/090004 | 2018-06-05 | ||
EP18193916.6 | 2018-09-12 | ||
CNPCT/CN2019/086019 | 2019-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ768960A true NZ768960A (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3802539B1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
EP3995495A1 (en) | Selectively substituted quinoline compounds | |
EP3953356B1 (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
EP3856737B1 (en) | Heterocyclyl compounds for the treatment of autoimmune disease | |
EP3807271A1 (en) | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease | |
EP3623369B1 (en) | Novel morpholinyl amine compounds for the treatment of autoimmune disease | |
WO2021099406A1 (en) | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease | |
CN114728976B (en) | Hydrogen-1H-pyrrolo [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | |
NZ768960A (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
EP4061814A1 (en) | Triazatricycle compounds for the treatment of autoimmune disease | |
CN114728987B (en) | 1, 8-Naphthyridin-2-one compounds for the treatment of autoimmune diseases | |
CN114599652B (en) | Hydropyrazino [1,2-d ] [1,4] diazepine compounds for the treatment of autoimmune diseases |